Aspen Neuroscience ASPE Director, 10% owner · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 1055951
Orbimed Advisors
Director at Aspen Neuroscience, ADARx Pharmaceuticals, Electra Therapeutics, BlossomHill Therapeutics, Braveheart Bio, Scribe Therapeutics, Yarrow Bioscience, Sionna Therapeutics, Shattuck Labs, Q32 Bio, Prelude Therapeutics, ImageneBio, Turnstone Biologics, Corvus Pharmaceuticals, Compass Therapeutics, Edgewise Therapeutics, MBX Biosciences and Lomond Therapeutics Holdings; 10% owner at Enliven Therapeutics, Traws Pharma, Adicet Bio, PMV Pharmaceuticals, NeuroPace and Xtant Medical Holdings; Shareholder; Director at Keros Therapeutics; Shareholder at Disc Medicine; Stockholder at Passage BIO
Earlier: Upstream Bio, ARS Pharmaceuticals, scPharmaceuticals, Terns Pharmaceuticals, TELA Bio, Alpine Immune Sciences, Kinnate Biopharma, Verona Pharma, Theseus Pharmaceuticals, ArriVent Biopharma, Galecto, Gracell Biotechnologies, Tricida, Third Harmonic Bio, SpringWorks Therapeutics, Sierra Oncology, Arcutis Biotherapeutics, 89bio, Janux Therapeutics, Repare Therapeutics, Acutus Medical, Synlogic, Oric Pharmaceuticals, Decibel Therapeutics, Prevail Therapeutics, Cti Biopharma, Aerpio Pharmaceuticals, LogicBio Therapeutics, Graybug Vision, Inspire Medical Systems, Pandion Therapeutics, Fusion Pharmaceuticals, Alector, Principia Biopharma, NextCure, Turning Point Therapeutics, Avedro, Synthorx, SI-BONE, Guardant Health, Arvinas Holding Company, SteadyMed, ViewRay, Constellation Pharmaceuticals, Crinetics Pharmaceuticals, ARMO BioSciences, Adaptimmune Therapeutics, Rhythm Pharmaceuticals, Pieris Pharmaceuticals, Audentes Therapeutics, GLAUKOS, Kala Pharmaceuticals, Loxo Oncology, Arsanis, Roka BioScience, Aeglea BioTherapeutics, Nabriva Therapeutics, Response Biomedical, Relypsa, Selecta Biosciences, Intellia Therapeutics, Otonomy, Dimension Therapeutics, Sientra, Intercept Pharmaceuticals, Mirati Therapeutics, Acceleron Pharma, Ambit Biosciences, Supernus Pharmaceuticals, Anthera Pharmaceuticals, Amarin, Complete Genomics, Pacira Pharmaceuticals, ChemoCentryx, Athersys, NxStage Medical, Kun Run Biotechnology, Biodel, ARYx Therapeutics, Cryocor, Insulet, Volcano, Avanir Pharmaceuticals, Given Imaging, Dov Pharmaceutical, Orphan Medical, Aerogen, Memory Pharmaceuticals, Orthovita and Lifecell
Sold on Form 4$2B
Noticed on Form 144$671.1M
Bought on Form 4$985M
Companies117
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Aspen Neuroscience ASPE | Series A-1 Convertible Preferred Stock into Common Stock | See footnotes | 642,745 | Oct 29, 2026 · Filing · EDGAR |
| Aspen Neuroscience ASPE | Series B Convertible Preferred Stock into Common Stock | See footnotes | 625,743 | Oct 29, 2026 · Filing · EDGAR |
| Aspen Neuroscience ASPE | Series A-2 Convertible Preferred Stock into Common Stock | See footnotes | 616,984 | Oct 29, 2026 · Filing · EDGAR |
| Aspen Neuroscience ASPE | Series C Convertible Preferred Stock into Common Stock | See footnotes | 507,119 | Oct 29, 2026 · Filing · EDGAR |
| Aspen Neuroscience ASPE | Series Seed-2 Convertible Preferred Stock into Common Stock | See footnotes | 196,541 | Oct 29, 2026 · Filing · EDGAR |
| ADARx Pharmaceuticals ADRX | Common Stock | See footnotes | 588,235 | Sep 28, 2026 · Filing · EDGAR |
| Electra Therapeutics ETRA | Common Stock | See footnotes | 1,758,279 | Sep 21, 2026 · Filing · EDGAR |
| BlossomHill Therapeutics BLSM | Common Stock | See footnotes | 2,714,279 | Aug 10, 2026 · Filing · EDGAR |
| Braveheart Bio BRVE | Common Stock | See footnotes | 273,333 | Aug 7, 2026 · Filing · EDGAR |
| Yarrow Bioscience YARW | Common Stock | See footnote | 33,287 | Jul 27, 2026 · Filing · EDGAR |
| Yarrow Bioscience YARW | Pre-Funded Warrants (right to buy) exercise $0.00, into Common Stock | See footnote | 583,545 | Jul 27, 2026 · Filing · EDGAR |
| Scribe Therapeutics SCTX | Common Stock | See footnotes | 1,348,825 | Jul 27, 2026 · Filing · EDGAR |
| Sionna Therapeutics SION | Common Stock | See footnotes( | 2,671,822 | May 11, 2026 · Filing · EDGAR |
| Sionna Therapeutics SION | Common Stock | See footnotes | 2,469,959 | Jul 7, 2026 · Filing · EDGAR |
| Enliven Therapeutics IMRA | Common Stock | See Footnotes | 6,555,102 | Jun 22, 2026 · Filing · EDGAR |
| Enliven Therapeutics IMRA | Common Stock | By OrbiMed Private Investments VII, LP | 2,532,402 | Mar 16, 2020 · Filing · EDGAR |
| Shattuck Labs STTK | Common Stock | See Footnote | 1,051,021 | Jun 11, 2026 · Filing · EDGAR |
| Shattuck Labs STTK | Pre-Funded Warrants (right to buy) exercise $0.00, into Common Stock | See Footnote | 5,303,908 | Jun 11, 2026 · Filing · EDGAR |
| Q32 Bio QTTB | Common Stock | By OrbiMed Private Investments VII, LP | 2,252,987 | Mar 25, 2024 · Filing · EDGAR |
| Q32 Bio QTTB | Common Stock | See footnotes | 625,000 | May 28, 2026 · Filing · EDGAR |
| Traws Pharma TRAW | Common Stock | See Footnote | 1,203,250 | Apr 16, 2026 · Filing · EDGAR |
| Traws Pharma TRAW | Common Stock | By OrbiMed Private Investments VIII, LP | 1,045,261 | Apr 1, 2024 · Filing · EDGAR |
| Traws Pharma TRAW | Common Stock | See footnotes | 602,000 | Sep 16, 2024 · Filing · EDGAR |
| Traws Pharma TRAW | Series C Warrants (right to buy) exercise $1.67, into Common Stock | See Footnote | 1,793,187 | Apr 16, 2026 · Filing · EDGAR |
| Traws Pharma TRAW | Series A Warrants (right to buy) exercise $1.67, into Common Stock | See Footnote | 597,729 | Apr 16, 2026 · Filing · EDGAR |
| Traws Pharma TRAW | Series B Warrants (right to buy) exercise $1.67, into Common Stock | See Footnote | 597,729 | Apr 16, 2026 · Filing · EDGAR |
| Prelude Therapeutics PRLD | Common Stock | See footnote | 9,250,191 | Sep 29, 2020 · Filing · EDGAR |
| Prelude Therapeutics PRLD | Common Stock | See footnotes | 526,300 | Apr 21, 2026 · Filing · EDGAR |
| Prelude Therapeutics PRLD | Non-Voting Common Stock into Common Stock | See Footnotes | 5,596,886 | Jan 11, 2021 · Filing · EDGAR |
| ImageneBio IKNA | Common Stock | See Footnotes | 2,098,097 | Jun 24, 2022 · Filing · EDGAR |
| ImageneBio IKNA | Non-Voting Common Stock | See Footnotes | 157,288 | Jun 22, 2022 · Filing · EDGAR |
| ImageneBio IKNA | Common Stock | See Footnote | 20,691 | Apr 14, 2026 · Filing · EDGAR |
| ImageneBio IKNA | Non-Voting Common Stock | See Footnote | 13,107 | Jul 25, 2025 · Filing · EDGAR |
| ImageneBio IKNA | Pre-Funded Warrants (right to buy) exercise $0.00, into Common Stock | See Footnote | 384,689 | Apr 14, 2026 · Filing · EDGAR |
| Adicet Bio TORC | Stock Option (Right to Buy) exercise $16.11, expires Sep 17, 2030, into Common Stock | See Footnote | 30,000 | Sep 17, 2020 · Filing · EDGAR |
| Adicet Bio TORC | Stock Option (Right to Buy) exercise $16.11, expires Sep 17, 2030, into Common Stock | See Footnote | 30,000 | Sep 17, 2020 · Filing · EDGAR |
| Keros Therapeutics KROS | Common Stock | See footnote | 1,119,812 | Apr 13, 2020 · Filing · EDGAR |
| Keros Therapeutics KROS | Common Stock | See footnotes | 45,057 | Nov 21, 2025 · Filing · EDGAR |
| PMV Pharmaceuticals PMVP | Common Stock | See Footnotes | 4,975,291 | Oct 23, 2025 · Filing · EDGAR |
| PMV Pharmaceuticals PMVP | Common Stock | See footnote | 114,039 | Sep 29, 2020 · Filing · EDGAR |
| Corvus Pharmaceuticals CRVS | Common Stock | See Footnotes | 7,165,006 | Jun 27, 2025 · Filing · EDGAR |
| Passage BIO PASG | Common Stock | See footnotes | 6,066,343 | Jun 26, 2025 · Filing · EDGAR |
| Passage BIO PASG | Common Stock | See Footnote | 5,947,323 | Mar 3, 2020 · Filing · EDGAR |
| NeuroPace NPCE | Common Stock | See Footnotes | 3,238,199 | May 14, 2025 · Filing · EDGAR |
| NeuroPace NPCE | Common Stock | See Footnote | 235,000 | Apr 21, 2021 · Filing · EDGAR |
| Xtant Medical Holdings XTNT | Common Stock, $0.000001 par value | See footnote | 91,256 | Feb 5, 2020 · Filing · EDGAR |
| Compass Therapeutics CMPX | Common Stock | Directly | 12,714,404 | Jun 19, 2020 · Filing · EDGAR |
| Compass Therapeutics CMPX | Common Stock | See footnotes | 15,219,994 | Apr 9, 2025 · Filing · EDGAR |
| Edgewise Therapeutics EWTX | Common Stock | See footnotes | 443,792 | Apr 3, 2025 · Filing · EDGAR |
| Disc Medicine GMTX | Common Stock | See footnote | 1,139,507 | Dec 29, 2022 · Filing · EDGAR |
| Disc Medicine GMTX | Common Stock | See Footnotes | 186,541 | Mar 24, 2025 · Filing · EDGAR |
| MBX Biosciences MBX | Common Stock | By OrbiMed Private Investments VII, LP | 3,158,428 | Sep 16, 2024 · Filing · EDGAR |
| MBX Biosciences MBX | Common Stock | See footnotes | 747,887 | Feb 18, 2025 · Filing · EDGAR |
| MBX Biosciences MBX | Common Stock | By OrbiMed Genesis Master Fund, L.P. | 653,787 | Sep 16, 2024 · Filing · EDGAR |
| Lomond Therapeutics Holdings | Common Stock | See Footnote | 2,677,256 | Nov 1, 2024 · Filing · EDGAR |
| Upstream Bio | Common Stock | See Footnote | 4,554,873 | Oct 15, 2024 · Filing · EDGAR |
| Upstream Bio | Common Stock | By OrbiMed Private Investments VIII, LP | 1,007,040 | Oct 10, 2024 · Filing · EDGAR |
| Upstream Bio | Common Stock | By OrbiMed Israel Partners II, L.P. | 251,760 | Oct 10, 2024 · Filing · EDGAR |
| ARS Pharmaceuticals | Common Stock | See Footnote | 8,019,187 | Aug 26, 2024 · Filing · EDGAR |
| ARS Pharmaceuticals | Common Stock | By OrbiMed Private Investments VI, LP | 7,519,188 | Dec 8, 2020 · Filing · EDGAR |
| ARS Pharmaceuticals | Common Stock | By OrbiMed Partners Master Fund Limited | 952,377 | Dec 8, 2020 · Filing · EDGAR |
| ARS Pharmaceuticals | Common Stock | By OPI VI ? IP HoldCo LLC | 269,323 | Dec 3, 2020 · Filing · EDGAR |
| ARS Pharmaceuticals | Common Stock | By OPI VI -IP HoldCo LLC | 269,323 | Dec 8, 2020 · Filing · EDGAR |
| scPharmaceuticals | Common Stock | See footnotes | 252,858 | Aug 13, 2024 · Filing · EDGAR |
| Terns Pharmaceuticals | Common Stock | See footnotes | 755,635 | Jul 16, 2024 · Filing · EDGAR |
| Terns Pharmaceuticals | Pre-Funded Warrant into Common Stock | See footnotes | 64,050 | Aug 16, 2022 · Filing · EDGAR |
| TELA Bio | Common Stock | Directly | 3,027,542 | Nov 13, 2019 · Filing · EDGAR |
| TELA Bio | Common Stock | See footnotes | 2,407,242 | Jul 2, 2024 · Filing · EDGAR |
| TELA Bio | Warrant (right to buy) exercise $28.65, expires Jan 18, 2027, into Common Stock | Directly | 758,623 | Nov 13, 2019 · Filing · EDGAR |
| Theseus Pharmaceuticals | Common Stock | By OrbiMed Private Investments VII, LP | 16,339,518 | Oct 12, 2021 · Filing · EDGAR |
| Theseus Pharmaceuticals | Common Stock | By OrbiMed Genesis Master Fund, L.P. | 499,150 | Oct 12, 2021 · Filing · EDGAR |
| ArriVent Biopharma | Common Stock | See footnotes | 1,513,664 | Jan 30, 2024 · Filing · EDGAR |
| Galecto | Common Stock | See footnotes | 1,510,375 | Aug 15, 2023 · Filing · EDGAR |
| Galecto | Common Shares | See footnote | 1,031,811 | Nov 2, 2020 · Filing · EDGAR |
| Verona Pharma | Ordinary Shares | See footnotes | 3,777,778 | May 15, 2023 · Filing · EDGAR |
| Tricida | Common Stock | By OrbiMed Private Investments V, LP | 9,614,280 | Dec 11, 2019 · Filing · EDGAR |
| Tricida | Common Stock | By David P. Bonita | 5,511 | Dec 11, 2019 · Filing · EDGAR |
| Tricida | Comm on Warrants to Purchase Common Stock exercise $11.00, into Common Stock | See footnotes | 666,667 | Nov 15, 2021 · Filing · EDGAR |
| Third Harmonic Bio | Common Stock | See Footnote | 5,779,071 | Sep 19, 2022 · Filing · EDGAR |
| SpringWorks Therapeutics | Common Stock | See footnote | 7,406,307 | Sep 17, 2019 · Filing · EDGAR |
| SpringWorks Therapeutics | Common Stock | See Footnotes | 5,599,842 | Sep 12, 2022 · Filing · EDGAR |
| Sierra Oncology | Common Stock | See footnote (4), | 226,704 | Jan 26, 2022 · Filing · EDGAR |
| Sierra Oncology | Common Stock | See footnote | 226,704 | Jan 26, 2022 · Filing · EDGAR |
| Arcutis Biotherapeutics | Common Stock | See Footnotes | 415,142 | Jun 24, 2022 · Filing · EDGAR |
| 89bio | Common Stock | See footnote | 2,002,221 | Nov 13, 2019 · Filing · EDGAR |
| 89bio | Common Stock | See Footnotes | 1,829,436 | Jan 26, 2022 · Filing · EDGAR |
| Janux Therapeutics | Common Stock | See Footnotes | 231,098 | Dec 29, 2021 · Filing · EDGAR |
| Repare Therapeutics | Common Stock | See Footnote | 99,200 | Jun 23, 2020 · Filing · EDGAR |
| Repare Therapeutics | Common Stock | See Footnotes | 96,190 | Sep 7, 2021 · Filing · EDGAR |
| Acutus Medical | Common Stock | See Footnotes | 4,022 | Jul 19, 2021 · Filing · EDGAR |
| Synlogic | Common Stock, $0.001 par value | See Footnotes | 3,696,662 | Apr 20, 2021 · Filing · EDGAR |
| Oric Pharmaceuticals | Common Stock | See Footnotes | 2,212,571 | Mar 30, 2021 · Filing · EDGAR |
| Decibel Therapeutics | Common Stock | See footnotes | 883,418 | Feb 17, 2021 · Filing · EDGAR |
| Cti Biopharma | Common Stock | See Footnotes | 7,520,600 | Jan 7, 2021 · Filing · EDGAR |
| Cti Biopharma | Series X Preferred Stock into Common Stock | See footnotes | 2,980,000 | Mar 6, 2020 · Filing · EDGAR |
| Aerpio Pharmaceuticals | Common Stock | See Footnotes | 5,193,946 | Dec 8, 2020 · Filing · EDGAR |
| LogicBio Therapeutics | Common Stock | See Footnotes | 296,296 | Oct 1, 2020 · Filing · EDGAR |
| Graybug Vision | Common Stock | See footnote | 4,163,347 | Sep 29, 2020 · Filing · EDGAR |
| Inspire Medical Systems | Common Stock | Directly | 2,444,221 | May 7, 2018 · Filing · EDGAR |
| Pandion Therapeutics | Series B Preferred Stock into Common Stock | See footnote | 469,637 | Jul 16, 2020 · Filing · EDGAR |
| Fusion Pharmaceuticals | Common Shares | By OrbiMed Private Investments VII, L.P. | 2,930,670 | Jun 30, 2020 · Filing · EDGAR |
| Fusion Pharmaceuticals | Common Shares | By OrbiMed Partners Master Fund Limited | 192,100 | Jun 30, 2020 · Filing · EDGAR |
| Alector | Common Stock | See Footnotes | 1,906,718 | Apr 16, 2020 · Filing · EDGAR |
| Principia Biopharma | Common Stock | See footnote | 2,605,713 | Sep 18, 2018 · Filing · EDGAR |
| Principia Biopharma | Common Stock | See Footnotes | 1,605,713 | May 21, 2019 · Filing · EDGAR |
| NextCure | Common Stock | By OrbiMed Private Investments VI, LP | 2,711,013 | May 13, 2019 · Filing · EDGAR |
| Turning Point Therapeutics | Common Stock | See footnote | 2,027,550 | Apr 22, 2019 · Filing · EDGAR |
| Avedro | Common Stock | See Footnote | 4,240,128 | Feb 19, 2019 · Filing · EDGAR |
| Avedro | Series AA Warrant (right to buy) exercise $0.04, expires Mar 20, 2027, into Common Stock | See Footnote | 106,617 | Feb 19, 2019 · Filing · EDGAR |
| Synthorx | Common Stock | See Footnote | 5,316,355 | Dec 11, 2018 · Filing · EDGAR |
| SI-BONE | Common Stock | By OrbiMed Private Investments V, LP | 985,368 | Oct 19, 2018 · Filing · EDGAR |
| Guardant Health | Common Stock | By OrbiMed Royalties Opportunities II, LP | 8,972 | Oct 9, 2018 · Filing · EDGAR |
| Arvinas Holding Company | Series B Preferred Stock into Common Stock | See Footnote | 1,385,252 | Sep 26, 2018 · Filing · EDGAR |
| Arvinas Holding Company | Series C Preferred Stock into Common Stock | See Footnote | 218,558 | Sep 26, 2018 · Filing · EDGAR |
| SteadyMed | Ordinary Shares | See Footnote | 1,536,098 | Aug 4, 2016 · Filing · EDGAR |
| ViewRay | Common Stock | See footnote | 75,371 | Mar 30, 2016 · Filing · EDGAR |
| ViewRay | Common Stock | See Footnotes | 68,898 | Aug 20, 2018 · Filing · EDGAR |
| Constellation Pharmaceuticals | Common Stock | See footnote | 417,921 | Jul 23, 2018 · Filing · EDGAR |
| Crinetics Pharmaceuticals | Series B Preferred Stock into Common Stock | See Footnotes | 1,739,282 | Jul 17, 2018 · Filing · EDGAR |
| ARMO BioSciences | Common Stock | By OrbiMed Private Investments IV, LP | 3,709,356 | Jun 22, 2018 · Filing · EDGAR |
| ARMO BioSciences | Common Stock | By OrbiMed Private Investments V, LP | 409,547 | Jun 22, 2018 · Filing · EDGAR |
| Adaptimmune Therapeutics | Ordinary Shares with a nominal value of GBP0.001 per share | See Footnotes | 29,753,404 | May 24, 2016 · Filing · EDGAR |
| Adaptimmune Therapeutics | American Depositary Shares representing Ordinary Shares | See Footnotes | 4,901,310 | Jun 6, 2018 · Filing · EDGAR |
| Rhythm Pharmaceuticals | Common Stock | See Footnotes | 2,750,079 | May 22, 2018 · Filing · EDGAR |
| Pieris Pharmaceuticals | Common Stock | See Footnotes | 38,870 | Apr 30, 2018 · Filing · EDGAR |
| Audentes Therapeutics | Common Stock | See Footnotes | 3,539,997 | Mar 12, 2018 · Filing · EDGAR |
| Kala Pharmaceuticals | Common Stock | See Footnotes | 3,447,840 | Feb 8, 2018 · Filing · EDGAR |
| Loxo Oncology | Common Stock | See Footnotes | 941,000 | Dec 8, 2017 · Filing · EDGAR |
| Arsanis | Common Stock | See Footnotes | 1,868,966 | Nov 20, 2017 · Filing · EDGAR |
| Roka BioScience | Common Stock, par value $0.001 per share | See footnote | 44 | Jul 16, 2014 · Filing · EDGAR |
| Roka BioScience | Warrants into Common Stock | See Footnotes | 53,909 | Sep 21, 2016 · Filing · EDGAR |
| Roka BioScience | Series A Convertible Preferred Stock into Common Stock | See Footnotes | 37.74 | Sep 21, 2016 · Filing · EDGAR |
| Aeglea BioTherapeutics | Common Stock | See Footnotes | 1,469,524 | Feb 21, 2017 · Filing · EDGAR |
| Aeglea BioTherapeutics | Common Stock | See footnote | 1,360,224 | Apr 12, 2016 · Filing · EDGAR |
| Nabriva Therapeutics | Common Shares | See footnotes | 224,166 | Dec 30, 2016 · Filing · EDGAR |
| Relypsa | Common Stock | See Footnotes | 3,356,400 | Jul 25, 2016 · Filing · EDGAR |
| Selecta Biosciences | Common Stock | See Footnote | 1,825,415 | Jun 27, 2016 · Filing · EDGAR |
| Intellia Therapeutics | Common Stock | See Footnote | 2,662,180 | May 11, 2016 · Filing · EDGAR |
| Otonomy | Common Stock | See Footnotes | 1,850,094 | Nov 30, 2015 · Filing · EDGAR |
| Dimension Therapeutics | Common Stock | See Footnotes | 5,397,698 | Oct 27, 2015 · Filing · EDGAR |
| Sientra | Common Stock, par value $0.01 per share | See Footnotes | 17,100 | Oct 12, 2015 · Filing · EDGAR |
| Intercept Pharmaceuticals | Common Stock, par value $0.001 per share | See Footnote | 2,150,634 | Oct 16, 2012 · Filing · EDGAR |
| Intercept Pharmaceuticals | Common Stock, par value $0.001 per share | See Footnotes | 1,120,609 | Jul 17, 2015 · Filing · EDGAR |
| Mirati Therapeutics | Common Stock, par value $0.001 per share | See Footnotes | 1,267,000 | Feb 3, 2015 · Filing · EDGAR |
| Acceleron Pharma | Common Stock | See footnote | 576,889 | Sep 24, 2013 · Filing · EDGAR |
| Ambit Biosciences | Common Stock, $0.001 par value per share | See Footnotes | 14,067 | May 23, 2013 · Filing · EDGAR |
| Supernus Pharmaceuticals | Common Stock | See Footnotes | 817,000 | Feb 13, 2013 · Filing · EDGAR |
| Anthera Pharmaceuticals | Common Stock | See Footnotes | 7,462,000 | Jan 30, 2013 · Filing · EDGAR |
| Amarin | Ordinary Shares | See Footnote | 7,944 | Jul 27, 2012 · Filing · EDGAR |
| Amarin | Ordinary Shares | See Footnotes | 5,700 | Sep 4, 2012 · Filing · EDGAR |
| Complete Genomics | Common Stock | See Footnotes | 27,859 | Jul 13, 2012 · Filing · EDGAR |
| Pacira Pharmaceuticals | Common Stock | See footnote | 2,828,941 | Feb 8, 2011 · Filing · EDGAR |
| Pacira Pharmaceuticals | Common Stock | See footnotes | 2,446,000 | Mar 12, 2012 · Filing · EDGAR |
| ChemoCentryx | Common Stock | See Footnotes | 908,509 | Feb 13, 2012 · Filing · EDGAR |
| Athersys | Common Stock | See Foonotes | 1,693,100 | Apr 14, 2011 · Filing · EDGAR |
| Athersys | Common Stock | See Footnotes | 1,600,450 | Apr 26, 2011 · Filing · EDGAR |
| Athersys | Common Stock | See Foonote | 16,100 | Apr 14, 2011 · Filing · EDGAR |
| Athersys | Common Stock | See Footnote | 15,250 | Apr 26, 2011 · Filing · EDGAR |
| NxStage Medical | Common Stock | See Footnotes | 2,690,476 | Dec 9, 2010 · Filing · EDGAR |
| Kun Run Biotechnology | Series A Preferred Stock | By Caduceus Asia Partners, L.P. | 5,228,758 | Apr 30, 2010 · Filing · EDGAR |
| Kun Run Biotechnology | Warrant to Purchase Series A Preferred Stock into Common Stock | By Caduceus Asia Partners, L.P. | 1,568,627 | Apr 30, 2010 · Filing · EDGAR |
| Biodel | Common Stock | See footnote | 1,812,892 | Feb 12, 2008 · Filing · EDGAR |
| Biodel | Common Stock | See footnotes | 1,485,904 | Jun 10, 2009 · Filing · EDGAR |
| ARYx Therapeutics | Common Stock | See footnote | 3,340,139 | Nov 14, 2008 · Filing · EDGAR |
| ARYx Therapeutics | Common Stock | FN | 2,125,493 | Nov 13, 2007 · Filing · EDGAR |
| ARYx Therapeutics | Common Stock | See Footnotes | 1,340,139 | May 22, 2009 · Filing · EDGAR |
| Cryocor | Common Stock | Directly | 1,096,936 | Jul 13, 2005 · Filing · EDGAR |
| Cryocor | Common Stock | FN, 1, 2, 3 | 1,231,936 | Jul 13, 2005 · Filing · EDGAR |
| Cryocor | Common Stock | FN | 1,231,936 | Jul 13, 2005 · Filing · EDGAR |
| Cryocor | Common Stock | See Footnote | 389,432 | Jun 14, 2007 · Filing · EDGAR |
| Insulet | Common Stock | See Footnote | 1,568,841 | May 18, 2007 · Filing · EDGAR |
| Volcano | Common Stock | By Caduceus Private Investments II, LP | 1,578,832 | Jun 20, 2006 · Filing · EDGAR |
| Volcano | Common Stock | By Caduceus Private Investments II (QP), LP | 591,146 | Jun 20, 2006 · Filing · EDGAR |
| Volcano | Common Stock | By UBS Juniper Crossover Fund, L.L.C. | 195,705 | Jun 20, 2006 · Filing · EDGAR |
| Avanir Pharmaceuticals | Class A Common Stock | See FN | 2,335,258 | Feb 13, 2006 · Filing · EDGAR |
| Avanir Pharmaceuticals | Common Stock | FN | 1,706,137 | May 31, 2006 · Filing · EDGAR |
| Given Imaging | Common Stock | see footnotes below | 3,637,255 | Sep 21, 2004 · Filing · EDGAR |
| Given Imaging | Common Stock | FN 3 and 4 | 3,610,402 | May 24, 2006 · Filing · EDGAR |
| Dov Pharmaceutical | Common Stock | FN | 258,000 | May 16, 2006 · Filing · EDGAR |
| Aerogen | Series A-1 Convertible Preferred Stock exercise $3.00, into Common Stock | See | 917,510 | Mar 11, 2004 · Filing · EDGAR |
| Memory Pharmaceuticals | Common Stock | See | 1,006,280 | Apr 8, 2004 · Filing · EDGAR |
| Orthovita | Common Stock | see footnote 2 and 6 | 8,395,244 | Jul 22, 2003 · Filing · EDGAR |
| Orthovita | Common Stock | See footnote 1 and 2 | 6,365,144 | Sep 25, 2003 · Filing · EDGAR |
| Orthovita | Common Stock | See | 5,350,000 | Jan 14, 2004 · Filing · EDGAR |
| Orthovita | Common Stock | See footnote | 5,350,000 | Jan 14, 2004 · Filing · EDGAR |
| Lifecell | Common Stock | see footnote 2 | 1,643,000 | Dec 23, 2003 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q3 2026 | $3.9M | — | $96.1M |
| Q2 2026 | $96.4M | $107.3M | $28.5M |
| Q1 2026 | $1.4M | $497K | — |
| Q4 2025 | $7.9M | $175.3M | $5M |
| Q3 2025 | $900K | $4.9M | $5.5M |
| Q2 2025 | $44.3M | $6.4M | $10M |
| Q1 2025 | $20.4M | $32.5M | $11.9M |
| Q4 2024 | $268K | $2.7M | $14M |
| Q3 2024 | $24.6M | $23.7M | $14M |
| Q2 2024 | $33.3M | $25.1M | $3M |
| Q1 2024 | — | $18.2M | $20.5M |
| Q4 2023 | $61.5M | $203.7M | — |
| Q3 2023 | $1.8M | $6.5M | $9.6M |
| Q2 2023 | $12.2M | $64.5M | $15.6M |
| Q1 2023 | — | — | $2.5M |
| Q4 2022 | $138.2M | Not machine-readable | $7.3M |
| Q3 2022 | $15.4M | Not machine-readable | $19M |
| Q2 2022 | $25.9M | Not machine-readable | $2.6M |
| Q1 2022 | $10.9M | Not machine-readable | $6M |
| Q4 2021 | $10.6M | Not machine-readable | $28.8M |
| Q3 2021 | $11.6M | Not machine-readable | $34.5M |
| Q2 2021 | $12.1M | Not machine-readable | $16M |
| Q1 2021 | $123.7M | Not machine-readable | $55.1M |
| Q4 2020 | $8.6M | Not machine-readable | $72.3M |
| Q3 2020 | $45M | Not machine-readable | $57.1M |
| Q2 2020 | $11M | Not machine-readable | $60.5M |
| Q1 2020 | $149.6M | Not machine-readable | $31.2M |
| Q4 2019 | $96.6M | Not machine-readable | $18.4M |
| Q3 2019 | $11.6M | Not machine-readable | $5.7M |
| Q2 2019 | $30.3M | Not machine-readable | $37M |
| Q1 2019 | $20.5M | Not machine-readable | $9.8M |
| Q4 2018 | $23.1M | Not machine-readable | $29.9M |
| Q3 2018 | $43.1M | Not machine-readable | $14.2M |
| Q2 2018 | $13.7M | Not machine-readable | $8M |
| Q1 2018 | $72.2M | Not machine-readable | $34.2M |
| Q4 2017 | $61.7M | Not machine-readable | $17.7M |
| Q3 2017 | $54.5M | Not machine-readable | $4.8M |
| Q2 2017 | — | — | $6.9M |
| Q1 2017 | $20M | Not machine-readable | $10.4M |
| Q3 2016 | $164.3M | Not machine-readable | $3.9M |
| Q2 2016 | — | — | $39.8M |
| Q1 2016 | — | — | $8.3M |
| Q4 2015 | $33.9M | Not machine-readable | $8.9M |
| Q3 2015 | $2.1M | Not machine-readable | $4.4M |
| Q2 2015 | $49.7M | Not machine-readable | — |
| Q1 2015 | $102.1M | Not machine-readable | $2M |
| Q3 2014 | $79.7M | Not machine-readable | $10.9M |
| Q2 2014 | $28.2M | Not machine-readable | — |
| Q4 2013 | $26M | Not machine-readable | $12M |
| Q2 2013 | — | — | $5.7M |
| Q1 2013 | $2.3M | Not machine-readable | $1.1M |
| Q4 2012 | $2.1M | Not machine-readable | $5M |
| Q3 2012 | $12M | Not machine-readable | — |
| Q2 2012 | $8.9M | Not machine-readable | $5.5M |
| Q1 2012 | $7M | Not machine-readable | — |
| Q4 2011 | $2.2M | Not machine-readable | — |
| Q2 2011 | $76.9M | Not machine-readable | — |
| Q1 2011 | $5.9M | Not machine-readable | $3.7M |
| Q4 2010 | $53K | Not machine-readable | $5.4M |
| Q3 2010 | $33.8M | Not machine-readable | $81K |
| Q2 2009 | $8.1M | Not machine-readable | — |
| Q1 2009 | — | — | $126K |
| Q3 2008 | — | — | $549K |
| Q2 2008 | — | — | $26.1M |
| Q1 2008 | $2.2M | Not machine-readable | — |
| Q4 2007 | — | — | $3M |
| Q2 2007 | — | — | $15M |
| Q2 2006 | $9.2M | Not machine-readable | — |
| Q3 2005 | $4.1M | Not machine-readable | — |
| Q2 2004 | $5.1M | Not machine-readable | — |
| Q1 2004 | $790K | Not machine-readable | — |
| Q4 2003 | $4M | Not machine-readable | — |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Enliven Therapeutics IMRA · Jefferies · No 10b5-1 plan stated · 2 notices | ||||
| Jun 22, 2026 | 26,323 · ~$1.2M | Jun 22, 2026 | Not sold within 90 days | Filing · EDGAR |
| Jun 22, 2026 | 833,800 · ~$38.3M | Jun 22, 2026 | Partly sold Sold 811,870 in 2 sales, Jun 22 to Jun 22 · $36.8M likely match Form 4 | Filing · EDGAR |
| Enliven Therapeutics IMRA · Themis Trading · No 10b5-1 plan stated · 2 notices | ||||
| Jun 15, 2026 | 272,322 · ~$11.5M | Jun 15, 2026 | Sold as noticed Sold 273,799 in 2 sales, Jun 15 to Jun 22 · $12.3M Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Jun 15, 2026 | 9,086 · ~$385K | Jun 15, 2026 | Sold as noticed Sold 9,086 at $45.02 on Jun 15 · $409K Form 4 | Filing · EDGAR |
| Sionna Therapeutics SION · TD Cowen · 10b5-1 plan adopted Feb 10, 2025 · 3 notices | ||||
| Jun 1, 2026 | 210,876 · ~$9M | May 29, 2026 | Not sold within 90 days | Filing · EDGAR |
| May 29, 2026 | 1,082,480 · ~$46.3M | May 29, 2026 | Partly sold Sold 201,863 in 3 sales, May 27 to Jul 7 · $9.1M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Nov 24, 2025 | 1,047,770 · ~$46.5M | Nov 24, 2025 | Partly sold Sold 174,257 in 9 sales, Nov 24 to Feb 3 · $7.8M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4) | Filing · EDGAR |
| Adicet Bio TORC · Themis Trading · No 10b5-1 plan stated · 1 notice | ||||
| Apr 9, 2026 | 78,499 · ~$514K | Apr 9, 2026 | Partly sold Sold 64,242 in 3 sales, Apr 7 to Apr 8 · $411K likely match Form 4 | Filing · EDGAR |
| Keros Therapeutics KROS · Themis Trading · No 10b5-1 plan stated · 1 notice | ||||
| Mar 31, 2026 | 45,057 · ~$497K | Mar 31, 2026 | Not sold within 90 days | Filing · EDGAR |
| PMV Pharmaceuticals PMVP · Morgan Stanley · No 10b5-1 plan stated · 1 notice | ||||
| Oct 23, 2025 | 1,000,000 · ~$1.5M | Oct 23, 2025 | Not sold within 90 days | Filing · EDGAR |
| Disc Medicine GMTX · Themis Trading · No 10b5-1 plan stated · 12 notices | ||||
| Oct 20, 2025 | 482,308 · ~$43.4M | Oct 20, 2025 | Not sold within 90 days | Filing · EDGAR |
| Oct 20, 2025 | 186,541 · ~$16.8M | Oct 20, 2025 | Not sold within 90 days | Filing · EDGAR |
| Oct 20, 2025 | 746,171 · ~$67.1M | Oct 20, 2025 | Not sold within 90 days | Filing · EDGAR |
| Mar 10, 2025 | 74,800 · ~$4.2M | Mar 10, 2025 | Not sold within 90 days | Filing · EDGAR |
| Mar 10, 2025 | 193,400 · ~$10.8M | Mar 10, 2025 | Partly sold Sold 68,536 in 12 sales, Mar 12 to Mar 24 · $3.7M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Mar 10, 2025 | 299,200 · ~$16.7M | Mar 10, 2025 | Sold as noticed Sold 302,015 in 15 sales, Mar 10 to Mar 20 · $16.4M Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Dec 15, 2023 | 243,680 · ~$14.9M | Dec 12, 2023 | Not sold within 90 days | Filing · EDGAR |
| Dec 15, 2023 | 630,000 · ~$38.5M | Dec 12, 2023 | Not sold within 90 days | Filing · EDGAR |
| Dec 15, 2023 | 974,720 · ~$59.5M | Dec 12, 2023 | Not sold within 90 days | Filing · EDGAR |
| Dec 12, 2023 | 121,840 · ~$7.4M | Dec 12, 2023 | Not sold within 90 days | Filing · EDGAR |
| Dec 12, 2023 | 315,000 · ~$19.2M | Dec 12, 2023 | Partly sold Sold 147,600 at $56.75 on Dec 14 · $8.4M likely match Form 4 | Filing · EDGAR |
| Dec 12, 2023 | 487,360 · ~$29.7M | Dec 12, 2023 | Partly sold Sold 421,524 in 11 sales, Dec 12 to Dec 18 · $24.2M likely match Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| PMV Pharmaceuticals PMVP · Themis Trading · No 10b5-1 plan stated · 2 notices | ||||
| Sep 10, 2025 | 2,283,654 · ~$3.7M | Sep 10, 2025 | Partly sold Sold 1,500,000 in 2 sales, Sep 10 to Oct 23 · $2.4M likely match Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Nov 22, 2023 | 87,786 · ~$198K | Nov 22, 2023 | Sold as noticed Sold 87,786 at $2.23 on Nov 22 · $196K Form 4 | Filing · EDGAR |
| Passage BIO PASG · Themis Trading · No 10b5-1 plan stated · 7 notices | ||||
| Jul 21, 2025 | 132,645 · ~$738K | Jul 21, 2025 | Not sold within 90 days | Filing · EDGAR |
| Jul 15, 2025 | 53,293 · ~$362K | Jul 15, 2025 | Not sold within 90 days | Filing · EDGAR |
| Jul 7, 2025 | 259,000 · ~$112K | Jul 7, 2025 | Not sold within 90 days | Filing · EDGAR |
| Jun 24, 2025 | 1,076,120 · ~$378K | Jun 24, 2025 | Partly sold Sold 213,257 at $0.33 on Jun 26 · $70K likely match Form 4 | Filing · EDGAR |
| Jan 6, 2025 | 1,140,740 · ~$946K | Jan 6, 2025 | Not sold within 90 days | Filing · EDGAR |
| Dec 4, 2024 | 2,985,518 · ~$2.7M | Dec 4, 2024 | Partly sold Sold 600,564 in 7 sales, Dec 20 to Jan 14 · $384K likely match Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Sep 16, 2024 | 927,572 · ~$749K | Sep 16, 2024 | Partly sold Sold 398,810 in 9 sales, Sep 16 to Dec 11 · $304K likely match Form 4 (1) · Form 4 (2) · Form 4 (3) · Form 4 (4) | Filing · EDGAR |
| Passage BIO PASG · International Strategy & Investment Group · No 10b5-1 plan stated · 1 notice | ||||
| Apr 15, 2025 | 787,179 · ~$301K | Apr 15, 2025 | Partly sold Sold 755,026 in 8 sales, Apr 15 to Jun 25 · $255K likely match Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Compass Therapeutics CMPX · Jefferies · No 10b5-1 plan stated · 1 notice | ||||
| Apr 9, 2025 | 3,571,428 · ~$5.7M | Apr 9, 2025 | Sold as noticed Sold 3,571,428 at $1.59 on Apr 9 · $5.7M Form 4 | Filing · EDGAR |
| Keros Therapeutics KROS · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 2 notices | ||||
| Aug 13, 2024 | 29,400 · ~$1.3M | Aug 13, 2024 | Sold as noticed Sold 29,400 at $44.01 on Aug 13 · $1.3M Form 4 | Filing · EDGAR |
| Aug 13, 2024 | 220,600 · ~$9.9M | Aug 13, 2024 | Sold as noticed Sold 220,600 at $44.01 on Aug 13 · $9.7M Form 4 | Filing · EDGAR |
| Terns Pharmaceuticals · TD Cowen · No 10b5-1 plan stated · 3 notices | ||||
| Jul 15, 2024 | 131,700 · ~$1.2M | Jul 15, 2024 | Not sold within 90 days | Filing · EDGAR |
| Jul 15, 2024 | 976,800 · ~$9.1M | Jul 15, 2024 | Not sold within 90 days | Filing · EDGAR |
| Jul 15, 2024 | 152,400 · ~$1.4M | Jul 15, 2024 | Partly sold Sold 56,164 in 6 sales, Jul 15 to Jul 16 · $562K likely match Form 4 | Filing · EDGAR |
| TELA Bio · Themis Trading · No 10b5-1 plan stated · 2 notices | ||||
| Jun 28, 2024 | 428,386 · ~$2.2M | Jun 28, 2024 | Sold as noticed Sold 428,300 in 3 sales, Jun 28 to Jul 2 · $2M Form 4 | Filing · EDGAR |
| Apr 19, 2023 | 192,000 · ~$2M | Apr 19, 2023 | Sold as noticed Sold 192,000 in 3 sales, Apr 19 to Apr 21 · $1.8M Form 4 | Filing · EDGAR |
| Enliven Therapeutics IMRA · Morgan Stanley · No 10b5-1 plan stated · 2 notices | ||||
| May 17, 2024 | 1,000,000 · ~$22.1M | May 16, 2024 | Sold as noticed Sold 1,000,000 at $22.14 on May 16 · $22.1M Form 4 | Filing · EDGAR |
| May 17, 2024 | 33,300 · ~$737K | May 16, 2024 | Sold as noticed Sold 33,300 at $22.14 on May 16 · $737K Form 4 | Filing · EDGAR |
| Verona Pharma · Themis Trading · No 10b5-1 plan stated · 2 notices | ||||
| Mar 4, 2024 | 1,000,000 · ~$18.2M | Mar 4, 2024 | Not sold within 90 days | Filing · EDGAR |
| May 11, 2023 | 2,575,811 · ~$60.4M | May 11, 2023 | Partly sold Sold 482,913 in 4 sales, May 11 to May 15 · $9.9M likely match Form 4 | Filing · EDGAR |
| Alpine Immune Sciences · Themis Trading · No 10b5-1 plan stated · 2 notices | ||||
| Dec 27, 2023 | 1,385,131 · ~$28M | Dec 27, 2023 | Sold as noticed Sold 1,383,771 in 5 sales, Dec 27 to Dec 28 · $25.4M Form 4 | Filing · EDGAR |
| Dec 27, 2023 | 161,216 · ~$3.3M | Dec 27, 2023 | Sold as noticed Sold 162,576 at $19.96 on Dec 27 · $3.2M Form 4 | Filing · EDGAR |
| Galecto · Merrill Lynch, Pierce, Fenner & Smith · No 10b5-1 plan stated · 2 notices | ||||
| Oct 2, 2023 | 37,675 · ~$27K | Oct 2, 2023 | Not sold within 90 days | Filing · EDGAR |
| Oct 2, 2023 | 585,274 · ~$421K | Oct 2, 2023 | Not sold within 90 days | Filing · EDGAR |
| NeuroPace NPCE · JP Morgan Chase · No 10b5-1 plan stated · 1 notice | ||||
| Oct 2, 2023 | 288,100 · ~$2.6M | Oct 2, 2023 | Partly sold Sold 8,314 in 2 sales, Oct 2 to Oct 3 · $75K likely match Form 4 | Filing · EDGAR |
| Galecto · Bank of America · No 10b5-1 plan stated · 13 notices | ||||
| Aug 30, 2023 | 78,659 · ~$46K | Aug 30, 2023 | Not sold within 90 days | Filing · EDGAR |
| Aug 30, 2023 | 1,222,125 · ~$709K | Aug 30, 2023 | Not sold within 90 days | Filing · EDGAR |
| Aug 21, 2023 | 97,204 · ~$60K | Aug 21, 2023 | Not sold within 90 days | Filing · EDGAR |
| Aug 21, 2023 | 1,510,375 · ~$932K | Aug 21, 2023 | Not sold within 90 days | Filing · EDGAR |
| Aug 21, 2023 | 75,473 · ~$57K | Aug 15, 2023 | Not sold within 90 days | Filing · EDGAR |
| Aug 15, 2023 | 1,172,714 · ~$880K | Aug 15, 2023 | Not sold within 90 days | Filing · EDGAR |
| Aug 15, 2023 | 75,473 · ~$57K | Aug 15, 2023 | Not sold within 90 days | Filing · EDGAR |
| Jul 31, 2023 | 930,717 · ~$2.8M | Jul 31, 2023 | Sold as noticed Sold 937,431 in 3 sales, Jul 31 to Aug 15 · $1M Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Jul 31, 2023 | 162,153 · ~$490K | Jul 31, 2023 | Partly sold Sold 68,027 in 2 sales, Jul 31 to Aug 15 · $118K likely match Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Jul 25, 2023 | 26,700 · ~$63K | Jul 25, 2023 | Not sold within 90 days | Filing · EDGAR |
| Jul 25, 2023 | 7,800 · ~$18K | Jul 25, 2023 | Not sold within 90 days | Filing · EDGAR |
| Jul 13, 2023 | 132,100 · ~$337K | Jul 13, 2023 | Partly sold Sold 118,622 in 5 sales, Jul 13 to Jul 31 · $321K likely match Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Jul 13, 2023 | 9,800 · ~$25K | Jul 13, 2023 | Sold as noticed Sold 9,800 at $2.40 on Jul 13 · $24K Form 4 | Filing · EDGAR |
| Gracell Biotechnologies · Themis Trading · No 10b5-1 plan stated · 1 notice | ||||
| Jun 15, 2023 | 305,748 · ~$1.8M | Jun 15, 2023 | Not sold within 90 days | Filing · EDGAR |
| Galecto · Themis Trading · No 10b5-1 plan stated · 4 notices | ||||
| Apr 10, 2023 | 1,686 · ~$3K | Apr 10, 2023 | Not sold within 90 days | Filing · EDGAR |
| Apr 10, 2023 | 22,638 · ~$43K | Apr 10, 2023 | Partly sold Sold 19,541 in 3 sales, Apr 10 to Apr 17 · $36K likely match Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Apr 5, 2023 | 109,532 · ~$245K | Apr 5, 2023 | Sold as noticed Sold 109,298 in 11 sales, Apr 5 to Apr 17 · $232K Form 4 (1) · Form 4 (2) · Form 4 (3) | Filing · EDGAR |
| Apr 5, 2023 | 8,143 · ~$18K | Apr 5, 2023 | Partly sold Sold 7,913 in 4 sales, Apr 5 to Apr 12 · $17K likely match Form 4 (1) · Form 4 (2) | Filing · EDGAR |
| Sales without a matching Form 144 · 595 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Sold without notice Enliven Therapeutics (IMRA): Sold 46,776 at $45.00 on Jun 22, 2026 · $2.1M | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 184,639 at $46.22 on May 11, 2026 · $8.5M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 59,767 at $44.58 on May 8, 2026 · $2.7M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 48,546 at $44.61 on May 7, 2026 · $2.2M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 2,948 at $44.52 on Apr 18, 2026 · $131K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 52,397 at $44.68 on Apr 17, 2026 · $2.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 226,906 at $45.34 on Apr 16, 2026 · $10.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 235,863 at $44.64 on Apr 15, 2026 · $10.5M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Sionna Therapeutics (SION): Sold 47,814 at $44.51 on Apr 14, 2026 · $2.1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Sold without notice Adicet Bio (TORC): Sold 40,416 at $6.52 on Apr 8, 2026 · $264K | Filing · EDGAR |
| — | — | — | Sold without notice Corvus Pharmaceuticals (CRVS): Sold 1,176,332 at $4.16 on Jun 27, 2025 · $4.9M | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 34,000 at $15.94 on May 14, 2025 · $542K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 134,136 at $15.83 on May 14, 2025 · $2.1M | Filing · EDGAR |
| — | — | — | Sold without notice Xtant Medical Holdings (XTNT): Sold 17,109,618 at $0.42 on Apr 10, 2025 · $7.2M | Filing · EDGAR |
| — | — | — | Sold without notice Xtant Medical Holdings (XTNT): Sold 56,004,974 at $0.42 on Apr 10, 2025 · $23.5M | Filing · EDGAR |
| — | — | — | Sold without notice ARS Pharmaceuticals: Sold 83,695 at $13.00 on Aug 26, 2024 · $1.1M | Filing · EDGAR |
| — | — | — | Sold without notice ARS Pharmaceuticals: Sold 69,500 at $13.03 on Aug 23, 2024 · $906K | Filing · EDGAR |
| — | — | — | Sold without notice ARS Pharmaceuticals: Sold 391,482 at $12.94 on Aug 22, 2024 · $5.1M | Filing · EDGAR |
| — | — | — | Sold without notice ARS Pharmaceuticals: Sold 13,300 at $14.61 on Aug 21, 2024 · $194K | Filing · EDGAR |
| — | — | — | Sold without notice ARS Pharmaceuticals: Sold 394,400 at $13.52 on Aug 21, 2024 · $5.3M | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 4,674 at $14.03 on May 3, 2024 · $66K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 8,842 at $14.01 on May 2, 2024 · $124K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 15,690 at $14.02 on May 1, 2024 · $220K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 1,781 at $14.06 on Apr 24, 2024 · $25K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 21,791 at $14.29 on Apr 23, 2024 · $311K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 24,609 at $14.05 on Apr 22, 2024 · $346K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 18,253 at $14.02 on Apr 19, 2024 · $256K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 2,623 at $14.06 on Apr 18, 2024 · $37K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 300 at $14.15 on Apr 17, 2024 · $4K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 14,069 at $14.01 on Apr 16, 2024 · $197K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 23,101 at $14.42 on Apr 12, 2024 · $333K | Filing · EDGAR |
| — | — | — | Sold without notice NeuroPace (NPCE): Sold 461,899 at $14.49 on Apr 11, 2024 · $6.7M | Filing · EDGAR |
| — | — | — | Sold without notice Galecto: Sold 132,100 at $2.40 on Jul 13, 2023 · $317K | Filing · EDGAR |
| — | — | — | Sold without notice Galecto: Sold 8,878 at $1.97 on Apr 17, 2023 · $17K | Filing · EDGAR |
| — | — | — | Sold without notice Galecto: Sold 28,110 at $1.86 on Apr 14, 2023 · $52K | Filing · EDGAR |
| — | — | — | Sold without notice Galecto: Sold 11,245 at $1.86 on Apr 14, 2023 · $21K | Filing · EDGAR |
| — | — | — | Sold without notice Galecto: Sold 9,459 at $1.82 on Apr 13, 2023 · $17K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Galecto: Sold 9,459 at $1.82 on Apr 11, 2023 · $17K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Galecto: Sold 34,745 at $1.79 on Apr 10, 2023 · $62K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Verona Pharma: Sold 92,992 at $24.11 on Dec 23, 2022 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Verona Pharma: Sold 1,116,048 at $23.23 on Dec 23, 2022 · $25.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Verona Pharma: Sold 961,328 at $22.27 on Dec 23, 2022 · $21.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Verona Pharma: Sold 684,696 at $22.07 on Dec 22, 2022 · $15.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Verona Pharma: Sold 3,284,800 at $21.71 on Dec 22, 2022 · $71.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Tricida: Sold 3,629,226 at $0.22 on Nov 25, 2022 · $798K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Tricida: Sold 5,617,300 at $0.21 on Nov 23, 2022 · $1.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Tricida: Sold 1,034,421 at $0.22 on Nov 22, 2022 · $228K | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 30,000 at $31.98 on Sep 12, 2022 · $959K | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 123,897 at $31.96 on Sep 12, 2022 · $4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 69,568 at $37.47 on Aug 9, 2022 · $2.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 205,000 at $38.33 on Aug 8, 2022 · $7.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 35,944 at $21.31 on Jun 24, 2022 · $766K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 306,027 at $21.31 on Jun 24, 2022 · $6.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 26,253 at $15.93 on May 26, 2022 · $418K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 102,800 at $20.71 on Apr 8, 2022 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 97,200 at $20.71 on Apr 8, 2022 · $2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 177,196 at $20.66 on Apr 7, 2022 · $3.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 167,800 at $20.66 on Apr 7, 2022 · $3.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 171,204 at $20.69 on Apr 6, 2022 · $3.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Arcutis Biotherapeutics: Sold 162,000 at $20.69 on Apr 6, 2022 · $3.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 34,500 at $21.17 on Mar 31, 2022 · $730K | Filing · EDGAR |
| — | — | — | Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 75,000 at $22.39 on Mar 30, 2022 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable PMV Pharmaceuticals (PMVP): Sold 365,000 at $21.52 on Mar 29, 2022 · $7.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable 89bio: Sold 10,740 at $8.38 on Jan 26, 2022 · $90K | Filing · EDGAR |
| — | — | — | Notice not machine-readable 89bio: Sold 10,742 at $8.38 on Jan 26, 2022 · $90K | Filing · EDGAR |
| — | — | — | Notice not machine-readable 89bio: Sold 24,545 at $8.40 on Jan 25, 2022 · $206K | Filing · EDGAR |
| — | — | — | Notice not machine-readable 89bio: Sold 24,546 at $8.40 on Jan 25, 2022 · $206K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Janux Therapeutics: Sold 3,700 at $20.30 on Dec 29, 2021 · $75K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Janux Therapeutics: Sold 36,700 at $20.30 on Dec 29, 2021 · $745K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Janux Therapeutics: Sold 11,100 at $19.00 on Dec 21, 2021 · $211K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Janux Therapeutics: Sold 108,300 at $19.00 on Dec 21, 2021 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Janux Therapeutics: Sold 36,500 at $19.07 on Dec 16, 2021 · $696K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Janux Therapeutics: Sold 356,800 at $19.07 on Dec 16, 2021 · $6.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Corvus Pharmaceuticals (CRVS): Sold 1,109,644 at $6.09 on Sep 20, 2021 · $6.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 26 at $33.93 on Sep 7, 2021 · $882 (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 861 at $33.93 on Sep 7, 2021 · $29K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 212 at $34.00 on Sep 3, 2021 · $7K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 6,985 at $34.00 on Sep 3, 2021 · $237K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 483 at $34.24 on Sep 2, 2021 · $17K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 15,941 at $34.24 on Sep 2, 2021 · $546K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 382 at $33.98 on Sep 1, 2021 · $13K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 12,586 at $33.98 on Sep 1, 2021 · $428K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 249 at $33.94 on Aug 31, 2021 · $8K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 8,223 at $33.94 on Aug 31, 2021 · $279K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 197 at $33.92 on Aug 30, 2021 · $7K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 6,500 at $33.92 on Aug 30, 2021 · $220K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 209 at $33.94 on Aug 27, 2021 · $7K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 6,884 at $33.94 on Aug 27, 2021 · $234K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 126 at $34.52 on Aug 26, 2021 · $4K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 4,157 at $34.52 on Aug 26, 2021 · $143K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 208 at $34.34 on Aug 25, 2021 · $7K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 6,874 at $34.34 on Aug 25, 2021 · $236K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 119 at $34.07 on Aug 24, 2021 · $4K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 3,920 at $34.07 on Aug 24, 2021 · $134K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 209 at $34.06 on Aug 23, 2021 · $7K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 6,885 at $34.06 on Aug 23, 2021 · $235K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 78 at $33.99 on Aug 18, 2021 · $3K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 2,852 at $33.99 on Aug 18, 2021 · $97K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 512 at $34.12 on Aug 17, 2021 · $17K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Repare Therapeutics: Sold 16,886 at $34.12 on Aug 17, 2021 · $576K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 15,959 at $85.01 on Jul 1, 2021 · $1.4M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 6,502 at $85.17 on Jun 28, 2021 · $554K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 22,334 at $85.14 on Jun 25, 2021 · $1.9M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 34,200 at $85.22 on Jun 24, 2021 · $2.9M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 100 at $85.00 on Jun 23, 2021 · $9K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 30,852 at $85.09 on Jun 10, 2021 · $2.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 5,049 at $85.33 on Jun 9, 2021 · $431K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 42,633 at $85.37 on Jun 8, 2021 · $3.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 371 at $84.90 on Jun 7, 2021 · $31K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 27,869 at $23.93 on Mar 30, 2021 · $667K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 75,555 at $23.31 on Mar 29, 2021 · $1.8M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 27,816 at $23.88 on Mar 26, 2021 · $664K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 51,523 at $24.70 on Mar 25, 2021 · $1.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 32,959 at $24.80 on Mar 24, 2021 · $817K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 3,992 at $24.32 on Mar 23, 2021 · $97K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 7,673 at $26.47 on Mar 22, 2021 · $203K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 21,275 at $26.47 on Mar 19, 2021 · $563K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 6,059 at $28.03 on Mar 18, 2021 · $170K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 18,790 at $28.43 on Mar 17, 2021 · $534K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 41,353 at $27.72 on Mar 16, 2021 · $1.1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 89,210 at $29.14 on Mar 15, 2021 · $2.6M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 90,521 at $30.29 on Mar 12, 2021 · $2.7M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Oric Pharmaceuticals: Sold 58,551 at $33.04 on Mar 11, 2021 · $1.9M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable SpringWorks Therapeutics: Sold 1,220,000 at $83.19 on Mar 1, 2021 · $101.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Cti Biopharma: Sold 2,000,000 at $3.50 on Jan 7, 2021 · $7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alpine Immune Sciences: Sold 600,000 at $14.25 on Dec 28, 2020 · $8.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Aerpio Pharmaceuticals: Sold 21,400 at $1.96 on Dec 8, 2020 · $42K | Filing · EDGAR |
| — | — | — | Notice not machine-readable 89bio: Sold 137,500 at $28.00 on Sep 21, 2020 · $3.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable 89bio: Sold 137,500 at $28.00 on Sep 21, 2020 · $3.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 43,543 at $108.54 on Aug 18, 2020 · $4.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 94,900 at $107.49 on Aug 17, 2020 · $10.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 20,257 at $109.03 on Aug 14, 2020 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 29,251 at $109.93 on Aug 13, 2020 · $3.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 42,679 at $107.45 on Aug 12, 2020 · $4.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 39,877 at $105.78 on Aug 11, 2020 · $4.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 47,700 at $105.23 on Aug 10, 2020 · $5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 28,993 at $106.18 on Aug 7, 2020 · $3.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 15,086 at $23.53 on Apr 16, 2020 · $355K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 47,097 at $23.53 on Apr 16, 2020 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 5,636 at $23.52 on Apr 14, 2020 · $133K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 17,595 at $23.52 on Apr 14, 2020 · $414K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 69,893 at $23.79 on Apr 9, 2020 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 218,208 at $23.79 on Apr 9, 2020 · $5.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 20,041 at $23.65 on Apr 8, 2020 · $474K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 62,573 at $23.65 on Apr 8, 2020 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 2,224 at $23.10 on Apr 7, 2020 · $51K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 6,946 at $23.10 on Apr 7, 2020 · $160K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 60,645 at $24.50 on Mar 31, 2020 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 189,355 at $24.50 on Mar 31, 2020 · $4.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 13,684 at $24.66 on Mar 25, 2020 · $337K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 42,727 at $24.66 on Mar 25, 2020 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 16,409 at $24.45 on Mar 24, 2020 · $401K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 51,235 at $24.45 on Mar 24, 2020 · $1.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 3,541 at $26.05 on Mar 23, 2020 · $92K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 11,057 at $26.05 on Mar 23, 2020 · $288K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 500,000 at $83.52 on Mar 6, 2020 · $41.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 400,000 at $84.42 on Mar 3, 2020 · $33.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 25,000 at $84.55 on Mar 3, 2020 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 75,000 at $83.21 on Mar 3, 2020 · $6.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 38,808 at $26.00 on Mar 2, 2020 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 445,086 at $26.00 on Mar 2, 2020 · $11.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 1,390,309 at $26.00 on Mar 2, 2020 · $36.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 1,392 at $19.50 on Jan 9, 2020 · $27K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 91,818 at $19.50 on Jan 9, 2020 · $1.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 286,787 at $19.50 on Jan 9, 2020 · $5.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 1,200 at $18.60 on Dec 26, 2019 · $22K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 2,325 at $18.60 on Dec 26, 2019 · $43K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 7,275 at $18.60 on Dec 26, 2019 · $135K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 8,000 at $19.59 on Dec 24, 2019 · $157K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 15,476 at $19.59 on Dec 24, 2019 · $303K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 48,324 at $19.59 on Dec 24, 2019 · $947K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 10,400 at $19.82 on Dec 23, 2019 · $206K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 20,350 at $19.82 on Dec 23, 2019 · $403K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 63,535 at $19.82 on Dec 23, 2019 · $1.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 37,900 at $19.66 on Dec 20, 2019 · $745K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 73,879 at $19.66 on Dec 20, 2019 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 230,721 at $19.66 on Dec 20, 2019 · $4.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 105,500 at $18.52 on Dec 17, 2019 · $2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 205,793 at $18.52 on Dec 17, 2019 · $3.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 642,807 at $18.52 on Dec 17, 2019 · $11.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Tricida: Sold 1,500,000 at $40.00 on Dec 11, 2019 · $60M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 2,306 at $72.13 on Nov 27, 2019 · $166K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 47,981 at $71.67 on Nov 27, 2019 · $3.4M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 3,100 at $70.60 on Nov 27, 2019 · $219K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 50,478 at $70.16 on Nov 26, 2019 · $3.5M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 20,135 at $69.55 on Nov 26, 2019 · $1.4M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 157,636 at $17.90 on Aug 7, 2019 · $2.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Alector: Sold 492,364 at $17.90 on Aug 7, 2019 · $8.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Principia Biopharma: Sold 1,000,000 at $30.25 on May 21, 2019 · $30.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 290,231 at $57.75 on Mar 8, 2019 · $16.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 68,218 at $55.01 on Mar 7, 2019 · $3.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Inspire Medical Systems: Sold 614,772 at $37.60 on Dec 11, 2018 · $23.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable SteadyMed: Sold 2,123,098 at $4.46 on Aug 30, 2018 · $9.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable SteadyMed: Sold 2,123,098 at $4.46 on Aug 30, 2018 · $9.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 153,921 at $9.98 on Aug 20, 2018 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 153,921 at $9.98 on Aug 20, 2018 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 3,455 at $9.94 on Aug 16, 2018 · $34K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 362,765 at $9.94 on Aug 16, 2018 · $3.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 736 at $9.93 on Aug 15, 2018 · $7K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 77,314 at $9.93 on Aug 15, 2018 · $768K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 198 at $9.94 on Aug 14, 2018 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 20,777 at $9.94 on Aug 14, 2018 · $207K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 820 at $9.98 on Aug 13, 2018 · $8K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 86,103 at $9.98 on Aug 13, 2018 · $859K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 6,460 at $9.96 on Aug 10, 2018 · $64K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 678,333 at $9.96 on Aug 10, 2018 · $6.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 249 at $9.86 on Aug 9, 2018 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 26,139 at $9.86 on Aug 9, 2018 · $258K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 615 at $9.91 on Aug 9, 2018 · $6K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 64,575 at $9.91 on Aug 9, 2018 · $640K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 1,036 at $9.95 on Aug 9, 2018 · $10K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 108,729 at $9.95 on Aug 9, 2018 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 4,553 at $10.00 on Aug 8, 2018 · $46K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 478,107 at $10.00 on Aug 8, 2018 · $4.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 478 at $10.01 on Aug 7, 2018 · $5K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 50,149 at $10.01 on Aug 7, 2018 · $502K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 1,125 at $11.71 on Aug 3, 2018 · $13K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ViewRay: Sold 118,168 at $11.71 on Aug 3, 2018 · $1.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 1,600 at $13.49 on Jun 6, 2018 · $22K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 17,100 at $13.57 on Jun 4, 2018 · $232K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 50,000 at $13.49 on Jun 1, 2018 · $675K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 121,000 at $13.52 on May 30, 2018 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Rhythm Pharmaceuticals: Sold 1,600 at $30.96 on May 22, 2018 · $50K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Rhythm Pharmaceuticals: Sold 17,980 at $30.38 on May 22, 2018 · $546K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Rhythm Pharmaceuticals: Sold 62,500 at $31.01 on May 21, 2018 · $1.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Rhythm Pharmaceuticals: Sold 69,136 at $30.77 on May 18, 2018 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 10,300 at $13.50 on May 14, 2018 · $139K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 10,400 at $6.35 on Apr 30, 2018 · $66K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 989,600 at $6.35 on Apr 30, 2018 · $6.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 31,983 at $11.53 on Mar 29, 2018 · $369K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Adaptimmune Therapeutics: Sold 1,016,084 at $11.50 on Mar 27, 2018 · $11.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 16,937 at $34.92 on Mar 12, 2018 · $591K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 1,066 at $36.04 on Mar 12, 2018 · $38K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 11,305 at $36.44 on Mar 9, 2018 · $412K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 47,395 at $35.86 on Mar 9, 2018 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 21,300 at $34.67 on Mar 9, 2018 · $738K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 58,428 at $34.06 on Mar 8, 2018 · $2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 445 at $32.06 on Mar 6, 2018 · $14K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 46,676 at $32.06 on Mar 6, 2018 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 192 at $30.77 on Mar 6, 2018 · $6K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 20,114 at $30.77 on Mar 6, 2018 · $619K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 886 at $30.01 on Mar 6, 2018 · $27K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 93,008 at $30.01 on Mar 6, 2018 · $2.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 11,372 at $33.03 on Mar 6, 2018 · $376K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 768 at $33.06 on Mar 5, 2018 · $25K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 80,516 at $33.06 on Mar 5, 2018 · $2.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,220 at $32.05 on Mar 5, 2018 · $39K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 128,092 at $32.05 on Mar 5, 2018 · $4.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 200 at $36.06 on Mar 5, 2018 · $7K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,851 at $32.80 on Mar 2, 2018 · $61K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 194,433 at $32.80 on Mar 2, 2018 · $6.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 2,533 at $31.92 on Mar 2, 2018 · $81K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 265,766 at $31.92 on Mar 2, 2018 · $8.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 35,558 at $36.33 on Mar 2, 2018 · $1.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 386,080 at $35.06 on Mar 2, 2018 · $13.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 75 at $8.98 on Feb 13, 2018 · $674 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 7,822 at $8.98 on Feb 13, 2018 · $70K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 16,128 at $7.35 on Jan 3, 2018 · $119K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 1,693,492 at $7.35 on Jan 3, 2018 · $12.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 1,392 at $5.70 on Dec 18, 2017 · $8K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pieris Pharmaceuticals: Sold 146,243 at $5.70 on Dec 18, 2017 · $834K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 250,000 at $82.50 on Dec 8, 2017 · $20.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 267,000 at $75.00 on Nov 22, 2017 · $20M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 8,377 at $76.23 on Nov 16, 2017 · $639K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 71,598 at $75.37 on Nov 16, 2017 · $5.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 100,045 at $74.49 on Nov 16, 2017 · $7.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 43,300 at $73.48 on Nov 16, 2017 · $3.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 46,680 at $72.46 on Nov 16, 2017 · $3.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 1,899 at $0.68 on Oct 3, 2017 · $1K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 199,718 at $0.68 on Oct 3, 2017 · $136K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 888 at $0.74 on Sep 29, 2017 · $657 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 93,246 at $0.74 on Sep 29, 2017 · $69K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 672,000 at $28.25 on Sep 29, 2017 · $19M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 3,592 at $0.72 on Sep 28, 2017 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 376,950 at $0.72 on Sep 28, 2017 · $271K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 498 at $0.92 on Sep 27, 2017 · $458 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 52,301 at $0.92 on Sep 27, 2017 · $48K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 706 at $1.03 on Sep 26, 2017 · $727 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 74,096 at $1.03 on Sep 26, 2017 · $76K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Audentes Therapeutics: Sold 5,000 at $22.35 on Sep 7, 2017 · $112K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 553 at $40.77 on Sep 5, 2017 · $23K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 58,047 at $40.77 on Sep 5, 2017 · $2.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,808 at $39.63 on Sep 5, 2017 · $72K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 189,792 at $39.63 on Sep 5, 2017 · $7.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,651 at $37.94 on Sep 5, 2017 · $63K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 173,349 at $37.94 on Sep 5, 2017 · $6.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,038 at $37.72 on Sep 1, 2017 · $39K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 109,040 at $37.72 on Sep 1, 2017 · $4.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 424 at $37.82 on Aug 31, 2017 · $16K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 44,498 at $37.82 on Aug 31, 2017 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 125 at $1.50 on Aug 24, 2017 · $188 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 13,075 at $1.50 on Aug 24, 2017 · $20K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 10 at $1.50 on Aug 23, 2017 · $15 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 1,090 at $1.50 on Aug 23, 2017 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 52 at $1.52 on Aug 22, 2017 · $79 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 5,448 at $1.52 on Aug 22, 2017 · $8K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 28 at $1.49 on Aug 21, 2017 · $42 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 2,952 at $1.49 on Aug 21, 2017 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 630 at $1.52 on Aug 18, 2017 · $958 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Roka BioScience: Sold 66,166 at $1.52 on Aug 18, 2017 · $101K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 2,140 at $37.85 on Aug 17, 2017 · $81K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 224,780 at $37.85 on Aug 17, 2017 · $8.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 619 at $38.01 on Aug 16, 2017 · $24K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 64,961 at $38.01 on Aug 16, 2017 · $2.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 307 at $38.29 on Aug 15, 2017 · $12K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 32,193 at $38.29 on Aug 15, 2017 · $1.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 699 at $44.54 on Mar 14, 2017 · $31K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 73,401 at $44.54 on Mar 14, 2017 · $3.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 7 at $46.13 on Mar 13, 2017 · $323 | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 693 at $46.13 on Mar 13, 2017 · $32K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,998 at $45.30 on Mar 13, 2017 · $91K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 208,712 at $45.30 on Mar 13, 2017 · $9.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 915 at $45.98 on Mar 10, 2017 · $42K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 96,113 at $45.98 on Mar 10, 2017 · $4.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 526 at $47.05 on Mar 3, 2017 · $25K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 55,246 at $47.05 on Mar 3, 2017 · $2.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 133 at $33.72 on Aug 12, 2016 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 13,967 at $33.72 on Aug 12, 2016 · $471K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,518 at $33.63 on Aug 11, 2016 · $51K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 159,382 at $33.63 on Aug 11, 2016 · $5.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 1,113 at $33.77 on Aug 10, 2016 · $38K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 116,825 at $33.77 on Aug 10, 2016 · $3.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Loxo Oncology: Sold 447,857 at $26.96 on Aug 10, 2016 · $12.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 4,010 at $30.59 on Aug 3, 2016 · $123K | Filing · EDGAR |
| — | — | — | Notice not machine-readable GLAUKOS: Sold 420,990 at $30.59 on Aug 3, 2016 · $12.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 343,600 at $31.98 on Jul 25, 2016 · $11M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 3,700,000 at $32.00 on Jul 22, 2016 · $118.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 52,058 at $27.54 on Dec 23, 2015 · $1.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 47,942 at $26.78 on Dec 23, 2015 · $1.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 38,630 at $27.02 on Dec 22, 2015 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 111,370 at $26.39 on Dec 22, 2015 · $2.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 14,171 at $28.39 on Dec 21, 2015 · $402K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 235,829 at $27.50 on Dec 21, 2015 · $6.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 590 at $29.22 on Nov 30, 2015 · $17K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 2,716 at $28.64 on Nov 30, 2015 · $78K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 29,000 at $28.97 on Nov 27, 2015 · $840K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 34,800 at $28.91 on Nov 25, 2015 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 36,100 at $28.75 on Nov 24, 2015 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 80,800 at $28.45 on Nov 23, 2015 · $2.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 83,900 at $28.59 on Nov 20, 2015 · $2.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 127,300 at $28.60 on Nov 19, 2015 · $3.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 200 at $29.09 on Nov 17, 2015 · $6K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Otonomy: Sold 10,898 at $28.80 on Nov 17, 2015 · $314K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 2,785 at $5.98 on Oct 12, 2015 · $17K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 285,106 at $5.98 on Oct 12, 2015 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 2,041 at $7.03 on Oct 9, 2015 · $14K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 210,668 at $7.03 on Oct 9, 2015 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 3,837 at $7.24 on Oct 8, 2015 · $28K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 396,163 at $7.24 on Oct 8, 2015 · $2.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 454 at $7.36 on Oct 7, 2015 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 53,446 at $7.36 on Oct 7, 2015 · $393K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 59 at $7.80 on Oct 6, 2015 · $460 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 6,941 at $7.80 on Oct 6, 2015 · $54K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 1,163 at $8.19 on Oct 5, 2015 · $10K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 136,937 at $8.19 on Oct 5, 2015 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 403 at $10.34 on Oct 2, 2015 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 47,497 at $10.34 on Oct 2, 2015 · $491K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 400 at $10.34 on Oct 1, 2015 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 47,100 at $10.34 on Oct 1, 2015 · $487K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 369 at $10.17 on Sep 30, 2015 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 43,471 at $10.17 on Sep 30, 2015 · $442K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 89 at $10.08 on Sep 29, 2015 · $897 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 10,469 at $10.08 on Sep 29, 2015 · $106K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 89 at $10.30 on Sep 28, 2015 · $917 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 10,513 at $10.30 on Sep 28, 2015 · $108K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 311 at $11.07 on Sep 25, 2015 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 66,489 at $11.07 on Sep 25, 2015 · $736K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 800 at $10.07 on Sep 25, 2015 · $8K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 64,400 at $10.07 on Sep 25, 2015 · $649K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 8,152 at $11.00 on Sep 24, 2015 · $90K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 148 at $11.00 on Sep 24, 2015 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Sientra: Sold 6 at $9.78 on Sep 24, 2015 · $59 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 1,457,551 at $34.13 on May 18, 2015 · $49.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 90 at $294.82 on Mar 26, 2015 · $27K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 2,500 at $293.85 on Mar 26, 2015 · $735K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 6,000 at $292.13 on Mar 26, 2015 · $1.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,700 at $291.12 on Mar 26, 2015 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 13,974 at $290.02 on Mar 26, 2015 · $4.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 15,131 at $289.07 on Mar 26, 2015 · $4.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 26,028 at $288.11 on Mar 26, 2015 · $7.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 18,041 at $287.16 on Mar 26, 2015 · $5.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 7,611 at $286.24 on Mar 26, 2015 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 23,903 at $285.18 on Mar 26, 2015 · $6.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 16,845 at $284.20 on Mar 26, 2015 · $4.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 9,357 at $282.87 on Mar 26, 2015 · $2.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 8,397 at $282.13 on Mar 26, 2015 · $2.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 5,623 at $281.11 on Mar 26, 2015 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 2,800 at $270.23 on Mar 25, 2015 · $757K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,844 at $275.56 on Mar 24, 2015 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 12,066 at $275.00 on Mar 24, 2015 · $3.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 2,700 at $273.19 on Mar 24, 2015 · $738K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,050 at $272.13 on Mar 24, 2015 · $830K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 6,063 at $271.15 on Mar 24, 2015 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 9,574 at $270.13 on Mar 24, 2015 · $2.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,539 at $269.10 on Mar 24, 2015 · $414K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 6,764 at $268.13 on Mar 24, 2015 · $1.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,000 at $288.60 on Mar 23, 2015 · $289K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,400 at $286.04 on Mar 23, 2015 · $400K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 52 at $283.44 on Mar 23, 2015 · $15K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,548 at $283.29 on Mar 23, 2015 · $439K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,500 at $282.00 on Mar 23, 2015 · $987K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 6,306 at $281.01 on Mar 23, 2015 · $1.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 9,465 at $280.00 on Mar 23, 2015 · $2.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,668 at $279.00 on Mar 23, 2015 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 14,152 at $278.00 on Mar 23, 2015 · $3.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 8,195 at $276.96 on Mar 23, 2015 · $2.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 37,666 at $275.95 on Mar 23, 2015 · $10.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,579 at $274.86 on Mar 23, 2015 · $984K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 11,869 at $273.89 on Mar 23, 2015 · $3.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 8,638 at $272.79 on Mar 23, 2015 · $2.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 7,764 at $271.70 on Mar 23, 2015 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 40,598 at $270.70 on Mar 23, 2015 · $11M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 49,000 at $25.07 on Sep 17, 2014 · $1.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 2,600 at $26.06 on Sep 16, 2014 · $68K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 42,400 at $25.45 on Sep 16, 2014 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 400 at $302.34 on Aug 26, 2014 · $121K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 5,400 at $301.36 on Aug 26, 2014 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 45,058 at $300.11 on Aug 26, 2014 · $13.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 10,400 at $299.13 on Aug 26, 2014 · $3.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,990 at $297.26 on Aug 25, 2014 · $592K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 10,010 at $296.59 on Aug 25, 2014 · $3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 25,442 at $295.52 on Aug 25, 2014 · $7.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 12,558 at $294.67 on Aug 25, 2014 · $3.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Relypsa: Sold 990,000 at $26.35 on Aug 15, 2014 · $26.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 350 at $308.13 on Aug 14, 2014 · $108K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 14,640 at $307.06 on Aug 14, 2014 · $4.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 525 at $306.23 on Aug 14, 2014 · $161K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,732 at $305.14 on Aug 14, 2014 · $529K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,193 at $303.77 on Aug 14, 2014 · $362K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,100 at $302.55 on Aug 14, 2014 · $333K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 1,710 at $301.42 on Aug 14, 2014 · $515K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,985 at $300.21 on Aug 14, 2014 · $1.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 100 at $298.61 on Aug 14, 2014 · $30K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 9,985 at $297.76 on Aug 14, 2014 · $3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 6,192 at $296.86 on Aug 14, 2014 · $1.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 7,062 at $296.21 on Aug 14, 2014 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,254 at $294.96 on Aug 14, 2014 · $960K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 4,468 at $293.85 on Aug 14, 2014 · $1.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 3,704 at $292.70 on Aug 14, 2014 · $1.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirati Therapeutics: Sold 5,000 at $20.04 on Jul 1, 2014 · $100K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirati Therapeutics: Sold 4,717 at $21.11 on Jun 30, 2014 · $100K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirati Therapeutics: Sold 9,283 at $20.33 on Jun 30, 2014 · $189K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirati Therapeutics: Sold 9,212 at $23.09 on Jun 27, 2014 · $213K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirati Therapeutics: Sold 79,120 at $21.79 on Jun 27, 2014 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 81,305 at $320.00 on Apr 9, 2014 · $26M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 40,088 at $62.50 on Oct 21, 2013 · $2.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Intercept Pharmaceuticals: Sold 376,585 at $62.50 on Oct 15, 2013 · $23.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Supernus Pharmaceuticals: Sold 41,100 at $7.58 on Feb 13, 2013 · $311K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Supernus Pharmaceuticals: Sold 108,900 at $7.58 on Feb 13, 2013 · $825K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Supernus Pharmaceuticals: Sold 41,483 at $7.52 on Feb 12, 2013 · $312K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Supernus Pharmaceuticals: Sold 110,700 at $7.52 on Feb 12, 2013 · $833K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Supernus Pharmaceuticals: Sold 100,000 at $7.08 on Dec 18, 2012 · $708K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Supernus Pharmaceuticals: Sold 197,815 at $6.85 on Dec 17, 2012 · $1.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 2,244 at $14.43 on Sep 4, 2012 · $32K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 231,456 at $14.43 on Sep 4, 2012 · $3.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 3,456 at $14.61 on Jul 27, 2012 · $50K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 362,844 at $14.61 on Jul 27, 2012 · $5.3M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Complete Genomics: Sold 4,500 at $2.51 on Jul 13, 2012 · $11K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Complete Genomics: Sold 474,800 at $2.51 on Jul 13, 2012 · $1.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Complete Genomics: Sold 2,076 at $2.85 on Jul 12, 2012 · $6K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Complete Genomics: Sold 218,624 at $2.85 on Jul 12, 2012 · $623K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Complete Genomics: Sold 4,792 at $2.90 on Jul 11, 2012 · $14K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Complete Genomics: Sold 503,144 at $2.90 on Jul 11, 2012 · $1.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 1,283,300 at $0.73 on Jun 29, 2012 · $942K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 5,900 at $12.91 on Jun 19, 2012 · $76K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 611,200 at $12.91 on Jun 19, 2012 · $7.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 1,306,700 at $2.40 on Mar 22, 2012 · $3.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 125,000 at $2.87 on Mar 21, 2012 · $358K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 116,800 at $2.90 on Mar 20, 2012 · $339K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 700 at $11.03 on Mar 12, 2012 · $8K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 62,400 at $11.03 on Mar 12, 2012 · $688K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 300 at $11.25 on Mar 9, 2012 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 36,700 at $11.25 on Mar 9, 2012 · $413K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 3,000 at $10.86 on Feb 29, 2012 · $33K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 100 at $11.12 on Feb 28, 2012 · $1K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 10,000 at $11.12 on Feb 28, 2012 · $111K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 300 at $11.05 on Feb 27, 2012 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 28,700 at $11.05 on Feb 27, 2012 · $317K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 500 at $10.79 on Feb 3, 2012 · $5K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 49,500 at $10.79 on Feb 3, 2012 · $534K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 200 at $10.85 on Feb 2, 2012 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 23,100 at $10.85 on Feb 2, 2012 · $251K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 700 at $11.01 on Feb 1, 2012 · $8K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 69,300 at $11.01 on Feb 1, 2012 · $763K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 16,200 at $6.50 on Dec 13, 2011 · $105K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 40,000 at $6.75 on Dec 9, 2011 · $270K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 3,000 at $6.50 on Nov 18, 2011 · $20K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 24,000 at $6.67 on Nov 17, 2011 · $160K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 25,000 at $6.87 on Nov 16, 2011 · $172K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 50,000 at $6.93 on Nov 15, 2011 · $347K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 5,000 at $6.95 on Nov 14, 2011 · $35K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 5,000 at $7.14 on Nov 11, 2011 · $36K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 887 at $10.53 on Oct 31, 2011 · $9K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Pacira Pharmaceuticals: Sold 96,554 at $10.53 on Oct 31, 2011 · $1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 30,000 at $8.18 on Jun 10, 2011 · $245K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 37,000 at $8.11 on Jun 9, 2011 · $300K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 33,000 at $8.02 on Jun 8, 2011 · $265K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 34,200 at $8.53 on May 26, 2011 · $292K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 4,800 at $8.65 on May 25, 2011 · $42K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 69,334 at $8.03 on May 18, 2011 · $557K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 100,000 at $8.32 on May 17, 2011 · $832K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 12,000 at $7.20 on May 16, 2011 · $86K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 13,000 at $7.22 on May 11, 2011 · $94K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 106,400 at $7.23 on May 10, 2011 · $769K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Anthera Pharmaceuticals: Sold 10,000 at $7.26 on May 9, 2011 · $73K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 300 at $16.30 on May 2, 2011 · $5K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 32,600 at $16.30 on May 2, 2011 · $531K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 1,000 at $16.01 on Apr 29, 2011 · $16K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 99,000 at $16.01 on Apr 29, 2011 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 75 at $2.90 on Apr 26, 2011 · $218 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 7,625 at $2.90 on Apr 26, 2011 · $22K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 350 at $2.90 on Apr 25, 2011 · $1K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 36,250 at $2.90 on Apr 25, 2011 · $105K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 25 at $2.90 on Apr 21, 2011 · $73 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 1,975 at $2.90 on Apr 21, 2011 · $6K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 4,733 at $16.91 on Apr 21, 2011 · $80K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 495,267 at $16.91 on Apr 21, 2011 · $8.4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 2,367 at $16.18 on Apr 21, 2011 · $38K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 247,633 at $16.18 on Apr 21, 2011 · $4M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 1,300 at $2.90 on Apr 20, 2011 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 7,600 at $15.79 on Apr 20, 2011 · $120K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 792,400 at $15.79 on Apr 20, 2011 · $12.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 100 at $2.93 on Apr 18, 2011 · $293 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 15,600 at $2.93 on Apr 18, 2011 · $46K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 10 at $16.26 on Apr 18, 2011 · $163 (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 1,102 at $16.26 on Apr 18, 2011 · $18K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 11,522 at $15.65 on Apr 18, 2011 · $180K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 1,214,227 at $15.65 on Apr 18, 2011 · $19M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 16,668 at $14.86 on Apr 18, 2011 · $248K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 1,756,471 at $14.86 on Apr 18, 2011 · $26.1M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 300 at $2.90 on Apr 15, 2011 · $870 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 29,900 at $2.90 on Apr 15, 2011 · $87K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 200 at $2.91 on Apr 14, 2011 · $582 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 20,700 at $2.91 on Apr 14, 2011 · $60K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 500 at $2.94 on Apr 13, 2011 · $1K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 47,200 at $2.94 on Apr 13, 2011 · $139K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 100 at $2.90 on Apr 12, 2011 · $290 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 14,200 at $2.90 on Apr 12, 2011 · $41K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 100 at $2.91 on Apr 11, 2011 · $291 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Athersys: Sold 12,900 at $2.91 on Apr 11, 2011 · $38K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 900 at $7.35 on Mar 28, 2011 · $7K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 92,200 at $7.35 on Mar 28, 2011 · $678K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 500 at $7.47 on Mar 25, 2011 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 56,400 at $7.47 on Mar 25, 2011 · $421K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 200 at $7.50 on Mar 24, 2011 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 22,800 at $7.50 on Mar 24, 2011 · $171K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 700 at $7.05 on Mar 21, 2011 · $5K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 76,300 at $7.05 on Mar 21, 2011 · $538K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 500 at $7.24 on Mar 15, 2011 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 49,500 at $7.24 on Mar 15, 2011 · $358K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 700 at $7.33 on Mar 14, 2011 · $5K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 74,300 at $7.33 on Mar 14, 2011 · $545K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 900 at $7.43 on Mar 11, 2011 · $7K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 99,100 at $7.43 on Mar 11, 2011 · $736K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 200 at $7.68 on Mar 7, 2011 · $2K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 24,800 at $7.68 on Mar 7, 2011 · $190K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 400 at $7.62 on Mar 4, 2011 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 42,600 at $7.62 on Mar 4, 2011 · $325K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 100 at $7.76 on Mar 3, 2011 · $776 | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 6,900 at $7.76 on Mar 3, 2011 · $54K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 900 at $7.72 on Mar 2, 2011 · $7K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 94,100 at $7.72 on Mar 2, 2011 · $726K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 500 at $7.56 on Mar 1, 2011 · $4K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 49,500 at $7.56 on Mar 1, 2011 · $374K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 900 at $7.73 on Feb 28, 2011 · $7K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Amarin: Sold 99,100 at $7.73 on Feb 28, 2011 · $766K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 2,356 at $22.60 on Dec 9, 2010 · $53K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 54,000 at $16.23 on Sep 15, 2010 · $876K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 96,000 at $16.49 on Sep 14, 2010 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 100,000 at $16.70 on Sep 13, 2010 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 193,900 at $16.52 on Sep 10, 2010 · $3.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 8,800 at $16.36 on Sep 9, 2010 · $144K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 7,000 at $16.50 on Sep 8, 2010 · $116K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 40,100 at $16.79 on Sep 7, 2010 · $673K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 100,200 at $16.94 on Aug 18, 2010 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 288,000 at $17.06 on Aug 17, 2010 · $4.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 112,000 at $17.11 on Aug 16, 2010 · $1.9M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 101,100 at $16.31 on Aug 4, 2010 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 199,200 at $16.41 on Aug 3, 2010 · $3.3M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 17,400 at $16.39 on Aug 2, 2010 · $285K | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 128,000 at $16.66 on Jul 28, 2010 · $2.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable NxStage Medical: Sold 572,556 at $16.93 on Jul 27, 2010 · $9.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Biodel: Sold 26,988 at $5.24 on Jun 10, 2009 · $141K | Filing · EDGAR |
| — | — | — | Notice not machine-readable ARYx Therapeutics: Sold 2,000,000 at $4.00 on May 22, 2009 · $8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Biodel: Sold 154,000 at $14.48 on Feb 12, 2008 · $2.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Avanir Pharmaceuticals: Sold 629,121 at $9.79 on May 31, 2006 · $6.2M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Given Imaging: Sold 22,500 at $18.14 on May 24, 2006 · $408K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Dov Pharmaceutical: Sold 258,858 at $3.25 on May 16, 2006 · $841K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Dov Pharmaceutical: Sold 11,422 at $3.25 on May 16, 2006 · $37K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Dov Pharmaceutical: Sold 547,491 at $3.25 on May 16, 2006 · $1.8M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Dov Pharmaceutical: Sold 138,400 at $18.24 on Aug 15, 2005 · $2.5M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Dov Pharmaceutical: Sold 85,000 at $18.47 on Aug 12, 2005 · $1.6M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Given Imaging: Sold 170,000 at $30.08 on Jun 23, 2004 · $5.1M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Orthovita: Sold 200,000 at $3.95 on Jan 14, 2004 · $790K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Lifecell: Sold 700,750 at $5.65 on Dec 23, 2003 · $4M | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
ADARx Pharmaceuticals ADRX Director, 10% owner · filings 2026 to 2026 · bought $16.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Derivative converted | +10,690,530 | 10,690,530 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted | +2,000,962 | 12,691,492 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted | +769,601 | 13,461,093 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted | +564,187 | 14,025,280 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Open-market or private purchase | +300,249 | $17.00 | $5.1M | 14,325,529 See footnotes | Filing · EDGAR |
| Sep 28, 2026 | Derivative converted | +7,127,019 | 7,127,019 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted | +1,333,975 | 8,460,994 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted | +513,067 | 8,974,061 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted | +256,448 | 9,230,509 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Open-market or private purchase | +61,516 | $17.00 | $1M | 9,292,025 See footnotes | Filing · EDGAR |
| Sep 28, 2026 | Open-market or private purchase | +588,235 | $17.00 | $10M | 588,235 See footnotes | Filing · EDGAR |
| Sep 28, 2026 | Derivative converted Series A Preferred Stock | −10,690,530 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series B Preferred Stock | −2,000,962 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series B-1 Preferred Stock | −769,601 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series C Preferred Stock | −564,187 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series A Preferred Stock | −7,127,019 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series B Preferred Stock | −1,333,975 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series B-1 Preferred Stock | −513,067 | 0 See footnotes | Filing · EDGAR | ||
| Sep 28, 2026 | Derivative converted Series C Preferred Stock | −256,448 | 0 See footnotes | Filing · EDGAR |
Electra Therapeutics ETRA Director, 10% owner · filings 2026 to 2026 · bought $20M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Derivative converted | +2,002,310 | 2,002,310 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Derivative converted | +1,087,934 | 3,090,244 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Derivative converted | +1,703,314 | 4,793,558 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Open-market or private purchase | +333,333 | $15.00 | $5M | 5,126,891 See footnotes | Filing · EDGAR |
| Sep 21, 2026 | Derivative converted | +758,279 | 758,279 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Open-market or private purchase | +1,000,000 | $15.00 | $15M | 1,758,279 See footnotes | Filing · EDGAR |
| Sep 21, 2026 | Derivative converted Series A Convertible Preferred Stock | −2,002,310 | 0 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Derivative converted Series B Convertible Preferred Stock | −1,087,934 | 0 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Derivative converted Series C Convertible Preferred Stock | −1,703,314 | 0 See footnotes | Filing · EDGAR | ||
| Sep 21, 2026 | Derivative converted Series C Convertible Preferred Stock | −758,279 | 0 See footnotes | Filing · EDGAR |
BlossomHill Therapeutics BLSM Director · filings 2026 to 2026 · bought $10M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Derivative converted | +1,039,996 | 1,039,996 See footnotes | Filing · EDGAR | ||
| Aug 10, 2026 | Derivative converted | +1,049,283 | 2,089,279 See footnotes | Filing · EDGAR | ||
| Aug 10, 2026 | Open-market or private purchase | +625,000 | $16.00 | $10M | 2,714,279 See footnotes | Filing · EDGAR |
| Aug 10, 2026 | Derivative converted Series A Preferred Stock | −1,039,996 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2026 | Derivative converted Series B Preferred Stock | −1,049,283 | 0 See footnotes | Filing · EDGAR |
Braveheart Bio BRVE Director, 10% owner · filings 2026 to 2026 · bought $34.9M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Derivative converted | +9,132,420 | 10,235,159 See footnotes | Filing · EDGAR | ||
| Aug 7, 2026 | Open-market or private purchase | +1,666,667 | $18.00 | $30M | 11,901,826 See footnotes | Filing · EDGAR |
| Aug 7, 2026 | Open-market or private purchase | +273,333 | $18.00 | $4.9M | 273,333 See footnotes | Filing · EDGAR |
| Aug 7, 2026 | Derivative converted Series A Preferred Stock | −40,000,000 | 0 See footnotes | Filing · EDGAR |
Scribe Therapeutics SCTX Director · filings 2026 to 2026 · bought $15M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Derivative converted | +348,825 | 348,825 See footnotes | Filing · EDGAR | ||
| Jul 27, 2026 | Open-market or private purchase | +1,000,000 | $15.00 | $15M | 1,348,825 See footnotes | Filing · EDGAR |
| Jul 27, 2026 | Derivative converted Series B Preferred Stock | −2,065,672 | 0 See footnotes | Filing · EDGAR |
Yarrow Bioscience YARW Director · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Sionna Therapeutics SION Director · filings 2025 to 2026 · sold $55.7M · bought $9.9M · $101.9M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Sale under a 10b5-1 plan | −85,918 | $44.86 | $3.9M | 2,469,959 See footnotes | Filing · EDGAR |
| Jun 30, 2026 | Sale under a 10b5-1 plan | −115,844 | $45.50 | $5.3M | 2,555,877 See footnotes | Filing · EDGAR |
| May 27, 2026 | Sale under a 10b5-1 plan | −101 | $44.49 | $4K | 2,671,721 See footnotes | Filing · EDGAR |
| May 11, 2026 | Sale under a 10b5-1 plan | −184,639 | $46.22 | $8.5M | 2,671,822 See footnotes( | Filing · EDGAR |
| May 8, 2026 | Sale under a 10b5-1 plan | −59,767 | $44.58 | $2.7M | 2,856,461 See footnotes( | Filing · EDGAR |
| May 7, 2026 | Sale under a 10b5-1 plan | −48,546 | $44.61 | $2.2M | 2,916,228 See footnotes( | Filing · EDGAR |
| Apr 18, 2026 | Sale under a 10b5-1 plan | −2,948 | $44.52 | $131K | 2,964,774 See footnotes | Filing · EDGAR |
| Apr 17, 2026 | Sale under a 10b5-1 plan | −52,397 | $44.68 | $2.3M | 2,967,722 See footnotes | Filing · EDGAR |
| Apr 16, 2026 | Sale under a 10b5-1 plan | −226,906 | $45.34 | $10.3M | 3,020,119 See footnotes | Filing · EDGAR |
| Apr 15, 2026 | Sale under a 10b5-1 plan | −235,863 | $44.64 | $10.5M | 3,247,025 See footnotes | Filing · EDGAR |
| Apr 14, 2026 | Sale under a 10b5-1 plan | −47,814 | $44.51 | $2.1M | 3,482,888 See footnotes | Filing · EDGAR |
| Feb 3, 2026 | Sale under a 10b5-1 plan | −29,063 | $44.58 | $1.3M | 3,530,702 See footnotes | Filing · EDGAR |
| Feb 2, 2026 | Sale under a 10b5-1 plan | −1,890 | $44.57 | $84K | 3,559,765 See footnotes | Filing · EDGAR |
| Dec 24, 2025 | Sale under a 10b5-1 plan | −33,356 | $44.55 | $1.5M | 3,561,655 See footnotes | Filing · EDGAR |
| Dec 19, 2025 | Sale under a 10b5-1 plan | −875 | $44.49 | $39K | 3,595,011 See footnotes | Filing · EDGAR |
| Dec 18, 2025 | Sale under a 10b5-1 plan | −100 | $44.49 | $4K | 3,595,886 See footnotes | Filing · EDGAR |
| Dec 17, 2025 | Sale under a 10b5-1 plan | −900 | $44.50 | $40K | 3,595,986 See footnotes | Filing · EDGAR |
| Nov 26, 2025 | Sale under a 10b5-1 plan | −1,600 | $44.49 | $71K | 3,596,886 See footnotes | Filing · EDGAR |
| Nov 25, 2025 | Sale under a 10b5-1 plan | −11,890 | $44.60 | $530K | 3,598,486 See footnotes | Filing · EDGAR |
| Nov 24, 2025 | Sale under a 10b5-1 plan | −94,583 | $44.54 | $4.2M | 3,610,376 See footnotes | Filing · EDGAR |
| Feb 10, 2025 | Derivative converted | +3,154,959 | 3,154,959 See footnotes | Filing · EDGAR | ||
| Feb 10, 2025 | Open-market or private purchase | +550,000 | $18.00 | $9.9M | 3,704,959 See footnotes | Filing · EDGAR |
| Feb 10, 2025 | Derivative converted Series B convertible preferred stock | −2,560,951 | 0 See footnotes | Filing · EDGAR | ||
| Feb 10, 2025 | Derivative converted Series C convertible preferred stock | −2,048,760 | 0 See footnotes | Filing · EDGAR |
Enliven Therapeutics IMRA 10% owner · filings 2020 to 2026 · sold $74.6M · bought $25M · $74.3M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | Open-market or private sale | −24,846 | $45.38 | $1.1M | 220,882 See Footnotes | Filing · EDGAR |
| Jun 22, 2026 | Open-market or private sale | −1,477 | $45.00 | $66K | 219,405 See Footnotes | Filing · EDGAR |
| Jun 22, 2026 | Open-market or private sale | −787,024 | $45.38 | $35.7M | 6,601,878 See Footnotes | Filing · EDGAR |
| Jun 22, 2026 | Open-market or private sale | −46,776 | $45.00 | $2.1M | 6,555,102 See Footnotes | Filing · EDGAR |
| Jun 15, 2026 | Open-market or private sale | −9,086 | $45.02 | $409K | 245,728 See Footnotes | Filing · EDGAR |
| Jun 15, 2026 | Open-market or private sale | −272,322 | $45.02 | $12.3M | 7,388,902 See Footnotes | Filing · EDGAR |
| May 16, 2024 | Open-market or private sale | −33,300 | $22.14 | $737K | 254,814 See Footnotes | Filing · EDGAR |
| May 16, 2024 | Open-market or private sale | −1,000,000 | $22.14 | $22.1M | 7,663,349 See Footnotes | Filing · EDGAR |
| May 17, 2023 | Option or RSU exercised or converted | +2,125 | $4.28 | $9K | 8,663,349 See footnotes | Filing · EDGAR |
| May 17, 2023 | Option or RSU exercised or converted Stock Options (Right to Buy) | −2,125 | 0 See footnotes | Filing · EDGAR | ||
| Feb 23, 2023 | Grant or award from the company | +7,611,458 | 8,661,225 See footnotes | Filing · EDGAR | ||
| Feb 23, 2023 | Grant or award from the company | +288,114 | 288,114 See footnotes | Filing · EDGAR | ||
| Jul 16, 2021 | Open-market or private purchase | +1,666,666 | $6.00 | $10M | 4,199,068 See footnotes | Filing · EDGAR |
| Mar 16, 2020 | Derivative converted | +1,594,902 | 2,532,402 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Mar 16, 2020 | Derivative converted Series B Preferred Stock | −10,046,294 | 0 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Mar 12, 2020 | Open-market or private purchase | +937,500 | $16.00 | $15M | 937,500 By OrbiMed Private Investments VII, LP | Filing · EDGAR |
Shattuck Labs STTK Director · filings 2025 to 2026 · bought $5.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +1,041,667 | 26,519,541 See Footnote | Filing · EDGAR | ||
| Jun 11, 2026 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +208,333 | 5,303,908 See Footnote | Filing · EDGAR | ||
| Jun 8, 2026 | Derivative converted Pre-Funded Warrants (right to buy) | +15,366,490 | 25,477,874 See Footnote | Filing · EDGAR | ||
| Jun 8, 2026 | Derivative converted Pre-Funded Warrants (right to buy) | +3,073,298 | 5,095,575 See Footnote | Filing · EDGAR | ||
| Jun 8, 2026 | Derivative converted Common Warrants (right to buy) | −15,366,490 | 0 See Footnote | Filing · EDGAR | ||
| Jun 8, 2026 | Derivative converted Common Warrants (right to buy) | −3,073,298 | 0 See Footnote | Filing · EDGAR | ||
| Aug 25, 2025 | Open-market or private purchase | +5,255,106 | $0.87 | $4.6M | 5,255,106 See Footnote | Filing · EDGAR |
| Aug 25, 2025 | Open-market or private purchase | +1,051,021 | $0.87 | $912K | 1,051,021 See Footnote | Filing · EDGAR |
| Aug 25, 2025 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +10,111,384 | 10,111,384 See Footnote | Filing · EDGAR | ||
| Aug 25, 2025 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +2,022,277 | 2,022,277 See Footnote | Filing · EDGAR | ||
| Aug 25, 2025 | Open-market or private purchase Common Warrants (right to buy) | +15,366,490 | 15,366,490 See Footnote | Filing · EDGAR | ||
| Aug 25, 2025 | Open-market or private purchase Common Warrants (right to buy) | +3,073,298 | 3,073,298 See Footnote | Filing · EDGAR |
Q32 Bio QTTB Director, 10% owner · filings 2024 to 2026 · bought $15M
Traws Pharma TRAW 10% owner · filings 2024 to 2026 · bought $998K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | Open-market or private purchase | +597,729 | $1.67 | $998K | 1,203,250 See Footnote | Filing · EDGAR |
| Apr 16, 2026 | Open-market or private purchase Series A Warrants (right to buy) | +597,729 | 597,729 See Footnote | Filing · EDGAR | ||
| Apr 16, 2026 | Open-market or private purchase Series B Warrants (right to buy) | +597,729 | 597,729 See Footnote | Filing · EDGAR | ||
| Apr 16, 2026 | Open-market or private purchase Series C Warrants (right to buy) | +1,793,187 | 1,793,187 See Footnote | Filing · EDGAR | ||
| Dec 29, 2024 | Open-market or private purchase Pre-Funded Warrant (right to buy) | +96,348 | 96,348 See Footnote | Filing · EDGAR | ||
| Dec 29, 2024 | Open-market or private purchase Series A Warrant (right to buy) | +96,348 | 96,348 See Footnote | Filing · EDGAR |
Prelude Therapeutics PRLD Director, 10% owner · filings 2020 to 2026 · bought $41M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 21, 2026 | Open-market or private purchase | +1,689,189 | $4.44 | $7.5M | 11,808,945 See footnotes | Filing · EDGAR |
| Apr 21, 2026 | Open-market or private purchase | +1,126,126 | $4.44 | $5M | 1,126,126 See footnotes | Filing · EDGAR |
| May 22, 2023 | Open-market or private purchase | +869,565 | $5.75 | $5M | 10,119,756 See footnotes | Filing · EDGAR |
| Jan 11, 2021 | Open-market or private purchase Non-Voting Common Stock | +41,700 | $60.00 | $2.5M | 5,596,886 See Footnotes | Filing · EDGAR |
| Sep 29, 2020 | Derivative converted | +8,332,779 | 9,250,191 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series A Preferred Stock | −3,294,743 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series A Prefered Stock | −2,196,494 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series B Preferred Stock | −4,418,186 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series B Preferred Stock | −2,945,458 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series C Preferred Stock | −619,850 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series C Preferred Stock | −413,234 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Non-Voting Common Stock | +5,555,186 | 5,555,186 See footnote | Filing · EDGAR | ||
| Sep 25, 2020 | Open-market or private purchase | +526,300 | $19.00 | $10M | 526,300 See footnote | Filing · EDGAR |
| Sep 25, 2020 | Open-market or private purchase | +710,500 | $19.00 | $13.5M | 917,412 See footnote | Filing · EDGAR |
| Aug 21, 2020 | Open-market or private purchase Series C Preferred Stock | +1,033,084 | 1,033,084 See footnote | Filing · EDGAR | ||
| Mar 27, 2020 | Open-market or private purchase Series B Preferred Stock | +3,681,822 | 7,363,644 See footnote | Filing · EDGAR |
ImageneBio IKNA Director · filings 2021 to 2026 · bought $6.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +336,603 | 336,603 See Footnote | Filing · EDGAR | ||
| Apr 14, 2026 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +384,689 | 384,689 See Footnote | Filing · EDGAR | ||
| Jul 25, 2025 | Grant or award from the company | +83,611 | $2.49 | $208K | 287,885 See Footnote | Filing · EDGAR |
| Aug 4, 2023 | Grant or award from the company | +153,121 | 5,582,144 See Footnote | Filing · EDGAR | ||
| Aug 4, 2023 | Grant or award from the company Series A Preferred Stock | +353,192 | 353,192 See Footnote | Filing · EDGAR | ||
| Aug 4, 2023 | Grant or award from the company | +153,121 | 2,251,218 See Footnote | Filing · EDGAR | ||
| Jun 24, 2022 | Open-market or private purchase | −65,965 | $4.37 | $288K | 2,002,062 See Footnotes | Filing · EDGAR |
| Jun 24, 2022 | Open-market or private purchase | −96,035 | $5.37 | $516K | 2,098,097 See Footnotes | Filing · EDGAR |
| Jun 23, 2022 | Open-market or private purchase | −23,419 | $3.71 | $87K | 1,936,097 See Footnotes | Filing · EDGAR |
| Jun 22, 2022 | Open-market or private purchase | −66,806 | $3.55 | $237K | 1,912,678 See Footnotes | Filing · EDGAR |
| Mar 30, 2021 | Derivative converted | +1,470,872 | 1,470,872 See footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted | +42,614 | 42,614 See footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Open-market or private purchase | +375,000 | $16.00 | $6M | 1,845,872 See footnotes | Filing · EDGAR |
| Mar 30, 2021 | Open-market or private purchase | +48,400 | $16.00 | $774K | 91,014 See footnotes | Filing · EDGAR |
| Mar 30, 2021 | Derivative converted | +5,429,023 | 5,429,023 See footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted | +157,288 | 157,288 See footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series A Preferred Stock | −2,034,708 | 0 See foonotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series A Preferred Stock | −551,259 | 0 See foonotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series A-1 Preferred Stock | −2,411,260 | 0 See foonotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series A-1 Preferred Stock | −653,277 | 0 See foonotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series B Preferred Stock | −983,055 | 0 See foonotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series B Preferred Stock | −266,336 | 0 See foonotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series B Preferred Stock | −157,288 | 0 See footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series B Preferred Stock | −42,614 | 0 See footnotes | Filing · EDGAR | ||
| Dec 21, 2020 | Grant or award from the company Series B Preferred Stock | +8,938,148 | $1.40 | $12.5M | 8,938,148 See foonotes | Filing · EDGAR |
| Dec 21, 2020 | Grant or award from the company Series B Preferred Stock | +1,430,103 | $1.40 | $2M | 1,430,103 See footnotes | Filing · EDGAR |
Adicet Bio TORC 10% owner · filings 2018 to 2026 · sold $675K · bought $22.3M · $514K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 8, 2026 | Open-market or private sale | −32,523 | $6.29 | $205K | 0 See footnotes | Filing · EDGAR |
| Apr 8, 2026 | Open-market or private sale | −40,416 | $6.52 | $264K | 0 See footnotes | Filing · EDGAR |
| Apr 7, 2026 | Open-market or private sale | −29,319 | $6.53 | $191K | 34,923 See footnotes | Filing · EDGAR |
| Apr 7, 2026 | Open-market or private sale | −2,400 | $6.38 | $15K | 32,523 See footnotes | Filing · EDGAR |
| Oct 8, 2025 | Open-market or private purchase | +1,500,000 | $1.00 | $1.5M | 9,026,359 See footnotes | Filing · EDGAR |
| Oct 8, 2025 | Open-market or private purchase | +3,500,000 | $1.00 | $3.5M | 4,490,254 See footnotes | Filing · EDGAR |
| Jan 25, 2024 | Open-market or private purchase | +1,841,100 | $2.40 | $4.4M | 7,526,359 See footnotes | Filing · EDGAR |
| Jan 25, 2024 | Open-market or private purchase | +242,200 | $2.40 | $581K | 990,254 See footnotes | Filing · EDGAR |
| Jan 25, 2024 | Open-market or private purchase | +1,041,700 | $2.40 | $2.5M | 1,255,985 See footnotes | Filing · EDGAR |
| Jun 27, 2023 | Open-market or private purchase | +125,000 | $2.09 | $261K | 1,027,885 See footnotes | Filing · EDGAR |
| Jun 27, 2023 | Open-market or private purchase | +250,000 | $2.09 | $522K | 646,657 See footnotes | Filing · EDGAR |
| Jun 27, 2023 | Open-market or private purchase | +442,000 | $2.09 | $924K | 5,685,259 See footnotes | Filing · EDGAR |
| Jun 27, 2023 | Open-market or private purchase | +58,000 | $2.09 | $121K | 748,054 See footnotes | Filing · EDGAR |
| Dec 10, 2021 | Grant or award from the company | +214,285 | $14.00 | $3M | 242,285 See Footnotes | Filing · EDGAR |
| Feb 12, 2021 | Grant or award from the company | +420,299 | $13.00 | $5.5M | 5,243,259 See Footnotes | Filing · EDGAR |
| Feb 12, 2021 | Grant or award from the company | +104,050 | $13.00 | $1.4M | 396,657 See Footnotes | Filing · EDGAR |
| Sep 17, 2020 | Grant or award from the company Stock Option (Right to Buy) | +30,000 | 30,000 See Footnote | Filing · EDGAR | ||
| Sep 17, 2020 | Grant or award from the company Stock Option (Right to Buy) | +30,000 | 30,000 See Footnote | Filing · EDGAR | ||
| Sep 15, 2020 | Grant or award from the company | +4,822,960 | 4,822,960 See Footnotes | Filing · EDGAR | ||
| Sep 15, 2020 | Grant or award from the company | +902,885 | 902,855 See Footnotes | Filing · EDGAR | ||
| Sep 15, 2020 | Grant or award from the company | +292,607 | 292,607 See Footnotes | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted | +2,425,485 | 2,425,485 See Footnotes | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted | +1,871,569 | 4,297,054 See Footnotes | Filing · EDGAR | ||
| Jan 30, 2018 | Open-market or private purchase | +533,333 | $15.00 | $8M | 4,830,387 See Footnotes | Filing · EDGAR |
| Jan 30, 2018 | Derivative converted Series A Preferred Stock | −2,425,482 | 0 See Footnotes | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series B Preferred Stock | −1,871,569 | 0 See Footnotes | Filing · EDGAR |
Keros Therapeutics KROS Shareholder; Director · filings 2020 to 2026 · sold $11M · bought $6M · $11.7M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 21, 2025 | Returned to the company | −140,057 | $17.75 | $2.5M | 759,155 See footnotes | Filing · EDGAR |
| Nov 21, 2025 | Returned to the company | −74,465 | $17.75 | $1.3M | 45,057 See footnotes | Filing · EDGAR |
| Aug 13, 2024 | Open-market or private sale | −220,600 | $44.01 | $9.7M | 899,212 See footnotes | Filing · EDGAR |
| Aug 13, 2024 | Open-market or private sale | −29,400 | $44.01 | $1.3M | 119,522 See footnotes | Filing · EDGAR |
| Apr 13, 2020 | Derivative converted | +744,612 | 744,612 See footnote | Filing · EDGAR | ||
| Apr 13, 2020 | Derivative converted | +148,922 | 148,922 See footnote | Filing · EDGAR | ||
| Apr 13, 2020 | Open-market or private purchase | +375,200 | $16.00 | $6M | 1,119,812 See footnote | Filing · EDGAR |
| Apr 13, 2020 | Derivative converted Series C Preferred Stock | −744,612 | 0 See footnote | Filing · EDGAR | ||
| Apr 13, 2020 | Derivative converted Series C Preferred Stock | −148,922 | 0 See footnote | Filing · EDGAR |
PMV Pharmaceuticals PMVP 10% owner · filings 2020 to 2025 · sold $13.3M · bought $17.1M · $5.4M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 23, 2025 | Open-market or private sale | −1,000,000 | $1.52 | $1.5M | 4,975,291 See Footnotes | Filing · EDGAR |
| Sep 10, 2025 | Open-market or private sale | −500,000 | $1.80 | $900K | 5,975,291 See Footnotes | Filing · EDGAR |
| Nov 22, 2023 | Open-market or private sale | −87,786 | $2.23 | $196K | 0 See Footnotes | Filing · EDGAR |
| May 26, 2022 | Open-market or private sale | −26,253 | $15.93 | $418K | 87,786 See Footnotes | Filing · EDGAR |
| Mar 31, 2022 | Open-market or private sale | −34,500 | $21.17 | $730K | 0 See Footnotes | Filing · EDGAR |
| Mar 30, 2022 | Open-market or private sale | −75,000 | $22.39 | $1.7M | 34,500 See Footnotes | Filing · EDGAR |
| Mar 29, 2022 | Open-market or private sale | −365,000 | $21.52 | $7.9M | 109,500 See Footnotes | Filing · EDGAR |
| Sep 29, 2020 | Derivative converted | +4,025,076 | 4,500,076 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted | +1,076,891 | 5,576,967 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted | +518,191 | 6,095,158 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted | +380,133 | 6,475,291 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted | +114,039 | 114,039 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series A Preferred Stock | −4,025,076 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series B Preferred Stock | −1,076,891 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series C Preferred Stock | −518,191 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series D Preferred Stock | −380,133 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series D Preferred Stock | −114,039 | 0 See footnote | Filing · EDGAR | ||
| Sep 25, 2020 | Open-market or private purchase | +475,000 | $18.00 | $8.6M | 475,000 See footnote | Filing · EDGAR |
| Sep 25, 2020 | Open-market or private purchase | +475,000 | $18.00 | $8.6M | 475,000 See footnote | Filing · EDGAR |
Disc Medicine GMTX Shareholder · filings 2021 to 2025 · sold $52.7M · bought $5.5M · $328.1M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 24, 2025 | Open-market or private sale | −1,956 | $54.11 | $106K | 482,308 See Footnotes | Filing · EDGAR |
| Mar 24, 2025 | Open-market or private sale | −3,026 | $54.11 | $164K | 746,171 See Footnotes | Filing · EDGAR |
| Mar 24, 2025 | Open-market or private sale | −756 | $54.11 | $41K | 186,541 See Footnotes | Filing · EDGAR |
| Mar 21, 2025 | Open-market or private sale | −3,412 | $54.00 | $184K | 484,264 See Footnotes | Filing · EDGAR |
| Mar 21, 2025 | Open-market or private sale | −5,279 | $54.00 | $285K | 749,197 See Footnotes | Filing · EDGAR |
| Mar 21, 2025 | Open-market or private sale | −1,320 | $54.00 | $71K | 187,297 See Footnotes | Filing · EDGAR |
| Mar 20, 2025 | Open-market or private sale | −941 | $54.01 | $51K | 487,676 See Footnotes | Filing · EDGAR |
| Mar 20, 2025 | Open-market or private sale | −1,457 | $54.01 | $79K | 754,476 See Footnotes | Filing · EDGAR |
| Mar 20, 2025 | Open-market or private sale | −364 | $54.01 | $20K | 188,617 See Footnotes | Filing · EDGAR |
| Mar 19, 2025 | Open-market or private sale | −13,517 | $54.02 | $730K | 488,617 See Footnotes | Filing · EDGAR |
| Mar 19, 2025 | Open-market or private sale | −20,911 | $54.02 | $1.1M | 755,933 See Footnotes | Filing · EDGAR |
| Mar 19, 2025 | Open-market or private sale | −5,228 | $54.02 | $282K | 188,981 See Footnotes | Filing · EDGAR |
| Mar 12, 2025 | Open-market or private sale | −603 | $55.05 | $33K | 529,884 See Footnotes | Filing · EDGAR |
| Mar 12, 2025 | Open-market or private sale | −933 | $55.05 | $51K | 819,774 See Footnotes | Filing · EDGAR |
| Mar 12, 2025 | Open-market or private sale | −233 | $55.05 | $13K | 204,942 See Footnotes | Filing · EDGAR |
| Mar 12, 2025 | Open-market or private sale | −27,750 | $54.44 | $1.5M | 502,134 See Footnotes | Filing · EDGAR |
| Mar 12, 2025 | Open-market or private sale | −42,930 | $54.44 | $2.3M | 776,844 See Footnotes | Filing · EDGAR |
| Mar 12, 2025 | Open-market or private sale | −10,733 | $54.44 | $584K | 194,209 See Footnotes | Filing · EDGAR |
| Mar 11, 2025 | Open-market or private sale | −9,222 | $54.01 | $498K | 530,487 See Footnotes | Filing · EDGAR |
| Mar 11, 2025 | Open-market or private sale | −14,267 | $54.01 | $771K | 820,707 See Footnotes | Filing · EDGAR |
| Mar 11, 2025 | Open-market or private sale | −3,567 | $54.01 | $193K | 205,175 See Footnotes | Filing · EDGAR |
| Mar 10, 2025 | Open-market or private sale | −68,766 | $54.29 | $3.7M | 539,845 See Footnotes | Filing · EDGAR |
| Mar 10, 2025 | Open-market or private sale | −106,384 | $54.29 | $5.8M | 835,185 See Footnotes | Filing · EDGAR |
| Mar 10, 2025 | Open-market or private sale | −26,596 | $54.29 | $1.4M | 208,795 See Footnotes | Filing · EDGAR |
| Mar 10, 2025 | Open-market or private sale | −136 | $55.01 | $7K | 539,709 See Footnotes | Filing · EDGAR |
| Mar 10, 2025 | Open-market or private sale | −211 | $55.01 | $12K | 834,974 See Footnotes | Filing · EDGAR |
| Mar 10, 2025 | Open-market or private sale | −53 | $55.01 | $3K | 208,742 See Footnotes | Filing · EDGAR |
| Jun 17, 2024 | Open-market or private purchase | +28,404 | $36.00 | $1M | 608,611 See Footnotes | Filing · EDGAR |
| Jun 17, 2024 | Open-market or private purchase | +43,944 | $36.00 | $1.6M | 941,569 See Footnotes | Filing · EDGAR |
| Jun 17, 2024 | Open-market or private purchase | +10,986 | $36.00 | $395K | 235,391 See Footnotes | Filing · EDGAR |
| Dec 18, 2023 | Option or RSU exercised or converted | +1,724 | $38.00 | $66K | 1,724 direct | Filing · EDGAR |
| Dec 18, 2023 | Open-market or private sale | −1,724 | $59.24 | $102K | 0 direct | Filing · EDGAR |
| Dec 18, 2023 | Option or RSU exercised or converted Stock Options (Right to Buy) | −1,724 | 0 direct | Filing · EDGAR | ||
| Dec 14, 2023 | Open-market or private sale | −228,500 | $56.75 | $13M | 897,625 See footnotes | Filing · EDGAR |
| Dec 14, 2023 | Open-market or private sale | −147,600 | $56.75 | $8.4M | 580,207 See footnotes | Filing · EDGAR |
| Dec 14, 2023 | Open-market or private sale | −57,100 | $56.75 | $3.2M | 224,405 See footnotes | Filing · EDGAR |
| Dec 14, 2023 | Open-market or private sale | −100 | $57.73 | $6K | 1,126,125 See footnotes | Filing · EDGAR |
| Dec 14, 2023 | Open-market or private sale | −100 | $57.73 | $6K | 727,807 See footnotes | Filing · EDGAR |
| Dec 13, 2023 | Open-market or private sale | −56,200 | $58.56 | $3.3M | 1,126,225 See footnotes | Filing · EDGAR |
| Dec 13, 2023 | Open-market or private sale | −36,400 | $58.56 | $2.1M | 727,907 See footnotes | Filing · EDGAR |
| Dec 13, 2023 | Open-market or private sale | −14,100 | $58.56 | $826K | 281,505 See footnotes | Filing · EDGAR |
| Dec 12, 2023 | Open-market or private sale | −14,400 | $60.16 | $866K | 1,182,425 See footnotes | Filing · EDGAR |
| Dec 12, 2023 | Open-market or private sale | −9,300 | $60.16 | $559K | 764,307 See footnotes | Filing · EDGAR |
| Dec 12, 2023 | Open-market or private sale | −3,600 | $60.16 | $217K | 295,605 See footnotes | Filing · EDGAR |
| Feb 15, 2023 | Open-market or private purchase | +57,318 | $23.00 | $1.3M | 1,196,825 See footnotes | Filing · EDGAR |
| Feb 15, 2023 | Open-market or private purchase | +37,049 | $23.00 | $852K | 773,607 See footnotes | Filing · EDGAR |
| Feb 15, 2023 | Open-market or private purchase | +14,329 | $23.00 | $330K | 299,205 See footnotes | Filing · EDGAR |
| Dec 29, 2022 | Other acquisition or disposition (see the filing) | +284,876 | 284,876 See footnote | Filing · EDGAR | ||
| Dec 29, 2022 | Other acquisition or disposition (see the filing) | +582,622 | 582,622 See footnote | Filing · EDGAR | ||
| Dec 29, 2022 | Other acquisition or disposition (see the filing) | +153,936 | 736,558 See footnote | Filing · EDGAR | ||
| Dec 29, 2022 | Other acquisition or disposition (see the filing) | +1,139,507 | 1,139,507 See footnote | Filing · EDGAR |
Turnstone Biologics TSBX Director · filings 2023 to 2025 · bought $5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | Tendered in a change of control | −3,099,265 | $0.34 | $1.1M | 0 See Footnote | Filing · EDGAR |
| Jul 20, 2023 | Derivative converted | +2,682,599 | 2,682,599 See Footnote | Filing · EDGAR | ||
| Jul 20, 2023 | Open-market or private purchase | +416,666 | $12.00 | $5M | 3,099,265 See Footnote | Filing · EDGAR |
| Jul 20, 2023 | Derivative converted Series B-1 Preferred Stock | −937,372 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 20, 2023 | Derivative converted Series B-2 Preferred Stock | −1,249,829 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 20, 2023 | Derivative converted Series C Preferred Stock | −266,240 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 20, 2023 | Derivative converted Series D Preferred Stock | −229,158 | 0 See Footnotes | Filing · EDGAR |
Passage BIO PASG Stockholder · filings 2020 to 2025 · sold $1M · bought $10.7M · $6.2M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 26, 2025 | Open-market or private sale | −213,257 | $0.33 | $70K | 6,066,343 See footnotes | Filing · EDGAR |
| Jun 25, 2025 | Open-market or private sale | −138,800 | $0.33 | $46K | 6,279,600 See footnotes | Filing · EDGAR |
| Jun 24, 2025 | Open-market or private sale | −231,600 | $0.35 | $81K | 6,418,400 See footnotes | Filing · EDGAR |
| Apr 24, 2025 | Open-market or private sale | −68,195 | $0.32 | $22K | 6,650,000 See footnotes | Filing · EDGAR |
| Apr 23, 2025 | Open-market or private sale | −89,328 | $0.34 | $30K | 6,718,195 See footnotes | Filing · EDGAR |
| Apr 22, 2025 | Open-market or private sale | −78,049 | $0.34 | $27K | 6,807,523 See footnotes | Filing · EDGAR |
| Apr 17, 2025 | Open-market or private sale | −77,090 | $0.33 | $25K | 6,885,572 See footnotes | Filing · EDGAR |
| Apr 16, 2025 | Open-market or private sale | −61,638 | $0.33 | $20K | 6,962,662 See footnotes | Filing · EDGAR |
| Apr 15, 2025 | Open-market or private sale | −10,326 | $0.38 | $4K | 7,024,300 See footnotes | Filing · EDGAR |
| Jan 14, 2025 | Open-market or private sale | −79,024 | $0.60 | $47K | 7,034,626 See footnotes | Filing · EDGAR |
| Jan 13, 2025 | Open-market or private sale | −17,986 | $0.64 | $12K | 7,113,650 See footnotes | Filing · EDGAR |
| Jan 10, 2025 | Open-market or private sale | −126,209 | $0.66 | $83K | 7,131,636 See footnotes | Filing · EDGAR |
| Jan 8, 2025 | Open-market or private sale | −75,007 | $0.68 | $51K | 7,257,845 See footnotes | Filing · EDGAR |
| Jan 7, 2025 | Open-market or private sale | −52,536 | $0.71 | $37K | 7,332,852 See footnotes | Filing · EDGAR |
| Jan 6, 2025 | Open-market or private sale | −19,481 | $0.77 | $15K | 7,385,388 See footnotes | Filing · EDGAR |
| Dec 20, 2024 | Open-market or private sale | −230,321 | $0.60 | $138K | 7,404,869 See footnotes | Filing · EDGAR |
| Dec 11, 2024 | Open-market or private sale | −80 | $0.80 | $64 | 7,635,190 See footnotes | Filing · EDGAR |
| Dec 10, 2024 | Open-market or private sale | −8,015 | $0.80 | $6K | 7,635,270 See footnotes | Filing · EDGAR |
| Dec 9, 2024 | Open-market or private sale | −54,181 | $0.84 | $46K | 7,643,285 See footnotes | Filing · EDGAR |
| Dec 6, 2024 | Open-market or private sale | −20,903 | $0.82 | $17K | 7,697,466 See footnotes | Filing · EDGAR |
| Dec 4, 2024 | Open-market or private sale | −76,200 | $0.79 | $60K | 7,718,369 See footnotes | Filing · EDGAR |
| Sep 19, 2024 | Open-market or private sale | −39,300 | $0.71 | $28K | 7,794,569 See footnotes | Filing · EDGAR |
| Sep 18, 2024 | Open-market or private sale | −25,631 | $0.73 | $19K | 7,833,869 See footnotes | Filing · EDGAR |
| Sep 17, 2024 | Open-market or private sale | −111,400 | $0.73 | $81K | 7,859,500 See footnotes | Filing · EDGAR |
| Sep 16, 2024 | Open-market or private sale | −63,100 | $0.74 | $47K | 7,970,900 See footnotes | Filing · EDGAR |
| Jun 28, 2023 | Open-market or private purchase | +575,195 | $0.84 | $483K | 8,034,000 See footnotes | Filing · EDGAR |
| Jun 27, 2023 | Open-market or private purchase | +617,382 | $0.84 | $519K | 7,458,805 See footnotes | Filing · EDGAR |
| May 4, 2022 | Open-market or private purchase | +303,500 | $1.94 | $589K | 6,841,423 See Footnotes | Filing · EDGAR |
| May 3, 2022 | Open-market or private purchase | +221,500 | $1.93 | $427K | 6,537,923 See Footnotes | Filing · EDGAR |
| Jan 20, 2022 | Open-market or private purchase | +50,800 | $5.00 | $254K | 6,316,423 See Footnotes | Filing · EDGAR |
| Jan 19, 2022 | Open-market or private purchase | +43,300 | $5.11 | $221K | 6,265,623 See Footnotes | Filing · EDGAR |
| Jan 18, 2022 | Open-market or private purchase | +114,700 | $5.46 | $626K | 6,222,323 See Footnotes | Filing · EDGAR |
| Jan 14, 2022 | Open-market or private purchase | +10,300 | $5.60 | $58K | 6,107,623 See Footnotes | Filing · EDGAR |
| Jan 13, 2022 | Open-market or private purchase | +41,800 | $5.52 | $231K | 6,097,323 See Footnotes | Filing · EDGAR |
| Jan 12, 2022 | Open-market or private purchase | +100,000 | $5.65 | $565K | 6,055,523 See Footnotes | Filing · EDGAR |
| Jan 11, 2022 | Open-market or private purchase | +8,200 | $5.53 | $45K | 5,955,523 See Footnotes | Filing · EDGAR |
| Mar 3, 2020 | Derivative converted | +3,721,552 | 4,094,852 See Footnote | Filing · EDGAR | ||
| Mar 3, 2020 | Derivative converted | +1,311,469 | 5,406,321 See Footnote | Filing · EDGAR | ||
| Mar 3, 2020 | Derivative converted | +541,002 | 5,947,323 See Footnote | Filing · EDGAR | ||
| Mar 3, 2020 | Derivative converted Series A-1 Preferred Stock | −3,721,552 | 0 See Footnote | Filing · EDGAR | ||
| Mar 3, 2020 | Derivative converted Series A-2 Preferred Stock | −1,311,469 | 0 See Footnote | Filing · EDGAR | ||
| Mar 3, 2020 | Derivative converted Series B Preferred Stock | −541,002 | 0 See Footnote | Filing · EDGAR | ||
| Feb 28, 2020 | Open-market or private purchase | +373,300 | $18.00 | $6.7M | 373,300 See Footnote | Filing · EDGAR |
Corvus Pharmaceuticals CRVS Director, 10% owner · filings 2016 to 2025 · sold $11.6M · bought $22.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 27, 2025 | In-the-money option exercised | +1,397,684 | $3.50 | $4.9M | 8,341,338 See Footnotes | Filing · EDGAR |
| Jun 27, 2025 | Open-market or private sale | −1,176,332 | $4.16 | $4.9M | 7,165,006 See Footnotes | Filing · EDGAR |
| Jun 27, 2025 | In-the-money option exercised Common Warrants (right to buy) | −1,397,684 | 0 See Footnotes | Filing · EDGAR | ||
| May 6, 2024 | Open-market or private purchase Pre-Funded Warrants (right to buy) | +1,444,085 | $1.73 | $2.5M | 1,444,085 See Footnotes | Filing · EDGAR |
| May 6, 2024 | Open-market or private purchase Common Warrants (right to buy) | +1,397,684 | 1,397,684 See Footnotes | Filing · EDGAR | ||
| Sep 20, 2021 | Open-market or private sale | −1,109,644 | $6.09 | $6.8M | 6,943,654 See Footnotes | Filing · EDGAR |
| Feb 17, 2021 | Open-market or private purchase | +1,285,714 | $3.50 | $4.5M | 8,053,298 See Footnotes | Filing · EDGAR |
| Aug 6, 2019 | Open-market or private purchase | +142,656 | $3.51 | $501K | 6,767,584 See Footnotes | Filing · EDGAR |
| Jul 1, 2019 | Open-market or private purchase | +59,243 | $3.91 | $232K | 6,624,928 See Footnotes | Filing · EDGAR |
| Jun 28, 2019 | Open-market or private purchase | +565,178 | $3.72 | $2.1M | 6,565,685 See Footnotes | Filing · EDGAR |
| Jun 27, 2019 | Open-market or private purchase | +32,923 | $3.34 | $110K | 6,000,507 See Footnotes | Filing · EDGAR |
| Mar 12, 2018 | Open-market or private purchase | +588,235 | $8.50 | $5M | 5,967,584 See Footnotes | Filing · EDGAR |
| Jun 24, 2016 | Open-market or private purchase | +900 | $12.99 | $12K | 5,379,349 See Footnotes | Filing · EDGAR |
| Jun 23, 2016 | Open-market or private purchase | +100 | $12.92 | $1K | 5,378,449 See Footnotes | Filing · EDGAR |
| Jun 21, 2016 | Open-market or private purchase | +26,083 | $12.87 | $336K | 5,378,349 See Footnotes | Filing · EDGAR |
| Jun 17, 2016 | Open-market or private purchase | +12,300 | $12.48 | $154K | 5,352,266 See Footnotes | Filing · EDGAR |
| Jun 16, 2016 | Open-market or private purchase | +5,000 | $12.04 | $60K | 5,339,966 See Footnotes | Filing · EDGAR |
| Jun 15, 2016 | Open-market or private purchase | +5,000 | $11.94 | $60K | 5,334,966 See Footnotes | Filing · EDGAR |
| Jun 14, 2016 | Open-market or private purchase | +10,000 | $12.71 | $127K | 5,329,966 See Footnotes | Filing · EDGAR |
| Jun 10, 2016 | Open-market or private purchase | +20,000 | $12.98 | $260K | 5,319,966 See Footnotes | Filing · EDGAR |
| Jun 9, 2016 | Open-market or private purchase | +30,000 | $12.95 | $389K | 5,299,966 See Footnotes | Filing · EDGAR |
| May 20, 2016 | Open-market or private purchase | +4,716 | $13.09 | $62K | 5,269,966 See Footnotes | Filing · EDGAR |
| May 19, 2016 | Open-market or private purchase | +2,539 | $12.11 | $31K | 5,265,189 See Footnotes | Filing · EDGAR |
| May 19, 2016 | Open-market or private purchase | +61 | $12.75 | $778 | 5,265,250 See Footnotes | Filing · EDGAR |
| May 18, 2016 | Open-market or private purchase | +4,200 | $11.55 | $49K | 5,262,650 See Footnotes | Filing · EDGAR |
| Mar 29, 2016 | Derivative converted | +3,994,674 | 3,994,674 See Footnotes | Filing · EDGAR | ||
| Mar 29, 2016 | Derivative converted | +713,776 | 4,708,450 See Footnotes | Filing · EDGAR | ||
| Mar 29, 2016 | Open-market or private purchase | +550,000 | $15.00 | $8.3M | 5,258,450 See Footnotes | Filing · EDGAR |
| Mar 29, 2016 | Derivative converted Series A Convertible Preferred Stock | −3,994,674 | 0 See Footnotes | Filing · EDGAR | ||
| Mar 29, 2016 | Derivative converted Series B Convertible Preferred Stock | −713,776 | 0 See Footnotes | Filing · EDGAR |
NeuroPace NPCE 10% owner · filings 2021 to 2025 · sold $11.4M · bought $4M · $2.6M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 14, 2025 | Open-market or private sale | −134,136 | $15.83 | $2.1M | 3,272,199 See Footnotes | Filing · EDGAR |
| May 14, 2025 | Open-market or private sale | −34,000 | $15.94 | $542K | 3,238,199 See Footnotes | Filing · EDGAR |
| May 3, 2024 | Open-market or private sale | −4,674 | $14.03 | $66K | 3,406,335 See Footnotes | Filing · EDGAR |
| May 2, 2024 | Open-market or private sale | −8,842 | $14.01 | $124K | 3,411,009 See Footnotes | Filing · EDGAR |
| May 1, 2024 | Open-market or private sale | −15,690 | $14.02 | $220K | 3,419,851 See Footnotes | Filing · EDGAR |
| Apr 24, 2024 | Open-market or private sale | −1,781 | $14.06 | $25K | 3,435,541 See Footnotes | Filing · EDGAR |
| Apr 23, 2024 | Open-market or private sale | −21,791 | $14.29 | $311K | 3,437,322 See Footnotes | Filing · EDGAR |
| Apr 22, 2024 | Open-market or private sale | −24,609 | $14.05 | $346K | 3,459,113 See Footnotes | Filing · EDGAR |
| Apr 19, 2024 | Open-market or private sale | −18,253 | $14.02 | $256K | 3,483,722 See Footnotes | Filing · EDGAR |
| Apr 18, 2024 | Open-market or private sale | −2,623 | $14.06 | $37K | 3,501,975 See Footnotes | Filing · EDGAR |
| Apr 17, 2024 | Open-market or private sale | −300 | $14.15 | $4K | 3,504,598 See Footnotes | Filing · EDGAR |
| Apr 16, 2024 | Open-market or private sale | −14,069 | $14.01 | $197K | 3,504,898 See Footnotes | Filing · EDGAR |
| Apr 12, 2024 | Open-market or private sale | −23,101 | $14.42 | $333K | 3,518,967 See Footnotes | Filing · EDGAR |
| Apr 11, 2024 | Open-market or private sale | −461,899 | $14.49 | $6.7M | 3,542,068 See Footnotes | Filing · EDGAR |
| Oct 3, 2023 | Open-market or private sale | −700 | $9.02 | $6K | 4,003,967 See Footnotes | Filing · EDGAR |
| Oct 2, 2023 | Open-market or private sale | −7,614 | $9.08 | $69K | 4,004,667 See Footnotes | Filing · EDGAR |
| Apr 26, 2021 | Derivative converted | +3,777,281 | 4,012,281 See Footnotes | Filing · EDGAR | ||
| Apr 26, 2021 | Derivative converted Series A' Preferred Stock | −171,895 | 0 See Footnotes | Filing · EDGAR | ||
| Apr 26, 2021 | Derivative converted Series B' Preferred Stock | −3,605,386 | 0 See Footnotes | Filing · EDGAR | ||
| Apr 21, 2021 | Open-market or private purchase | +235,000 | $17.00 | $4M | 235,000 See Footnote | Filing · EDGAR |
Xtant Medical Holdings XTNT 10% owner · filings 2018 to 2025 · sold $30.7M · bought $6.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 10, 2025 | Open-market or private sale | −56,004,974 | $0.42 | $23.5M | 0 See footnotes | Filing · EDGAR |
| Apr 10, 2025 | Open-market or private sale | −17,109,618 | $0.42 | $7.2M | 0 See footnotes | Filing · EDGAR |
| Aug 15, 2022 | Other acquisition or disposition (see the filing) | +215,415 | 215,415 See Footnotes | Filing · EDGAR | ||
| Aug 15, 2022 | Other acquisition or disposition (see the filing) | +215,415 | 215,415 See Footnotes | Filing · EDGAR | ||
| Aug 15, 2021 | Other acquisition or disposition (see the filing) | +85,337 | 120,549 See Footnotes | Filing · EDGAR | ||
| Aug 15, 2021 | Other acquisition or disposition (see the filing) | +85,337 | 120,549 See Footnotes | Filing · EDGAR | ||
| Nov 17, 2020 | In-the-money option exercised | +765,992 | $0.01 | $8K | 53,468,376 See Footnotes | Filing · EDGAR |
| Nov 17, 2020 | In-the-money option exercised | +765,992 | $0.01 | $8K | 54,234,368 See Footnotes | Filing · EDGAR |
| Nov 17, 2020 | In-the-money option exercised | +1,531,984 | $0.01 | $15K | 55,766,352 See Footnotes | Filing · EDGAR |
| Nov 17, 2020 | In-the-money option exercised | +434,008 | $0.01 | $4K | 15,734,696 See Footnotes | Filing · EDGAR |
| Nov 17, 2020 | In-the-money option exercised | +434,008 | $0.01 | $4K | 16,168,704 See Footnotes | Filing · EDGAR |
| Nov 17, 2020 | In-the-money option exercised | +868,016 | $0.01 | $9K | 17,036,720 See Footnotes | Filing · EDGAR |
| Nov 17, 2020 | In-the-money option exercised Warrant (right to buy) | −765,992 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 17, 2020 | In-the-money option exercised Warrant (right to buy) | −434,008 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 17, 2020 | In-the-money option exercised Warrant (right to buy) | −765,992 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 17, 2020 | In-the-money option exercised Warrant (right to buy) | −434,008 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 17, 2020 | In-the-money option exercised Warrant (right to buy) | −1,531,984 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 17, 2020 | In-the-money option exercised Warrant (right to buy) | −868,016 | 0 See Footnotes | Filing · EDGAR | ||
| Oct 1, 2020 | Grant or award from the company | +46,784,775 | $1.07 | $50.1M | 52,702,384 See Footnotes | Filing · EDGAR |
| Oct 1, 2020 | Grant or award from the company | +11,969,619 | $1.07 | $12.8M | 15,300,688 See Footnotes | Filing · EDGAR |
| May 6, 2020 | Grant or award from the company Warrant (right to buy) | +1,531,984 | 1,531,984 See footnotes | Filing · EDGAR | ||
| May 6, 2020 | Grant or award from the company Warrant (right to buy) | +868,016 | 868,016 See footnotes | Filing · EDGAR | ||
| Feb 5, 2020 | Other acquisition or disposition (see the filing) | +70,423 | 91,256 See footnote | Filing · EDGAR | ||
| Feb 5, 2020 | Other acquisition or disposition (see the filing) | +70,423 | 91,256 See footnote | Filing · EDGAR | ||
| Oct 30, 2019 | Other acquisition or disposition (see the filing) | +20,833 | 20,833 See Footnote | Filing · EDGAR | ||
| Oct 30, 2019 | Other acquisition or disposition (see the filing) | +20,833 | 20,833 See Footnote | Filing · EDGAR | ||
| Apr 1, 2019 | Grant or award from the company Warrant (right to buy) | +765,992 | 765,992 See Footnotes | Filing · EDGAR | ||
| Apr 1, 2019 | Grant or award from the company Warrant (right to buy) | +434,008 | 434,008 See Footnotes | Filing · EDGAR | ||
| Sep 17, 2018 | Grant or award from the company Warrant (right to buy) | +765,992 | 765,992 See Footnotes | Filing · EDGAR | ||
| Sep 17, 2018 | Grant or award from the company Warrant (right to buy) | +434,008 | 434,008 See Footnotes | Filing · EDGAR | ||
| Feb 14, 2018 | Grant or award from the company | +5,126,534 | $7.20 | $36.9M | 5,287,197 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Grant or award from the company | +2,905,396 | $7.20 | $20.9M | 2,973,996 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Open-market or private purchase | +603,687 | $7.20 | $4.3M | 5,890,884 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Open-market or private purchase | +342,132 | $7.20 | $2.5M | 3,316,128 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Returned to the company Convertible Note | +33,190,000 | $46.56 | $1.5B | 0 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Returned to the company Convertible Note | +18,810,000 | $46.56 | $875.8M | 0 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Returned to the company Convertible Note | +1,428,553 | $34.80 | $49.7M | 0 See Footnotes | Filing · EDGAR |
| Feb 14, 2018 | Returned to the company Convertible Note | +809,614 | $34.80 | $28.2M | 0 See Footnotes | Filing · EDGAR |
Compass Therapeutics CMPX Director, 10% owner · filings 2020 to 2025 · sold $5.7M · bought $27.9M · $5.7M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | Open-market or private sale | −3,571,428 | $1.59 | $5.7M | 0 See footnotes | Filing · EDGAR |
| Nov 8, 2022 | Open-market or private purchase | +402,000 | $3.21 | $1.3M | 15,219,994 See Footnotes | Filing · EDGAR |
| May 13, 2022 | Open-market or private purchase | +30,722 | $2.49 | $76K | 14,817,994 See Footnotes | Filing · EDGAR |
| May 12, 2022 | Open-market or private purchase | +97,094 | $2.35 | $228K | 14,787,272 See Footnotes | Filing · EDGAR |
| May 11, 2022 | Open-market or private purchase | +64,700 | $1.79 | $116K | 14,690,178 See Footnotes | Filing · EDGAR |
| May 10, 2022 | Open-market or private purchase | +24,447 | $1.60 | $39K | 14,625,478 See Footnotes | Filing · EDGAR |
| May 9, 2022 | Open-market or private purchase | +90,712 | $1.56 | $142K | 14,601,031 See Footnotes | Filing · EDGAR |
| May 6, 2022 | Open-market or private purchase | +10,200 | $1.63 | $17K | 14,510,319 See Footnotes | Filing · EDGAR |
| Nov 4, 2021 | Open-market or private purchase | +1,785,715 | $3.50 | $6.3M | 14,500,119 See Footnotes | Filing · EDGAR |
| Nov 4, 2021 | Open-market or private purchase | +3,571,428 | $3.50 | $12.5M | 3,571,428 See Footnotes | Filing · EDGAR |
| Jun 19, 2020 | Open-market or private purchase | +1,455,132 | $5.00 | $7.3M | 12,714,404 direct | Filing · EDGAR |
Edgewise Therapeutics EWTX Director, 10% owner · filings 2021 to 2025 · bought $26.7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 3, 2025 | Open-market or private purchase | +372,578 | $20.13 | $7.5M | 14,809,075 See footnotes | Filing · EDGAR |
| Apr 3, 2025 | Open-market or private purchase | +124,193 | $20.13 | $2.5M | 443,792 See footnotes | Filing · EDGAR |
| Jan 23, 2024 | Open-market or private purchase | +454,545 | $11.00 | $5M | 14,436,497 See footnotes | Filing · EDGAR |
| Sep 16, 2022 | Open-market or private purchase | +484,496 | $10.32 | $5M | 13,981,952 See Footnotes | Filing · EDGAR |
| May 18, 2022 | Open-market or private purchase | +138,000 | $7.21 | $995K | 13,497,456 See Footnotes | Filing · EDGAR |
| Mar 30, 2021 | Derivative converted | +12,730,036 | 13,046,956 See Footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted | +272,724 | 272,724 See Footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Open-market or private purchase | +46,875 | $16.00 | $750K | 319,599 See Footnotes | Filing · EDGAR |
| Mar 30, 2021 | Open-market or private purchase | +312,500 | $16.00 | $5M | 13,359,456 See Footnotes | Filing · EDGAR |
| Mar 30, 2021 | Derivative converted Series A Preferred Stock | −8,187,100 | 0 See Footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series B-1 Preferred Stock | −1,572,960 | 0 See Footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series B-2 Preferred Stock | −1,301,626 | 0 See Footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series C Preferred Stock | −1,668,350 | 0 See Footnotes | Filing · EDGAR | ||
| Mar 30, 2021 | Derivative converted Series C Preferred Stock | −272,724 | 0 See Footnotes | Filing · EDGAR |
MBX Biosciences MBX Director, 10% owner · filings 2024 to 2025 · bought $14M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 18, 2025 | Open-market or private purchase | +49,070 | $10.84 | $532K | 3,255,000 See footnotes | Filing · EDGAR |
| Feb 18, 2025 | Open-market or private purchase | +94,100 | $10.84 | $1M | 747,887 See footnotes | Filing · EDGAR |
| Feb 14, 2025 | Open-market or private purchase | +17,962 | $9.90 | $178K | 3,176,390 See footnotes | Filing · EDGAR |
| Feb 14, 2025 | Open-market or private purchase | +29,540 | $9.85 | $291K | 3,205,930 See footnotes | Filing · EDGAR |
| Sep 16, 2024 | Derivative converted | +2,658,428 | 2,658,428 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted | +403,787 | 403,787 By OrbiMed Genesis Master Fund, L.P. | Filing · EDGAR | ||
| Sep 16, 2024 | Open-market or private purchase | +500,000 | $16.00 | $8M | 3,158,428 By OrbiMed Private Investments VII, LP | Filing · EDGAR |
| Sep 16, 2024 | Open-market or private purchase | +250,000 | $16.00 | $4M | 653,787 By OrbiMed Genesis Master Fund, L.P. | Filing · EDGAR |
| Sep 16, 2024 | Derivative converted Series A Convertible Preferred Stock | −12,372,634 | 0 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted Series B Convertible Preferred Stock | −19,587,284 | 0 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Sep 16, 2024 | Derivative converted Series C Convertible Preferred Stock | −4,854,368 | 0 By OrbiMed Genesis Master Fund, L.P. | Filing · EDGAR |
Lomond Therapeutics Holdings Director · filings 2024 to 2024
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | Derivative converted | +323,916 | $3.20 | $1M | 323,916 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Derivative converted | +215,146 | $3.20 | $688K | 539,062 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Derivative converted | +389,078 | $3.60 | $1.4M | 928,140 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Derivative converted | +230,753 | $3.60 | $831K | 1,158,893 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Derivative converted | +74,613 | $3.60 | $269K | 1,233,506 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Grant or award from the company | +808,894 | $4.00 | $3.2M | 2,042,400 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Grant or award from the company | +479,736 | $4.00 | $1.9M | 2,522,136 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Grant or award from the company | +155,120 | $4.00 | $620K | 2,677,256 See Footnote | Filing · EDGAR |
| Nov 1, 2024 | Derivative converted Simple Agreement for Future Equity | −323,916 | 0 See Footnote | Filing · EDGAR | ||
| Nov 1, 2024 | Derivative converted Simple Agreement for Future Equity | −215,146 | 0 See Footnote | Filing · EDGAR | ||
| Nov 1, 2024 | Derivative converted Simple Agreement for Future Equity | −389,078 | 0 See Footnote | Filing · EDGAR | ||
| Nov 1, 2024 | Derivative converted Simple Agreement for Future Equity | −230,753 | 0 See Footnote | Filing · EDGAR | ||
| Nov 1, 2024 | Derivative converted Simple Agreement for Future Equity | −74,613 | 0 See Footnote | Filing · EDGAR |
Upstream Bio Director, 10% owner · filings 2024 to 2024 · bought $14M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | Derivative converted | +721,956 | 973,716 See Footnote | Filing · EDGAR | ||
| Oct 15, 2024 | Open-market or private purchase | +165,000 | $17.00 | $2.8M | 1,138,716 See Footnote | Filing · EDGAR |
| Oct 15, 2024 | Derivative converted | +2,887,833 | 3,894,873 See Footnote | Filing · EDGAR | ||
| Oct 15, 2024 | Open-market or private purchase | +660,000 | $17.00 | $11.2M | 4,554,873 See Footnote | Filing · EDGAR |
| Oct 15, 2024 | Derivative converted Series A redeemable convertible preferred stock | −524,500 | 0 See Footnote | Filing · EDGAR | ||
| Oct 15, 2024 | Derivative converted Series A redeemable convertible preferred stock | −2,098,000 | 0 See Footnote | Filing · EDGAR | ||
| Oct 15, 2024 | Derivative converted Series B redeemable convertible preferred stock | −197,456 | 0 See Footnote | Filing · EDGAR | ||
| Oct 15, 2024 | Derivative converted Series B redeemable convertible preferred stock | −789,833 | 0 See Footnote | Filing · EDGAR |
ARS Pharmaceuticals Director · filings 2020 to 2024 · sold $12.6M · bought $28.1M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 26, 2024 | Open-market or private sale | −83,695 | $13.00 | $1.1M | 0 See Footnote | Filing · EDGAR |
| Aug 23, 2024 | Open-market or private sale | −69,500 | $13.03 | $906K | 83,695 See Footnote | Filing · EDGAR |
| Aug 22, 2024 | Open-market or private sale | −391,482 | $12.94 | $5.1M | 153,195 See Footnote | Filing · EDGAR |
| Aug 21, 2024 | Open-market or private sale | −394,400 | $13.52 | $5.3M | 557,977 See Footnote | Filing · EDGAR |
| Aug 21, 2024 | Open-market or private sale | −13,300 | $14.61 | $194K | 544,677 See Footnote | Filing · EDGAR |
| Aug 29, 2023 | Open-market or private purchase | +500,000 | $6.20 | $3.1M | 8,019,187 See Footnote | Filing · EDGAR |
| Dec 8, 2020 | Open-market or private purchase | +238,100 | $21.00 | $5M | 507,423 By OrbiMed Private Investments VI, LP | Filing · EDGAR |
| Dec 8, 2020 | Derivative converted | +3,462,737 | 3,970,160 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| Dec 8, 2020 | Derivative converted | +2,493,741 | 6,463,901 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| Dec 8, 2020 | Derivative converted | +1,055,287 | 7,519,188 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| Dec 8, 2020 | Open-market or private purchase | +952,377 | $21.00 | $20M | 952,377 By OrbiMed Partners Master Fund Limited | Filing · EDGAR |
| Dec 8, 2020 | Derivative converted Series A Preferred Stock | −12,857,142 | 0 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| Dec 8, 2020 | Derivative converted Series B Preferred Stock | −9,259,259 | 0 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| Dec 8, 2020 | Derivative converted Series C Preferred Stock | −3,918,279 | 0 By OrbiMed Private Investments VI, LP | Filing · EDGAR |
scPharmaceuticals 10% owner · filings 2017 to 2024 · bought $29.7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Open-market or private purchase | +478,342 | $4.00 | $1.9M | 5,806,670 See footnotes | Filing · EDGAR |
| Aug 13, 2024 | Open-market or private purchase | +21,658 | $4.00 | $87K | 252,858 See footnotes | Filing · EDGAR |
| Nov 25, 2022 | Open-market or private purchase | +762,380 | $5.25 | $4M | 5,328,328 See Footnotes | Filing · EDGAR |
| May 21, 2020 | Open-market or private purchase | +1,156,083 | $8.65 | $10M | 4,565,948 See Footnotes | Filing · EDGAR |
| May 21, 2020 | Open-market or private purchase | +231,200 | $8.65 | $2M | 231,200 See Footnotes | Filing · EDGAR |
| Nov 21, 2017 | Derivative converted | +2,576,532 | 2,576,532 See Footnotes | Filing · EDGAR | ||
| Nov 21, 2017 | Open-market or private purchase | +833,333 | $14.00 | $11.7M | 3,409,865 See Footnotes | Filing · EDGAR |
| Nov 21, 2017 | Derivative converted Series B Preferred Stock | −18,500,000 | 0 See Footnotes | Filing · EDGAR |
Terns Pharmaceuticals Director, 10% owner · filings 2021 to 2024 · sold $562K · bought $18M · $11.7M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 16, 2024 | Sale under a 10b5-1 plan | −4,009 | $10.00 | $40K | 4,839,412 See footnotes | Filing · EDGAR |
| Jul 16, 2024 | Sale under a 10b5-1 plan | −556 | $10.00 | $6K | 1,967,924 See footnotes | Filing · EDGAR |
| Jul 16, 2024 | Sale under a 10b5-1 plan | −623 | $10.00 | $6K | 755,635 See footnotes | Filing · EDGAR |
| Jul 15, 2024 | Sale under a 10b5-1 plan | −39,433 | $10.00 | $394K | 4,843,421 See footnotes | Filing · EDGAR |
| Jul 15, 2024 | Sale under a 10b5-1 plan | −5,401 | $10.00 | $54K | 1,968,480 See footnotes | Filing · EDGAR |
| Jul 15, 2024 | Sale under a 10b5-1 plan | −6,142 | $10.00 | $61K | 756,258 See footnotes | Filing · EDGAR |
| Dec 23, 2022 | Open-market or private purchase | +137,931 | $7.25 | $1M | 4,882,854 See footnotes | Filing · EDGAR |
| Aug 16, 2022 | Open-market or private purchase | +2,470,200 | $2.42 | $6M | 4,744,923 See footnotes | Filing · EDGAR |
| Aug 16, 2022 | Open-market or private purchase | +457,400 | $2.42 | $1.1M | 1,973,881 See footnotes | Filing · EDGAR |
| Aug 16, 2022 | Open-market or private purchase | +762,400 | $2.42 | $1.8M | 762,400 See footnotes | Filing · EDGAR |
| Aug 16, 2022 | Open-market or private purchase Pre-Funded Warrant | +207,500 | 207,500 See footnotes | Filing · EDGAR | ||
| Aug 16, 2022 | Open-market or private purchase Pre-Funded Warrant | +38,450 | 38,450 See footnotes | Filing · EDGAR | ||
| Aug 16, 2022 | Open-market or private purchase Pre-Funded Warrant | +64,050 | 64,050 See footnotes | Filing · EDGAR | ||
| Feb 9, 2021 | Derivative converted | +1,326,481 | 1,326,481 See footnotes | Filing · EDGAR | ||
| Feb 9, 2021 | Derivative converted | +1,989,723 | 1,989,723 See footnotes | Filing · EDGAR | ||
| Feb 9, 2021 | Open-market or private purchase | +190,000 | $17.00 | $3.2M | 1,516,481 See footnotes | Filing · EDGAR |
| Feb 9, 2021 | Open-market or private purchase | +285,000 | $17.00 | $4.8M | 2,274,723 See footnotes | Filing · EDGAR |
| Feb 9, 2021 | Derivative converted Series B Preferred Stock | −714,285 | 0 See footnotes | Filing · EDGAR | ||
| Feb 9, 2021 | Derivative converted Series B Preferred Stock | −1,071,428 | 0 See footnotes | Filing · EDGAR | ||
| Feb 9, 2021 | Derivative converted Series C Preferred Stock | −612,196 | 0 See footnotes | Filing · EDGAR | ||
| Feb 9, 2021 | Derivative converted Series C Preferred Stock | −918,295 | 0 See footnotes | Filing · EDGAR |
TELA Bio 10% owner · filings 2019 to 2024 · sold $3.8M · bought $5M · $4.2M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 2, 2024 | Open-market or private sale | −36,600 | $4.54 | $166K | 2,407,242 See footnotes | Filing · EDGAR |
| Jul 1, 2024 | Open-market or private sale | −13,700 | $4.68 | $64K | 2,443,842 See footnotes | Filing · EDGAR |
| Jun 28, 2024 | Open-market or private sale | −378,000 | $4.74 | $1.8M | 2,457,542 See footnotes | Filing · EDGAR |
| Apr 21, 2023 | Open-market or private sale | −27,700 | $9.41 | $261K | 2,835,542 See footnotes | Filing · EDGAR |
| Apr 20, 2023 | Open-market or private sale | −28,300 | $9.43 | $267K | 2,863,242 See footnotes | Filing · EDGAR |
| Apr 19, 2023 | Open-market or private sale | −136,000 | $9.30 | $1.3M | 2,891,542 See footnotes | Filing · EDGAR |
| Nov 13, 2019 | Derivative converted | +481,095 | 2,049,722 direct | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted | +977,820 | 3,027,542 direct | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted Series A Preferred Stock | −11,878,249 | 0 direct | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted Series B Preferred Stock | −24,142,419 | 0 direct | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted Warrant (right to buy) | −758,623 | 0 direct | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted Warrant (right to buy) | +758,623 | 758,623 direct | Filing · EDGAR | ||
| Nov 8, 2019 | Open-market or private purchase | +384,615 | $13.00 | $5M | 1,568,627 direct | Filing · EDGAR |
Alpine Immune Sciences Director · filings 2017 to 2024 · sold $37.2M · bought $11.5M · $31.3M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 18, 2024 | Tendered in a change of control | −2,416,181 | $0.00 | $2K | 0 See footnotes | Filing · EDGAR |
| May 18, 2024 | Tendered in a change of control | −264,315 | $0.00 | $264 | 0 See footnotes | Filing · EDGAR |
| Jan 11, 2024 | In-the-money option exercised | +145,251 | $12.74 | $1.9M | 2,416,181 See footnotes | Filing · EDGAR |
| Jan 11, 2024 | In-the-money option exercised Warrant (Right to Buy) | −145,251 | 0 See footnotes | Filing · EDGAR | ||
| Dec 28, 2023 | Open-market or private sale | −26,872 | $19.82 | $533K | 3,466,613 See footnotes | Filing · EDGAR |
| Dec 28, 2023 | Open-market or private sale | −3,128 | $19.82 | $62K | 403,481 See footnotes | Filing · EDGAR |
| Dec 28, 2023 | Open-market or private sale | −1,195,683 | $18.32 | $21.9M | 2,270,930 See footnotes | Filing · EDGAR |
| Dec 28, 2023 | Open-market or private sale | −139,166 | $18.32 | $2.5M | 264,315 See footnotes | Filing · EDGAR |
| Dec 27, 2023 | Open-market or private sale | −162,576 | $19.96 | $3.2M | 3,493,485 See footnotes | Filing · EDGAR |
| Dec 27, 2023 | Open-market or private sale | −18,922 | $19.96 | $378K | 406,609 See footnotes | Filing · EDGAR |
| Sep 17, 2021 | Open-market or private purchase | +585,106 | $9.40 | $5.5M | 3,656,061 See Footnotes | Filing · EDGAR |
| Sep 17, 2021 | Open-market or private purchase | +425,531 | $9.40 | $4M | 425,531 See Footnotes | Filing · EDGAR |
| Dec 28, 2020 | Open-market or private sale | −600,000 | $14.25 | $8.6M | 3,070,955 See Footnotes | Filing · EDGAR |
| Jan 18, 2019 | Open-market or private purchase | +372,439 | $5.37 | $2M | 3,670,955 See Footnotes | Filing · EDGAR |
| Jan 18, 2019 | Open-market or private purchase Warrants to Purchase Common Stock | +145,251 | 145,251 See Footnotes | Filing · EDGAR | ||
| Jul 24, 2017 | Grant or award from the company | +3,298,516 | 3,298,516 See Footnotes | Filing · EDGAR |
Kinnate Biopharma Director, 10% owner · filings 2020 to 2024 · bought $24.7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 3, 2024 | Returned to the company | −1,368,339 | 0 See footnotes | Filing · EDGAR | ||
| Apr 3, 2024 | Returned to the company | −4,738,453 | 0 See footnotes | Filing · EDGAR | ||
| Apr 3, 2024 | Returned to the company | −1,368,338 | 0 See footnotes | Filing · EDGAR | ||
| Apr 3, 2024 | Returned to the company | −84,599 | 0 See footnotes | Filing · EDGAR | ||
| Apr 3, 2024 | Returned to the company | −450,000 | 0 See footnotes | Filing · EDGAR | ||
| May 5, 2023 | Open-market or private purchase | +490,512 | $2.82 | $1.4M | 1,368,339 See footnotes | Filing · EDGAR |
| May 5, 2023 | Open-market or private purchase | +490,511 | $2.82 | $1.4M | 1,368,338 See footnotes | Filing · EDGAR |
| May 4, 2023 | Open-market or private purchase | +83,459 | $2.75 | $230K | 877,827 See footnotes | Filing · EDGAR |
| May 4, 2023 | Open-market or private purchase | +312,991 | $2.75 | $861K | 4,738,453 See footnotes | Filing · EDGAR |
| May 4, 2023 | Open-market or private purchase | +83,459 | $2.75 | $230K | 877,827 See footnotes | Filing · EDGAR |
| May 2, 2023 | Open-market or private purchase | +58,826 | $2.67 | $157K | 794,368 See footnotes | Filing · EDGAR |
| May 2, 2023 | Open-market or private purchase | +220,610 | $2.67 | $589K | 4,425,462 See footnotes | Filing · EDGAR |
| May 2, 2023 | Open-market or private purchase | +58,826 | $2.67 | $157K | 794,368 See footnotes | Filing · EDGAR |
| May 1, 2023 | Open-market or private purchase | +124,544 | $2.62 | $326K | 735,542 See footnotes | Filing · EDGAR |
| May 1, 2023 | Open-market or private purchase | +467,068 | $2.62 | $1.2M | 4,204,852 See footnotes | Filing · EDGAR |
| May 1, 2023 | Open-market or private purchase | +124,545 | $2.62 | $326K | 735,542 See footnotes | Filing · EDGAR |
| Apr 28, 2023 | Open-market or private purchase | +60,998 | $2.55 | $156K | 610,998 See footnotes | Filing · EDGAR |
| Apr 28, 2023 | Open-market or private purchase | +228,754 | $2.55 | $583K | 3,737,784 See footnotes | Filing · EDGAR |
| Apr 28, 2023 | Open-market or private purchase | +60,997 | $2.55 | $156K | 610,997 See footnotes | Filing · EDGAR |
| Feb 17, 2023 | Grant or award from the company | +550,000 | 550,000 See footnotes | Filing · EDGAR | ||
| Feb 17, 2023 | Grant or award from the company | +550,000 | 550,000 See footnotes | Filing · EDGAR | ||
| Feb 15, 2022 | Open-market or private purchase | +9,000 | $9.96 | $90K | 3,509,030 See Footnotes | Filing · EDGAR |
| Feb 14, 2022 | Open-market or private purchase | +20,700 | $9.98 | $207K | 3,490,030 See Footnotes | Filing · EDGAR |
| Feb 14, 2022 | Open-market or private purchase | +10,000 | $9.89 | $99K | 3,500,030 See Footnotes | Filing · EDGAR |
| Feb 11, 2022 | Open-market or private purchase | +156,000 | $10.22 | $1.6M | 3,469,330 See Footnotes | Filing · EDGAR |
| Dec 7, 2020 | Derivative converted | +243,494 | 543,494 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted | +2,651,042 | 3,194,536 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted | +118,794 | 3,313,330 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted | +50,501 | 50,501 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted | +9,461 | 59,962 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted | +24,637 | 84,599 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted Series A Preferred Stock | −243,494 | 0 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted Series B Preferred Stock | −2,651,042 | 0 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted Series C Preferred Stock | −118,398 | 0 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted Series A Preferred Stock | −50,501 | 0 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted Series B Preferred Stock | −9,461 | 0 See footnotes | Filing · EDGAR | ||
| Dec 7, 2020 | Derivative converted Series C Preferred Stock | −24,555 | 0 See footnotes | Filing · EDGAR | ||
| Dec 2, 2020 | Open-market or private purchase | +300,000 | $20.00 | $6M | 300,000 See footnotes | Filing · EDGAR |
| Dec 2, 2020 | Open-market or private purchase | +450,000 | $20.00 | $9M | 450,000 See footnotes | Filing · EDGAR |
Verona Pharma Shareholder · filings 2021 to 2024 · sold $145.9M · $78.5M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 15, 2023 | Open-market or private sale | −14,400 | $21.96 | $316K | 4,123,091 See footnotes | Filing · EDGAR |
| May 15, 2023 | Open-market or private sale | −345,313 | $20.00 | $6.9M | 3,777,778 See footnotes | Filing · EDGAR |
| May 12, 2023 | Open-market or private sale | −43,200 | $21.64 | $935K | 4,137,491 See footnotes | Filing · EDGAR |
| May 11, 2023 | Open-market or private sale | −80,000 | $22.26 | $1.8M | 4,180,691 See footnotes | Filing · EDGAR |
| Dec 23, 2022 | Open-market or private sale | −961,328 | $22.27 | $21.4M | 35,294,568 See footnotes | Filing · EDGAR |
| Dec 23, 2022 | Open-market or private sale | −1,116,048 | $23.23 | $25.9M | 34,178,520 See footnotes | Filing · EDGAR |
| Dec 23, 2022 | Open-market or private sale | −92,992 | $24.11 | $2.2M | 34,085,528 See footnotes | Filing · EDGAR |
| Dec 22, 2022 | Open-market or private sale | −3,284,800 | $21.71 | $71.3M | 36,940,592 See footnotes | Filing · EDGAR |
| Dec 22, 2022 | Open-market or private sale | −684,696 | $22.07 | $15.1M | 36,255,896 See footnotes | Filing · EDGAR |
Theseus Pharmaceuticals Director, 10% owner · filings 2021 to 2024 · bought $14.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 14, 2024 | Tendered in a change of control | −17,063,000 | $4.05 | $69.1M | 0 See Footnotes | Filing · EDGAR |
| Feb 14, 2024 | Tendered in a change of control | −650,600 | $4.05 | $2.6M | 0 See Footnotes | Filing · EDGAR |
| Jul 17, 2023 | Open-market or private purchase | +328,482 | $3.05 | $1M | 17,063,000 See Footnotes | Filing · EDGAR |
| Jul 17, 2023 | Open-market or private purchase | +151,450 | $3.05 | $462K | 650,600 See Footnotes | Filing · EDGAR |
| Nov 7, 2022 | Open-market or private purchase | +192,000 | $5.21 | $1M | 16,734,518 See Footnotes | Filing · EDGAR |
| Jan 21, 2022 | Open-market or private purchase | +111,896 | $9.97 | $1.1M | 16,542,652 See Footnotes | Filing · EDGAR |
| Jan 20, 2022 | Open-market or private purchase | +35,000 | $9.95 | $348K | 16,430,756 See Footnotes | Filing · EDGAR |
| Jan 19, 2022 | Open-market or private purchase | +11,521 | $9.97 | $115K | 16,395,756 See Footnotes | Filing · EDGAR |
| Jan 13, 2022 | Open-market or private purchase | +17,320 | $9.43 | $163K | 16,384,235 See Footnotes | Filing · EDGAR |
| Jan 12, 2022 | Open-market or private purchase | +18,897 | $10.06 | $190K | 16,366,915 See Footnotes | Filing · EDGAR |
| Jan 11, 2022 | Open-market or private purchase | +1,600 | $9.81 | $16K | 16,341,118 See Footnotes | Filing · EDGAR |
| Jan 11, 2022 | Open-market or private purchase | +6,900 | $10.67 | $74K | 16,348,018 See Footnotes | Filing · EDGAR |
| Oct 12, 2021 | Derivative converted | +15,777,018 | 15,777,018 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Oct 12, 2021 | Derivative converted | +436,650 | 436,650 By OrbiMed Genesis Master Fund, L.P. | Filing · EDGAR | ||
| Oct 12, 2021 | Open-market or private purchase | +562,500 | $16.00 | $9M | 16,339,518 By OrbiMed Private Investments VII, LP | Filing · EDGAR |
| Oct 12, 2021 | Open-market or private purchase | +62,500 | $16.00 | $1M | 499,150 By OrbiMed Genesis Master Fund, L.P. | Filing · EDGAR |
| Oct 12, 2021 | Derivative converted Series A Convertible Preferred Stock | −14,903,718 | 0 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Oct 12, 2021 | Derivative converted Series B Convertible Preferred Stock | −873,300 | 0 By OrbiMed Private Investments VII, LP | Filing · EDGAR | ||
| Oct 12, 2021 | Derivative converted Series B Convertible Preferred Stock | −436,650 | 0 By OrbiMed Genesis Master Fund, L.P. | Filing · EDGAR |
ArriVent Biopharma Director, 10% owner · filings 2024 to 2024 · bought $8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 30, 2024 | Derivative converted | +821,827 | 821,827 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Derivative converted | +821,827 | 821,827 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Derivative converted | +469,615 | 1,291,442 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Derivative converted | +469,615 | 1,291,442 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Open-market or private purchase | +222,222 | $18.00 | $4M | 1,513,664 See footnotes | Filing · EDGAR |
| Jan 30, 2024 | Open-market or private purchase | +222,222 | $18.00 | $4M | 1,513,664 See footnotes | Filing · EDGAR |
| Jan 30, 2024 | Derivative converted Series A Preferred Stock | −821,827 | 0 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Derivative converted Series A Preferred Stock | −821,827 | 0 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Derivative converted Series B Preferred Stock | −469,615 | 0 See footnotes | Filing · EDGAR | ||
| Jan 30, 2024 | Derivative converted Series B Preferred Stock | −469,615 | 0 See footnotes | Filing · EDGAR |
Galecto Shareholder · filings 2020 to 2023 · sold $2.3M · bought $11M · $7.2M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 15, 2023 | Open-market or private sale | −38,327 | $0.75 | $29K | 97,204 See footnotes | Filing · EDGAR |
| Aug 15, 2023 | Open-market or private sale | −248,819 | $0.75 | $187K | 631,048 See footnotes | Filing · EDGAR |
| Aug 15, 2023 | Open-market or private sale | −535,534 | $0.75 | $402K | 1,510,375 See footnotes | Filing · EDGAR |
| Jul 31, 2023 | Open-market or private sale | −26,622 | $3.00 | $80K | 135,531 See footnotes | Filing · EDGAR |
| Jul 31, 2023 | Open-market or private sale | −29,700 | $3.00 | $89K | 879,867 See footnotes | Filing · EDGAR |
| Jul 31, 2023 | Open-market or private sale | −153,078 | $3.00 | $459K | 2,105,909 See footnotes | Filing · EDGAR |
| Jul 25, 2023 | Open-market or private sale | −7,800 | $2.92 | $23K | 162,153 See footnotes | Filing · EDGAR |
| Jul 25, 2023 | Open-market or private sale | −4,700 | $2.92 | $14K | 909,567 See footnotes | Filing · EDGAR |
| Jul 25, 2023 | Open-market or private sale | −26,700 | $2.92 | $78K | 2,258,987 See footnotes | Filing · EDGAR |
| Jul 13, 2023 | Open-market or private sale | −9,800 | $2.40 | $24K | 169,953 See footnotes | Filing · EDGAR |
| Jul 13, 2023 | Open-market or private sale | −52,800 | $2.40 | $127K | 914,267 See footnotes | Filing · EDGAR |
| Jul 13, 2023 | Open-market or private sale | −132,100 | $2.40 | $317K | 2,285,687 See footnotes | Filing · EDGAR |
| Apr 17, 2023 | Open-market or private sale | −660 | $1.97 | $1K | 179,753 See footnotes | Filing · EDGAR |
| Apr 17, 2023 | Open-market or private sale | −3,551 | $1.97 | $7K | 967,067 See footnotes | Filing · EDGAR |
| Apr 17, 2023 | Open-market or private sale | −8,878 | $1.97 | $17K | 2,417,787 See footnotes | Filing · EDGAR |
| Apr 14, 2023 | Open-market or private sale | −2,091 | $1.86 | $4K | 180,413 See footnotes | Filing · EDGAR |
| Apr 14, 2023 | Open-market or private sale | −11,245 | $1.86 | $21K | 970,618 See footnotes | Filing · EDGAR |
| Apr 14, 2023 | Open-market or private sale | −28,110 | $1.86 | $52K | 2,426,665 See footnotes | Filing · EDGAR |
| Apr 13, 2023 | Open-market or private sale | −703 | $1.82 | $1K | 182,504 See footnotes | Filing · EDGAR |
| Apr 13, 2023 | Open-market or private sale | −3,784 | $1.82 | $7K | 981,863 See footnotes | Filing · EDGAR |
| Apr 13, 2023 | Open-market or private sale | −9,459 | $1.82 | $17K | 2,454,775 See footnotes | Filing · EDGAR |
| Apr 12, 2023 | Open-market or private sale | −119 | $1.81 | $215 | 183,207 See footnotes | Filing · EDGAR |
| Apr 12, 2023 | Open-market or private sale | −641 | $1.81 | $1K | 985,647 See footnotes | Filing · EDGAR |
| Apr 12, 2023 | Open-market or private sale | −1,603 | $1.81 | $3K | 2,464,234 See footnotes | Filing · EDGAR |
| Apr 11, 2023 | Open-market or private sale | −703 | $1.82 | $1K | 183,326 See footnotes | Filing · EDGAR |
| Apr 11, 2023 | Open-market or private sale | −3,784 | $1.82 | $7K | 986,288 See footnotes | Filing · EDGAR |
| Apr 11, 2023 | Open-market or private sale | −9,459 | $1.82 | $17K | 2,465,837 See footnotes | Filing · EDGAR |
| Apr 10, 2023 | Open-market or private sale | −2,584 | $1.79 | $5K | 185,910 See footnotes | Filing · EDGAR |
| Apr 10, 2023 | Open-market or private sale | −13,899 | $1.79 | $25K | 1,000,187 See footnotes | Filing · EDGAR |
| Apr 10, 2023 | Open-market or private sale | −34,745 | $1.79 | $62K | 2,500,582 See footnotes | Filing · EDGAR |
| Apr 6, 2023 | Open-market or private sale | −487 | $2.00 | $974 | 186,613 See footnotes | Filing · EDGAR |
| Apr 6, 2023 | Open-market or private sale | −2,620 | $2.00 | $5K | 1,003,971 See footnotes | Filing · EDGAR |
| Apr 6, 2023 | Open-market or private sale | −6,558 | $2.00 | $13K | 2,510,041 See footnotes | Filing · EDGAR |
| Apr 5, 2023 | Open-market or private sale | −4,687 | $2.18 | $10K | 187,100 See footnotes | Filing · EDGAR |
| Apr 5, 2023 | Open-market or private sale | −25,220 | $2.18 | $55K | 1,006,591 See footnotes | Filing · EDGAR |
| Apr 5, 2023 | Open-market or private sale | −63,058 | $2.18 | $137K | 2,516,599 See footnotes | Filing · EDGAR |
| Nov 2, 2020 | Derivative converted | +2,055,824 | 2,055,824 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted | +822,311 | 822,311 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted | +191,787 | 191,787 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Open-market or private purchase | +523,833 | $15.00 | $7.9M | 2,579,657 See footnote | Filing · EDGAR |
| Nov 2, 2020 | Open-market or private purchase | +209,500 | $15.00 | $3.1M | 1,031,811 See footnote | Filing · EDGAR |
| Nov 2, 2020 | Derivative converted Series C-2 Preferred Stock | −291,999 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series C-2 Preferred Stock | −116,800 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series C-4 Preferred Stock | −272,533 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series C-4 Preferred Stock | −109,013 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series C-5 Preferred Stock | −77,866 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series C-5 Preferred Stock | −31,147 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series D Preferred Stock | −148,395 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series D Preferred Stock | −59,350 | 0 See footnote | Filing · EDGAR | ||
| Nov 2, 2020 | Derivative converted Series D Preferred Stock | −73,773 | 0 See footnote | Filing · EDGAR | ||
| Sep 25, 2020 | Grant or award from the company Series D Preferred Stock | −148,395 | $27.11 | $4M | 148,395 See footnote | Filing · EDGAR |
| Sep 25, 2020 | Grant or award from the company Series D Preferred Stock | −59,350 | $27.11 | $1.6M | 59,350 See footnote | Filing · EDGAR |
| Sep 25, 2020 | Grant or award from the company Series D Preferred Stock | −73,773 | $27.11 | $2M | 73,773 See footnote | Filing · EDGAR |
Gracell Biotechnologies Shareholder · filings 2023 to 2023 · $1.8M noticed on Form 144
No transactions in the filings read; Form 144 notices are listed above.
Tricida Director, 10% owner · filings 2018 to 2022 · sold $62.2M · bought $15.1M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 25, 2022 | Open-market or private sale | −3,629,226 | $0.22 | $798K | 0 See Footnotes | Filing · EDGAR |
| Nov 23, 2022 | Open-market or private sale | −5,617,300 | $0.21 | $1.2M | 3,629,226 See Footnotes | Filing · EDGAR |
| Nov 22, 2022 | Open-market or private sale | −1,034,421 | $0.22 | $228K | 9,246,526 See Footnotes | Filing · EDGAR |
| Nov 15, 2021 | Grant or award from the company | +666,667 | $6.00 | $4M | 10,280,947 See Footnotes | Filing · EDGAR |
| Nov 15, 2021 | Grant or award from the company Comm on Warrants to Purchase Common Stock | +666,667 | 666,667 See footnotes | Filing · EDGAR | ||
| Dec 11, 2019 | Open-market or private sale | −1,500,000 | $40.00 | $60M | 9,614,280 By OrbiMed Private Investments V, LP | Filing · EDGAR |
| Apr 3, 2019 | Open-market or private purchase | +225,000 | $36.00 | $8.1M | 11,114,280 By OrbiMed Private Investments V, LP | Filing · EDGAR |
| Jul 2, 2018 | Derivative converted | +1,559,716 | 1,559,716 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Derivative converted | +4,300,774 | 5,860,490 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Derivative converted | +3,591,194 | 9,451,684 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Derivative converted | +1,069,175 | 10,520,859 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Open-market or private purchase | +368,421 | $19.00 | $7M | 10,889,280 By OrbiMed Private Investments V, LP | Filing · EDGAR |
| Jul 2, 2018 | Derivative converted Series A Convertible Preferred Stock | −6,207,674 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Derivative converted Series B Convertible Preferred Stock | −17,117,085 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Derivative converted Series C Convertible Preferred Stock | −14,292,958 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jul 2, 2018 | Derivative converted Series D Convertible Preferred Stock | −4,255,319 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR |
Third Harmonic Bio Director, 10% owner · filings 2022 to 2022 · bought $5.1M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 19, 2022 | Derivative converted | +5,479,071 | 5,479,071 See Footnote | Filing · EDGAR | ||
| Sep 19, 2022 | Open-market or private purchase | +300,000 | $17.00 | $5.1M | 5,779,071 See Footnote | Filing · EDGAR |
| Sep 19, 2022 | Derivative converted Series A-2 Preferred Stock | −8,593,750 | 0 See Footnote | Filing · EDGAR | ||
| Sep 19, 2022 | Derivative converted Series A-3 Preferred Stock | −2,441,407 | 0 See Footnote | Filing · EDGAR | ||
| Sep 19, 2022 | Derivative converted Series B Preferred Stock | −1,342,065 | 0 See Footnote | Filing · EDGAR |
SpringWorks Therapeutics 10% owner · filings 2019 to 2022 · sold $130.3M · bought $5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 12, 2022 | Open-market or private sale | −123,897 | $31.96 | $4M | 5,629,842 See Footnotes | Filing · EDGAR |
| Sep 12, 2022 | Open-market or private sale | −30,000 | $31.98 | $959K | 5,599,842 See Footnotes | Filing · EDGAR |
| Aug 9, 2022 | Open-market or private sale | −69,568 | $37.47 | $2.6M | 5,753,739 See Footnotes | Filing · EDGAR |
| Aug 8, 2022 | Open-market or private sale | −205,000 | $38.33 | $7.9M | 5,823,307 See Footnotes | Filing · EDGAR |
| Jul 1, 2021 | Sale under a 10b5-1 plan | −15,959 | $85.01 | $1.4M | 6,028,307 See Footnotes | Filing · EDGAR |
| Jun 28, 2021 | Sale under a 10b5-1 plan | −6,502 | $85.17 | $554K | 6,044,266 See Footnotes | Filing · EDGAR |
| Jun 25, 2021 | Sale under a 10b5-1 plan | −22,334 | $85.14 | $1.9M | 6,050,768 See Footnotes | Filing · EDGAR |
| Jun 24, 2021 | Sale under a 10b5-1 plan | −34,200 | $85.22 | $2.9M | 6,073,102 See Footnotes | Filing · EDGAR |
| Jun 23, 2021 | Sale under a 10b5-1 plan | −100 | $85.00 | $9K | 6,107,302 See Footnotes | Filing · EDGAR |
| Jun 10, 2021 | Sale under a 10b5-1 plan | −30,852 | $85.09 | $2.6M | 6,107,402 See Footnotes | Filing · EDGAR |
| Jun 9, 2021 | Sale under a 10b5-1 plan | −5,049 | $85.33 | $431K | 6,138,254 See Footnotes | Filing · EDGAR |
| Jun 8, 2021 | Sale under a 10b5-1 plan | −42,633 | $85.37 | $3.6M | 6,143,303 See Footnotes | Filing · EDGAR |
| Jun 7, 2021 | Sale under a 10b5-1 plan | −371 | $84.90 | $31K | 6,185,936 See Footnotes | Filing · EDGAR |
| Mar 1, 2021 | Open-market or private sale | −1,220,000 | $83.19 | $101.5M | 6,186,307 See Footnotes | Filing · EDGAR |
| Sep 17, 2019 | Derivative converted | +6,078,103 | 6,078,103 See footnote | Filing · EDGAR | ||
| Sep 17, 2019 | Derivative converted | +1,053,204 | 7,131,307 See footnote | Filing · EDGAR | ||
| Sep 17, 2019 | Open-market or private purchase | +275,000 | $18.00 | $5M | 7,406,307 See footnote | Filing · EDGAR |
| Sep 17, 2019 | Derivative converted Series A Convertible Preferred Stock | −6,078,103 | 0 See footnote | Filing · EDGAR | ||
| Sep 17, 2019 | Derivative converted Series B Convertible Preferred Stock | −1,053,204 | 0 See footnote | Filing · EDGAR |
Sierra Oncology Director, 10% owner · filings 2015 to 2022 · bought $3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 1, 2022 | Returned to the company | −1,511,362 | $55.00 | $83.1M | 0 See footnotes | Filing · EDGAR |
| Jul 1, 2022 | Returned to the company | −226,704 | $55.00 | $12.5M | 0 See footnotes | Filing · EDGAR |
| Jul 1, 2022 | Returned to the company | −226,704 | $55.00 | $12.5M | 0 See footnotes | Filing · EDGAR |
| Jul 1, 2022 | Returned to the company Series A Warrants | −1,136,250 | 0 See footnotes | Filing · EDGAR | ||
| Jul 1, 2022 | Returned to the company Series A Warrants | −170,437 | 0 See footnotes | Filing · EDGAR | ||
| Jul 1, 2022 | Returned to the company Series A Warrants | −170,437 | 0 See footnotes | Filing · EDGAR | ||
| Jan 26, 2022 | In-the-money option exercised | +374,962 | $13.20 | $4.9M | 1,511,362 See footnote (4), | Filing · EDGAR |
| Jan 26, 2022 | In-the-money option exercised | +56,244 | $13.20 | $742K | 226,704 See footnote (4), | Filing · EDGAR |
| Jan 26, 2022 | In-the-money option exercised | +56,244 | $13.20 | $742K | 226,704 See footnote | Filing · EDGAR |
| Jan 26, 2022 | In-the-money option exercised Series B Warrants | −374,962 | 0 See footnote | Filing · EDGAR | ||
| Jan 26, 2022 | In-the-money option exercised Series B Warrants | −56,244 | 0 See footnote | Filing · EDGAR | ||
| Jan 26, 2022 | In-the-money option exercised Series B Warrants | −56,244 | 0 See footnote | Filing · EDGAR | ||
| Jan 29, 2020 | Derivative converted | +1,477,320 | 1,477,320 See footnotes | Filing · EDGAR | ||
| Jan 29, 2020 | Derivative converted Series A Convertible Voting Preferred Stock | −19,500 | 0 See footnotes | Filing · EDGAR | ||
| Jul 21, 2015 | Derivative converted | +1,725,790 | 1,725,790 See Footnotes | Filing · EDGAR | ||
| Jul 21, 2015 | Other acquisition or disposition (see the filing) | +89,159 | $5.22 | $465K | 1,814,949 See Footnotes | Filing · EDGAR |
| Jul 21, 2015 | Open-market or private purchase | +175,000 | $17.00 | $3M | 1,989,949 See Footnotes | Filing · EDGAR |
| Jul 21, 2015 | Derivative converted Series D Preferred Stock | −1,725,790 | 0 See Footnotes | Filing · EDGAR |
Arcutis Biotherapeutics 10% owner · filings 2020 to 2022 · sold $25.5M · bought $21.9M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 24, 2022 | Open-market or private sale | −306,027 | $21.31 | $6.5M | 3,534,537 See Footnotes | Filing · EDGAR |
| Jun 24, 2022 | Open-market or private sale | −35,944 | $21.31 | $766K | 415,142 See Footnotes | Filing · EDGAR |
| Apr 8, 2022 | Open-market or private sale | −97,200 | $20.71 | $2M | 3,840,564 See Footnotes | Filing · EDGAR |
| Apr 8, 2022 | Open-market or private sale | −102,800 | $20.71 | $2.1M | 451,086 See Footnotes | Filing · EDGAR |
| Apr 7, 2022 | Open-market or private sale | −167,800 | $20.66 | $3.5M | 3,937,764 See Footnotes | Filing · EDGAR |
| Apr 7, 2022 | Open-market or private sale | −177,196 | $20.66 | $3.7M | 553,886 See Footnotes | Filing · EDGAR |
| Apr 6, 2022 | Open-market or private sale | −162,000 | $20.69 | $3.4M | 4,105,564 See Footnotes | Filing · EDGAR |
| Apr 6, 2022 | Open-market or private sale | −171,204 | $20.69 | $3.5M | 731,082 See Footnotes | Filing · EDGAR |
| Oct 2, 2020 | Open-market or private purchase | +200,000 | $25.00 | $5M | 4,267,564 See Footnotes | Filing · EDGAR |
| Oct 2, 2020 | Open-market or private purchase | +296,000 | $25.00 | $7.4M | 902,286 See Footnotes | Filing · EDGAR |
| Feb 4, 2020 | Derivative converted | +2,825,603 | 3,207,991 See Footnotes | Filing · EDGAR | ||
| Feb 4, 2020 | Derivative converted | +859,573 | 4,067,564 See Footnotes | Filing · EDGAR | ||
| Feb 4, 2020 | Derivative converted | +429,786 | 606,286 See Footnotes | Filing · EDGAR | ||
| Feb 4, 2020 | Derivative converted Series B Preferred Stock | −2,825,603 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 4, 2020 | Derivative converted Series C Preferred Stock | −859,573 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 4, 2020 | Derivative converted Series C Preferred Stock | −429,786 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 3, 2020 | Open-market or private purchase | +382,388 | $17.00 | $6.5M | 382,388 See Footnotes | Filing · EDGAR |
| Feb 3, 2020 | Open-market or private purchase | +176,500 | $17.00 | $3M | 176,500 See Footnotes | Filing · EDGAR |
89bio 10% owner · filings 2019 to 2022 · sold $8.3M · bought $13.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 26, 2022 | Open-market or private sale | −10,742 | $8.38 | $90K | 1,829,433 See Footnotes | Filing · EDGAR |
| Jan 26, 2022 | Open-market or private sale | −10,740 | $8.38 | $90K | 1,829,436 See Footnotes | Filing · EDGAR |
| Jan 25, 2022 | Open-market or private sale | −24,546 | $8.40 | $206K | 1,840,175 See Footnotes | Filing · EDGAR |
| Jan 25, 2022 | Open-market or private sale | −24,545 | $8.40 | $206K | 1,840,176 See Footnotes | Filing · EDGAR |
| Sep 21, 2020 | Open-market or private sale | −137,500 | $28.00 | $3.9M | 1,864,721 See Footnotes | Filing · EDGAR |
| Sep 21, 2020 | Open-market or private sale | −137,500 | $28.00 | $3.9M | 1,864,721 See Footnotes | Filing · EDGAR |
| Nov 13, 2019 | Derivative converted | +1,277,858 | 2,002,221 See footnote | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted | +1,277,858 | 2,002,221 See footnote | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted Series A Preferred Stock | −7,944,444 | 0 See footnote | Filing · EDGAR | ||
| Nov 13, 2019 | Derivative converted Series A Preferred Stock | −7,944,444 | 0 See footnote | Filing · EDGAR | ||
| Nov 11, 2019 | Open-market or private purchase | +418,750 | $16.00 | $6.7M | 724,363 See footnote | Filing · EDGAR |
| Nov 11, 2019 | Open-market or private purchase | +418,750 | $16.00 | $6.7M | 724,363 See footnote | Filing · EDGAR |
Janux Therapeutics Director · filings 2021 to 2021 · sold $10.6M · bought $12M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 29, 2021 | Open-market or private sale | −36,700 | $20.30 | $745K | 2,258,566 See Footnotes | Filing · EDGAR |
| Dec 29, 2021 | Open-market or private sale | −3,700 | $20.30 | $75K | 231,098 See Footnotes | Filing · EDGAR |
| Dec 21, 2021 | Open-market or private sale | −108,300 | $19.00 | $2.1M | 2,295,266 See Footnotes | Filing · EDGAR |
| Dec 21, 2021 | Open-market or private sale | −11,100 | $19.00 | $211K | 234,798 See Footnotes | Filing · EDGAR |
| Dec 16, 2021 | Open-market or private sale | −356,800 | $19.07 | $6.8M | 2,403,566 See Footnotes | Filing · EDGAR |
| Dec 16, 2021 | Open-market or private sale | −36,500 | $19.07 | $696K | 245,898 See Footnotes | Filing · EDGAR |
| Jun 15, 2021 | Derivative converted | +1,348,421 | 1,348,421 See footnotes | Filing · EDGAR | ||
| Jun 15, 2021 | Derivative converted | +823,742 | 2,172,163 See footnotes | Filing · EDGAR | ||
| Jun 15, 2021 | Open-market or private purchase | +588,203 | $17.00 | $10M | 2,760,366 See footnotes | Filing · EDGAR |
| Jun 15, 2021 | Derivative converted | +164,748 | 164,748 See footnotes | Filing · EDGAR | ||
| Jun 15, 2021 | Open-market or private purchase | +117,650 | $17.00 | $2M | 282,398 See footnotes | Filing · EDGAR |
| Jun 15, 2021 | Derivative converted Series A Convertible Preferred Stock | −1,052,632 | 0 See footnotes | Filing · EDGAR | ||
| Jun 15, 2021 | Derivative converted Series B Convertible Preferred Stock | −643,046 | 0 See footnotes | Filing · EDGAR | ||
| Jun 15, 2021 | Derivative converted Series B Convertible Preferred Stock | −128,609 | 0 See footnotes | Filing · EDGAR |
Repare Therapeutics Director · filings 2020 to 2021 · sold $3.5M · bought $15.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 7, 2021 | Sale under a 10b5-1 plan | −861 | $33.93 | $29K | 3,177,041 See Footnotes | Filing · EDGAR |
| Sep 7, 2021 | Sale under a 10b5-1 plan | −26 | $33.93 | $882 | 96,190 See Footnotes | Filing · EDGAR |
| Sep 3, 2021 | Sale under a 10b5-1 plan | −6,985 | $34.00 | $237K | 3,177,902 See Footnotes | Filing · EDGAR |
| Sep 3, 2021 | Sale under a 10b5-1 plan | −212 | $34.00 | $7K | 96,216 See Footnotes | Filing · EDGAR |
| Sep 2, 2021 | Sale under a 10b5-1 plan | −15,941 | $34.24 | $546K | 3,184,887 See Footnotes | Filing · EDGAR |
| Sep 2, 2021 | Sale under a 10b5-1 plan | −483 | $34.24 | $17K | 96,428 See Footnotes | Filing · EDGAR |
| Sep 1, 2021 | Sale under a 10b5-1 plan | −12,586 | $33.98 | $428K | 3,200,828 See Footnotes | Filing · EDGAR |
| Sep 1, 2021 | Sale under a 10b5-1 plan | −382 | $33.98 | $13K | 96,911 See Footnotes | Filing · EDGAR |
| Aug 31, 2021 | Sale under a 10b5-1 plan | −8,223 | $33.94 | $279K | 3,213,414 See Footnotes | Filing · EDGAR |
| Aug 31, 2021 | Sale under a 10b5-1 plan | −249 | $33.94 | $8K | 97,293 See Footnotes | Filing · EDGAR |
| Aug 30, 2021 | Sale under a 10b5-1 plan | −6,500 | $33.92 | $220K | 3,221,637 See Footnotes | Filing · EDGAR |
| Aug 30, 2021 | Sale under a 10b5-1 plan | −197 | $33.92 | $7K | 97,542 See Footnotes | Filing · EDGAR |
| Aug 27, 2021 | Sale under a 10b5-1 plan | −6,884 | $33.94 | $234K | 3,228,137 See Footnotes | Filing · EDGAR |
| Aug 27, 2021 | Sale under a 10b5-1 plan | −209 | $33.94 | $7K | 97,739 See Footnotes | Filing · EDGAR |
| Aug 26, 2021 | Sale under a 10b5-1 plan | −4,157 | $34.52 | $143K | 3,235,021 See Footnotes | Filing · EDGAR |
| Aug 26, 2021 | Sale under a 10b5-1 plan | −126 | $34.52 | $4K | 97,948 See Footnotes | Filing · EDGAR |
| Aug 25, 2021 | Sale under a 10b5-1 plan | −6,874 | $34.34 | $236K | 3,239,178 See Footnotes | Filing · EDGAR |
| Aug 25, 2021 | Sale under a 10b5-1 plan | −208 | $34.34 | $7K | 98,074 See Footnotes | Filing · EDGAR |
| Aug 24, 2021 | Sale under a 10b5-1 plan | −3,920 | $34.07 | $134K | 3,246,052 See Footnotes | Filing · EDGAR |
| Aug 24, 2021 | Sale under a 10b5-1 plan | −119 | $34.07 | $4K | 98,282 See Footnotes | Filing · EDGAR |
| Aug 23, 2021 | Sale under a 10b5-1 plan | −6,885 | $34.06 | $235K | 3,249,972 See Footnotes | Filing · EDGAR |
| Aug 23, 2021 | Sale under a 10b5-1 plan | −209 | $34.06 | $7K | 98,401 See Footnotes | Filing · EDGAR |
| Aug 18, 2021 | Sale under a 10b5-1 plan | −2,852 | $33.99 | $97K | 3,256,857 See Footnotes | Filing · EDGAR |
| Aug 18, 2021 | Sale under a 10b5-1 plan | −78 | $33.99 | $3K | 98,610 See Footnotes | Filing · EDGAR |
| Aug 17, 2021 | Sale under a 10b5-1 plan | −16,886 | $34.12 | $576K | 3,259,439 See Footnotes | Filing · EDGAR |
| Aug 17, 2021 | Sale under a 10b5-1 plan | −512 | $34.12 | $17K | 98,688 See Footnotes | Filing · EDGAR |
| Jun 23, 2020 | Derivative converted | +2,601,325 | 2,601,325 See Footnotes | Filing · EDGAR | ||
| Jun 23, 2020 | Open-market or private purchase | +675,000 | $20.00 | $13.5M | 3,276,325 See Footnotes | Filing · EDGAR |
| Jun 23, 2020 | Open-market or private purchase | +99,200 | $20.00 | $2M | 99,200 See Footnote | Filing · EDGAR |
| Jun 23, 2020 | Derivative converted Class B Preferred Shares | −2,601,325 | 0 See Footnotes | Filing · EDGAR |
Acutus Medical Director, 10% owner · filings 2020 to 2021 · bought $22.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 19, 2021 | Open-market or private purchase | +714,285 | $14.00 | $10M | 4,872,025 See Footnotes | Filing · EDGAR |
| Jul 19, 2021 | Open-market or private purchase | +357,143 | $14.00 | $5M | 1,677,361 See Footnotes | Filing · EDGAR |
| Aug 10, 2020 | Open-market or private purchase | +373,500 | $18.00 | $6.7M | 373,500 See footnotes | Filing · EDGAR |
| Aug 10, 2020 | Open-market or private purchase | +41,500 | $18.00 | $747K | 41,500 See footnotes | Filing · EDGAR |
| Aug 10, 2020 | Derivative converted | +3,784,240 | 4,157,740 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted | +1,278,718 | 1,320,218 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series B Convertible Preferred Stock | −872,302 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series B Convertible Preferred Stock | −673,123 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series C Convertible Preferred Stock | −647,582 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series C Convertible Preferred Stock | −899,985 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series D Convertible Preferred Stock | −389,116 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series D Convertible Preferred Stock | −1,202,117 | 0 See footnotes | Filing · EDGAR | ||
| Aug 10, 2020 | Derivative converted Series D Convertible Preferred Stock | −378,733 | 0 See footnotes | Filing · EDGAR |
Synlogic Director · filings 2017 to 2021
Oric Pharmaceuticals Director · filings 2020 to 2021 · sold $15.2M · bought $4.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 30, 2021 | Sale under a 10b5-1 plan | −27,869 | $23.93 | $667K | 2,212,571 See Footnotes | Filing · EDGAR |
| Mar 29, 2021 | Sale under a 10b5-1 plan | −75,555 | $23.31 | $1.8M | 2,240,440 See Footnotes | Filing · EDGAR |
| Mar 26, 2021 | Sale under a 10b5-1 plan | −27,816 | $23.88 | $664K | 2,315,995 See Footnotes | Filing · EDGAR |
| Mar 25, 2021 | Sale under a 10b5-1 plan | −51,523 | $24.70 | $1.3M | 2,343,811 See Footnotes | Filing · EDGAR |
| Mar 24, 2021 | Sale under a 10b5-1 plan | −32,959 | $24.80 | $817K | 2,395,334 See Footnotes | Filing · EDGAR |
| Mar 23, 2021 | Sale under a 10b5-1 plan | −3,992 | $24.32 | $97K | 2,428,293 See Footnotes | Filing · EDGAR |
| Mar 22, 2021 | Sale under a 10b5-1 plan | −7,673 | $26.47 | $203K | 2,432,285 See Footnotes | Filing · EDGAR |
| Mar 19, 2021 | Sale under a 10b5-1 plan | −21,275 | $26.47 | $563K | 2,439,958 See Footnotes | Filing · EDGAR |
| Mar 18, 2021 | Sale under a 10b5-1 plan | −6,059 | $28.03 | $170K | 2,461,233 See Footnotes | Filing · EDGAR |
| Mar 17, 2021 | Sale under a 10b5-1 plan | −18,790 | $28.43 | $534K | 2,467,292 See Footnotes | Filing · EDGAR |
| Mar 16, 2021 | Sale under a 10b5-1 plan | −41,353 | $27.72 | $1.1M | 2,486,082 See Footnotes | Filing · EDGAR |
| Mar 15, 2021 | Sale under a 10b5-1 plan | −89,210 | $29.14 | $2.6M | 2,527,435 See Footnotes | Filing · EDGAR |
| Mar 12, 2021 | Sale under a 10b5-1 plan | −90,521 | $30.29 | $2.7M | 2,616,645 See Footnotes | Filing · EDGAR |
| Mar 11, 2021 | Sale under a 10b5-1 plan | −58,551 | $33.04 | $1.9M | 2,707,166 See Footnotes | Filing · EDGAR |
| Apr 28, 2020 | Derivative converted | +1,875,000 | 2,156,250 See footnotes | Filing · EDGAR | ||
| Apr 28, 2020 | Derivative converted | +373,356 | 2,529,606 See footnotes | Filing · EDGAR | ||
| Apr 28, 2020 | Derivative converted | +236,111 | 2,765,717 See footnotes | Filing · EDGAR | ||
| Apr 28, 2020 | Derivative converted Series B Preferred Stock | −1,875,000 | 0 See footnotes | Filing · EDGAR | ||
| Apr 28, 2020 | Derivative converted Series C Preferred Stock | −373,356 | 0 See footnotes | Filing · EDGAR | ||
| Apr 28, 2020 | Derivative converted Series D Preferred Stock | −236,111 | 0 See footnotes | Filing · EDGAR | ||
| Apr 24, 2020 | Open-market or private purchase | +281,250 | $16.00 | $4.5M | 281,250 See footnotes | Filing · EDGAR |
Decibel Therapeutics Director, 10% owner · filings 2021 to 2021 · bought $30M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 17, 2021 | Derivative converted | +2,732,106 | 2,732,106 See footnotes | Filing · EDGAR | ||
| Feb 17, 2021 | Derivative converted | +327,852 | 327,852 See footnotes | Filing · EDGAR | ||
| Feb 17, 2021 | Derivative converted | +218,568 | 218,568 See footnotes | Filing · EDGAR | ||
| Feb 17, 2021 | Open-market or private purchase | +1,111,100 | $18.00 | $20M | 3,843,206 See footnotes | Filing · EDGAR |
| Feb 17, 2021 | Open-market or private purchase | +555,566 | $18.00 | $10M | 883,418 See footnotes | Filing · EDGAR |
| Feb 17, 2021 | Derivative converted Series D Preferred Stock | −14,480,162 | 0 See footnotes | Filing · EDGAR | ||
| Feb 17, 2021 | Derivative converted Series D Preferred Stock | −1,737,619 | 0 See footnotes | Filing · EDGAR | ||
| Feb 17, 2021 | Derivative converted Series D Preferred Stock | −1,158,412 | 0 See footnotes | Filing · EDGAR |
Prevail Therapeutics Director, 10% owner · filings 2019 to 2021 · bought $15M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 22, 2021 | Tendered in a change of control | −13,822,463 | $22.50 | $311M | 0 See Footnotes | Filing · EDGAR |
| Jun 24, 2019 | Derivative converted | +10,510,111 | 12,940,111 See Footnotes | Filing · EDGAR | ||
| Jun 24, 2019 | Open-market or private purchase | +882,352 | $17.00 | $15M | 13,822,463 See Footnotes | Filing · EDGAR |
| Jun 24, 2019 | Derivative converted Series Seed Preferred Stock | −6,399,000 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 24, 2019 | Derivative converted Series A Preferred Stock | −3,099,612 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 24, 2019 | Derivative converted Series B Preferred Stock | −1,011,499 | 0 See Footnotes | Filing · EDGAR |
Cti Biopharma 10% owner · filings 2017 to 2021 · sold $7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 7, 2021 | Open-market or private sale | −2,000,000 | $3.50 | $7M | 7,520,600 See Footnotes | Filing · EDGAR |
| Jun 13, 2017 | Derivative converted | +5,000,000 | 5,000,000 See Footnotes | Filing · EDGAR | ||
| Jun 13, 2017 | Derivative converted Series N-3 Preferred Stock | −7,500 | 0 See Footnotes | Filing · EDGAR |
Aerpio Pharmaceuticals 10% owner · filings 2017 to 2020 · sold $42K · bought $6.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 8, 2020 | In-the-money option exercised | +21,400 | $0.96 | $21K | 21,400 See Footnotes | Filing · EDGAR |
| Dec 8, 2020 | Open-market or private sale | −21,400 | $1.96 | $42K | 0 See Footnotes | Filing · EDGAR |
| Dec 8, 2020 | In-the-money option exercised Stock Option (Right to Buy) | −21,400 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 28, 2018 | Open-market or private purchase | +777,500 | $3.85 | $3M | 5,193,946 See Footnotes | Filing · EDGAR |
| Mar 15, 2017 | Open-market or private purchase | +762,995 | $5.00 | $3.8M | 4,416,446 See Footnotes | Filing · EDGAR |
LogicBio Therapeutics Director, 10% owner · filings 2018 to 2020 · bought $20.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 1, 2020 | Open-market or private purchase | +545,974 | $6.00 | $3.3M | 3,524,997 See Footnotes | Filing · EDGAR |
| Oct 1, 2020 | Open-market or private purchase | +639,212 | $6.00 | $3.8M | 4,126,972 See Footnotes | Filing · EDGAR |
| Oct 1, 2020 | Open-market or private purchase | +296,296 | $6.00 | $1.8M | 296,296 See Footnotes | Filing · EDGAR |
| Oct 23, 2018 | Derivative converted | +2,997,760 | 2,997,760 See Footnotes | Filing · EDGAR | ||
| Oct 23, 2018 | Derivative converted | +2,279,023 | 5,276,783 See Footnotes | Filing · EDGAR | ||
| Oct 23, 2018 | Open-market or private purchase | +490,000 | $10.00 | $4.9M | 5,766,783 See Footnotes | Filing · EDGAR |
| Oct 23, 2018 | Open-market or private purchase | +700,000 | $10.00 | $7M | 6,466,783 See Footnotes | Filing · EDGAR |
| Oct 23, 2018 | Derivative converted Series A Convertible Preferred Stock | −2,678,571 | 0 See Footnotes | Filing · EDGAR | ||
| Oct 23, 2018 | Derivative converted Series B Convertible Preferred Stock | −3,046,943 | 2,279,023 See Footnotes | Filing · EDGAR | ||
| Oct 23, 2018 | Derivative converted Series B Convertible Preferred Stock | −4,352,775 | 0 See Footnotes | Filing · EDGAR |
Graybug Vision 10% owner · filings 2020 to 2020 · bought $9M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 29, 2020 | Derivative converted | +3,600,847 | 4,163,347 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series B Preferred Stock | −2,754,273 | 0 See footnote | Filing · EDGAR | ||
| Sep 29, 2020 | Derivative converted Series C Preferred Stock | −846,574 | 0 See footnote | Filing · EDGAR | ||
| Sep 25, 2020 | Open-market or private purchase | +562,500 | $16.00 | $9M | 562,500 See footnote | Filing · EDGAR |
Inspire Medical Systems Director · filings 2018 to 2020 · sold $173.5M · bought $5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 18, 2020 | Open-market or private sale | −43,543 | $108.54 | $4.7M | 0 See Footnotes | Filing · EDGAR |
| Aug 17, 2020 | Open-market or private sale | −94,900 | $107.49 | $10.2M | 43,543 See Footnotes | Filing · EDGAR |
| Aug 14, 2020 | Open-market or private sale | −20,257 | $109.03 | $2.2M | 138,443 See Footnotes | Filing · EDGAR |
| Aug 13, 2020 | Open-market or private sale | −29,251 | $109.93 | $3.2M | 158,500 See Footnotes | Filing · EDGAR |
| Aug 12, 2020 | Open-market or private sale | −42,679 | $107.45 | $4.6M | 187,751 See Footnotes | Filing · EDGAR |
| Aug 11, 2020 | Open-market or private sale | −39,877 | $105.78 | $4.2M | 230,430 See Footnotes | Filing · EDGAR |
| Aug 10, 2020 | Open-market or private sale | −47,700 | $105.23 | $5M | 270,307 See Footnotes | Filing · EDGAR |
| Aug 7, 2020 | Open-market or private sale | −28,993 | $106.18 | $3.1M | 318,007 See Footnotes | Filing · EDGAR |
| Mar 6, 2020 | Open-market or private sale | −500,000 | $83.52 | $41.8M | 347,000 See Footnotes | Filing · EDGAR |
| Mar 3, 2020 | Open-market or private sale | −75,000 | $83.21 | $6.2M | 1,272,000 See Footnotes | Filing · EDGAR |
| Mar 3, 2020 | Open-market or private sale | −25,000 | $84.55 | $2.1M | 1,247,000 See Footnotes | Filing · EDGAR |
| Mar 3, 2020 | Open-market or private sale | −400,000 | $84.42 | $33.8M | 847,000 See Footnotes | Filing · EDGAR |
| Nov 27, 2019 | Sale under a 10b5-1 plan | −3,100 | $70.60 | $219K | 1,398,613 See Footnotes | Filing · EDGAR |
| Nov 27, 2019 | Sale under a 10b5-1 plan | −47,981 | $71.67 | $3.4M | 1,350,632 See Footnotes | Filing · EDGAR |
| Nov 27, 2019 | Sale under a 10b5-1 plan | −2,306 | $72.13 | $166K | 1,348,326 See Footnotes | Filing · EDGAR |
| Nov 26, 2019 | Sale under a 10b5-1 plan | −20,135 | $69.55 | $1.4M | 1,452,191 See Footnotes | Filing · EDGAR |
| Nov 26, 2019 | Sale under a 10b5-1 plan | −50,478 | $70.16 | $3.5M | 1,401,713 See Footnotes | Filing · EDGAR |
| Mar 8, 2019 | Open-market or private sale | −290,231 | $57.75 | $16.8M | 1,471,725 See Footnotes | Filing · EDGAR |
| Mar 7, 2019 | Open-market or private sale | −68,218 | $55.01 | $3.8M | 1,761,956 See Footnotes | Filing · EDGAR |
| Dec 11, 2018 | Open-market or private sale | −614,772 | $37.60 | $23.1M | Filing · EDGAR | |
| May 7, 2018 | Derivative converted | +1,582,904 | 1,582,904 direct | Filing · EDGAR | ||
| May 7, 2018 | Derivative converted | +548,817 | 2,131,721 direct | Filing · EDGAR | ||
| May 7, 2018 | Open-market or private purchase | +312,500 | $16.00 | $5M | 2,444,221 direct | Filing · EDGAR |
| May 7, 2018 | Derivative converted Series E Convertible Preferred Stock | −9,160,305 | 0 direct | Filing · EDGAR | ||
| May 7, 2018 | Derivative converted Series F Convertible Preferred Stock | −3,649,635 | 0 direct | Filing · EDGAR |
Pandion Therapeutics 10% owner · filings 2020 to 2020
No transactions in the filings read; Form 144 notices are listed above.
Fusion Pharmaceuticals Director · filings 2020 to 2020 · bought $15.3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2020 | Derivative converted | +2,224,770 | 2,224,770 By OrbiMed Private Investments VII, L.P. | Filing · EDGAR | ||
| Jun 30, 2020 | Open-market or private purchase | +705,900 | $17.00 | $12M | 2,930,670 By OrbiMed Private Investments VII, L.P. | Filing · EDGAR |
| Jun 30, 2020 | Open-market or private purchase | +192,100 | $17.00 | $3.3M | 192,100 By OrbiMed Partners Master Fund Limited | Filing · EDGAR |
| Jun 30, 2020 | Derivative converted Class B Preferred Shares | −11,878,051 | 0 By OrbiMed Private Investments VII, L.P. | Filing · EDGAR |
Alector 10% owner · filings 2019 to 2020 · sold $116.2M · bought $7.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 16, 2020 | Open-market or private sale | −47,097 | $23.53 | $1.1M | 5,955,674 See Footnotes | Filing · EDGAR |
| Apr 16, 2020 | Open-market or private sale | −15,086 | $23.53 | $355K | 1,906,718 See Footnotes | Filing · EDGAR |
| Apr 14, 2020 | Open-market or private sale | −17,595 | $23.52 | $414K | 6,002,771 See Footnotes | Filing · EDGAR |
| Apr 14, 2020 | Open-market or private sale | −5,636 | $23.52 | $133K | 1,921,804 See Footnotes | Filing · EDGAR |
| Apr 9, 2020 | Open-market or private sale | −218,208 | $23.79 | $5.2M | 6,020,366 See Footnotes | Filing · EDGAR |
| Apr 9, 2020 | Open-market or private sale | −69,893 | $23.79 | $1.7M | 1,927,440 See Footnotes | Filing · EDGAR |
| Apr 8, 2020 | Open-market or private sale | −62,573 | $23.65 | $1.5M | 6,238,574 See Footnotes | Filing · EDGAR |
| Apr 8, 2020 | Open-market or private sale | −20,041 | $23.65 | $474K | 1,997,333 See Footnotes | Filing · EDGAR |
| Apr 7, 2020 | Open-market or private sale | −6,946 | $23.10 | $160K | 6,301,147 See Footnotes | Filing · EDGAR |
| Apr 7, 2020 | Open-market or private sale | −2,224 | $23.10 | $51K | 2,017,374 See Footnotes | Filing · EDGAR |
| Mar 31, 2020 | Open-market or private sale | −189,355 | $24.50 | $4.6M | 6,308,093 See Footnotes | Filing · EDGAR |
| Mar 31, 2020 | Open-market or private sale | −60,645 | $24.50 | $1.5M | 2,019,598 See Footnotes | Filing · EDGAR |
| Mar 25, 2020 | Open-market or private sale | −42,727 | $24.66 | $1.1M | 6,497,448 See Footnotes | Filing · EDGAR |
| Mar 25, 2020 | Open-market or private sale | −13,684 | $24.66 | $337K | 2,080,243 See Footnotes | Filing · EDGAR |
| Mar 24, 2020 | Open-market or private sale | −51,235 | $24.45 | $1.3M | 6,540,175 See Footnotes | Filing · EDGAR |
| Mar 24, 2020 | Open-market or private sale | −16,409 | $24.45 | $401K | 2,093,927 See Footnotes | Filing · EDGAR |
| Mar 23, 2020 | Open-market or private sale | −11,057 | $26.05 | $288K | 6,591,410 See Footnotes | Filing · EDGAR |
| Mar 23, 2020 | Open-market or private sale | −3,541 | $26.05 | $92K | 2,110,336 See Footnotes | Filing · EDGAR |
| Mar 2, 2020 | Open-market or private sale | −1,390,309 | $26.00 | $36.1M | 6,602,467 See Footnotes | Filing · EDGAR |
| Mar 2, 2020 | Open-market or private sale | −445,086 | $26.00 | $11.6M | 2,113,877 See Footnotes | Filing · EDGAR |
| Mar 2, 2020 | Open-market or private sale | −38,808 | $26.00 | $1M | 0 See Footnotes | Filing · EDGAR |
| Jan 9, 2020 | Open-market or private sale | −286,787 | $19.50 | $5.6M | 7,992,776 See Footnotes | Filing · EDGAR |
| Jan 9, 2020 | Open-market or private sale | −91,818 | $19.50 | $1.8M | 2,558,963 See Footnotes | Filing · EDGAR |
| Jan 9, 2020 | Open-market or private sale | −1,392 | $19.50 | $27K | 38,808 See Footnotes | Filing · EDGAR |
| Dec 26, 2019 | Open-market or private sale | −7,275 | $18.60 | $135K | 8,279,563 See Footnotes | Filing · EDGAR |
| Dec 26, 2019 | Open-market or private sale | −2,325 | $18.60 | $43K | 2,650,781 See Footnotes | Filing · EDGAR |
| Dec 26, 2019 | Open-market or private sale | −1,200 | $18.60 | $22K | 40,200 See Footnotes | Filing · EDGAR |
| Dec 24, 2019 | Open-market or private sale | −48,324 | $19.59 | $947K | 8,286,838 See Footnotes | Filing · EDGAR |
| Dec 24, 2019 | Open-market or private sale | −15,476 | $19.59 | $303K | 2,653,106 See Footnotes | Filing · EDGAR |
| Dec 24, 2019 | Open-market or private sale | −8,000 | $19.59 | $157K | 41,400 See Footnotes | Filing · EDGAR |
| Dec 23, 2019 | Open-market or private sale | −63,535 | $19.82 | $1.3M | 8,335,162 See Footnotes | Filing · EDGAR |
| Dec 23, 2019 | Open-market or private sale | −20,350 | $19.82 | $403K | 2,668,582 See Footnotes | Filing · EDGAR |
| Dec 23, 2019 | Open-market or private sale | −10,400 | $19.82 | $206K | 49,400 See Footnotes | Filing · EDGAR |
| Dec 20, 2019 | Open-market or private sale | −230,721 | $19.66 | $4.5M | 8,398,697 See Footnotes | Filing · EDGAR |
| Dec 20, 2019 | Open-market or private sale | −73,879 | $19.66 | $1.5M | 2,688,932 See Footnotes | Filing · EDGAR |
| Dec 20, 2019 | Open-market or private sale | −37,900 | $19.66 | $745K | 59,800 See Footnotes | Filing · EDGAR |
| Dec 17, 2019 | Open-market or private sale | −642,807 | $18.52 | $11.9M | 8,629,418 See Footnotes | Filing · EDGAR |
| Dec 17, 2019 | Open-market or private sale | −205,793 | $18.52 | $3.8M | 2,762,811 See Footnotes | Filing · EDGAR |
| Dec 17, 2019 | Open-market or private sale | −105,500 | $18.52 | $2M | 97,700 See Footnotes | Filing · EDGAR |
| Aug 7, 2019 | Open-market or private sale | −492,364 | $17.90 | $8.8M | 9,272,225 See Footnotes | Filing · EDGAR |
| Aug 7, 2019 | Open-market or private sale | −157,636 | $17.90 | $2.8M | 2,968,604 See Footnotes | Filing · EDGAR |
| Feb 11, 2019 | Derivative converted | +405,925 | 405,925 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +4,282,288 | 4,688,213 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +2,029,626 | 6,717,839 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +2,280,479 | 8,998,318 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +1,012,282 | 10,010,600 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +266,437 | 10,277,037 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Open-market or private purchase | +157,939 | $19.00 | $3M | 10,434,976 See footnotes | Filing · EDGAR |
| Feb 11, 2019 | Derivative converted | +94,075 | 94,075 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +992,437 | 1,086,512 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +470,374 | 1,556,886 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +528,510 | 2,085,396 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +234,601 | 2,319,997 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted | +85,295 | 2,405,292 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Open-market or private purchase | +50,561 | $19.00 | $961K | 2,455,853 See footnotes | Filing · EDGAR |
| Feb 11, 2019 | Open-market or private purchase | +203,200 | $19.00 | $3.9M | 203,200 See footnotes | Filing · EDGAR |
| Feb 11, 2019 | Derivative converted Series A-1 Preferred Stock | −405,925 | 0 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted Series A-1 Preferred Stock | −94,075 | 0 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted Series A-2 Preferred Stock | −4,282,288 | 0 See footnotes | Filing · EDGAR | ||
| Feb 11, 2019 | Derivative converted Series A-2 Preferred Stock | −992,437 | 0 See footnotes | Filing · EDGAR |
8 earlier transactions are in the filing list below.
Principia Biopharma 10% owner · filings 2018 to 2019 · sold $30.3M · bought $4.3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 21, 2019 | Open-market or private sale | −1,000,000 | $30.25 | $30.3M | 1,605,713 See Footnotes | Filing · EDGAR |
| Sep 18, 2018 | Derivative converted | +1,070,771 | 1,070,771 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted | +312,741 | 1,383,512 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted | +260,617 | 1,644,129 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted | +544,047 | 2,188,176 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted | +167,537 | 2,355,713 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Open-market or private purchase | +250,000 | $17.00 | $4.3M | 2,605,713 See footnote | Filing · EDGAR |
| Sep 18, 2018 | Derivative converted Series A Convertible Preferred Stock | −1,070,771 | 0 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted Series B-1 Convertible Preferred Stock | −312,741 | 0 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted Series B-2 Convertible Preferred Stock | −260,617 | 0 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted Series B-3 Convertible Preferred Stock | −544,047 | 0 See footnote | Filing · EDGAR | ||
| Sep 18, 2018 | Derivative converted Series C Convertible Preferred Stock | −167,537 | 0 See footnote | Filing · EDGAR |
NextCure Director, 10% owner · filings 2019 to 2019 · bought $5.3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 13, 2019 | Derivative converted | +445,866 | 445,866 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| May 13, 2019 | Derivative converted | +743,110 | 1,188,976 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| May 13, 2019 | Derivative converted | +729,599 | 1,918,575 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| May 13, 2019 | Derivative converted | +442,438 | 2,361,013 By OrbiMed Private Investments VI, LP | Filing · EDGAR | ||
| May 13, 2019 | Open-market or private purchase | +350,000 | $15.00 | $5.3M | 2,711,013 By OrbiMed Private Investments VI, LP | Filing · EDGAR |
| May 13, 2019 | Derivative converted Series A-1 Preferred Stock | −3,582,000 | 0 See footnotes | Filing · EDGAR | ||
| May 13, 2019 | Derivative converted Series A-2 Preferred Stock | −5,970,000 | 0 See footnotes | Filing · EDGAR | ||
| May 13, 2019 | Derivative converted Series A-3 Preferred Stock | −5,861,455 | 0 See footnotes | Filing · EDGAR | ||
| May 13, 2019 | Derivative converted Series B-1 Preferred Stock | −3,554,466 | 0 See footnotes | Filing · EDGAR |
Turning Point Therapeutics Director · filings 2019 to 2019 · bought $6.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 22, 2019 | Derivative converted | +1,120,730 | 1,120,730 See footnote | Filing · EDGAR | ||
| Apr 22, 2019 | Derivative converted | +546,820 | 1,667,550 See footnote | Filing · EDGAR | ||
| Apr 22, 2019 | Open-market or private purchase | +360,000 | $18.00 | $6.5M | 2,027,550 See footnote | Filing · EDGAR |
| Apr 22, 2019 | Derivative converted Series C Preferred Stock | −4,314,809 | 0 See footnote | Filing · EDGAR | ||
| Apr 22, 2019 | Derivative converted Series D Preferred Stock | −2,105,259 | 0 See footnote | Filing · EDGAR |
Avedro 10% owner · filings 2019 to 2019
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 19, 2019 | Derivative converted | +3,370,786 | 3,523,204 See Footnote | Filing · EDGAR | ||
| Feb 19, 2019 | Derivative converted | +333,178 | 3,856,382 See Footnote | Filing · EDGAR | ||
| Feb 19, 2019 | Derivative converted | +383,746 | 4,240,128 See Footnote | Filing · EDGAR | ||
| Feb 19, 2019 | Derivative converted Series AA Convertible Preferred Stock | −3,370,786 | 0 See Footnote | Filing · EDGAR | ||
| Feb 19, 2019 | Derivative converted Series BB Convertible Preferred Stock | −333,178 | 0 See Footnote | Filing · EDGAR | ||
| Feb 19, 2019 | Derivative converted Series CC Convertible Preferred Stock | −383,746 | 0 See Footnote | Filing · EDGAR |
Synthorx Director, 10% owner · filings 2018 to 2018 · bought $15M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 11, 2018 | Open-market or private purchase | +1,363,636 | $11.00 | $15M | 1,363,636 See Footnote | Filing · EDGAR |
| Dec 11, 2018 | Derivative converted | +3,952,719 | 5,316,355 See Footnote | Filing · EDGAR | ||
| Dec 11, 2018 | Derivative converted Series C Preferred Stock | −6,333,206 | 0 See Footnote | Filing · EDGAR |
SI-BONE Director · filings 2018 to 2018 · bought $3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 19, 2018 | Derivative converted | +605,964 | 605,964 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Oct 19, 2018 | Derivative converted | +179,404 | 785,368 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Oct 19, 2018 | Open-market or private purchase | +200,000 | $15.00 | $3M | 985,368 By OrbiMed Private Investments V, LP | Filing · EDGAR |
| Oct 19, 2018 | Derivative converted Series 6 Preferred Stock | −572,326 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Oct 19, 2018 | Derivative converted Series 7 Preferred Stock | −179,404 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR |
Guardant Health 10% owner · filings 2018 to 2018
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 9, 2018 | Derivative converted | +1,525,492 | 1,525,492 By OrbiMed Royalties Opportunities II, LP | Filing · EDGAR | ||
| Oct 9, 2018 | Derivative converted | +8,972 | 8,972 By OrbiMed Royalties Opportunities II, LP | Filing · EDGAR | ||
| Oct 9, 2018 | Derivative converted SERIES D PREFERRED STOCK | −1,525,492 | 0 By OrbiMed Royalties Opportunities II, LP | Filing · EDGAR | ||
| Oct 9, 2018 | Derivative converted SERIES E PREFERRED STOCK | −8,972 | 0 By OrbiMed Royalties Opportunities II, LP | Filing · EDGAR |
Arvinas Holding Company 10% owner · filings 2018 to 2018
No transactions in the filings read; Form 144 notices are listed above.
SteadyMed 10% owner · filings 2016 to 2018 · sold $18.9M · bought $6.9M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 30, 2018 | Open-market or private sale | −2,123,098 | $4.46 | $9.5M | 0 See Footnotes | Filing · EDGAR |
| Aug 30, 2018 | Open-market or private sale | −2,123,098 | $4.46 | $9.5M | 0 See Footnotes | Filing · EDGAR |
| Aug 30, 2018 | Open-market or private purchase Warrants to Purchase Ordinary Shares | +55,000 | $3.85 | $212K | 348,500 See Footnotes | Filing · EDGAR |
| Aug 30, 2018 | Open-market or private purchase Warrants to Purchase Ordinary Shares | +55,000 | $3.85 | $212K | 348,500 See Footnotes | Filing · EDGAR |
| Aug 30, 2018 | Open-market or private sale Warrants to Purchase Ordinary Shares | −1,536,098 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 30, 2018 | Open-market or private sale Warrants to Purchase Ordinary Shares | 0 See Footnotes | Filing · EDGAR | |||
| Aug 30, 2018 | Open-market or private sale Warrants to Purchase Ordinary Shares | −348,500 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 30, 2018 | Open-market or private sale Warrants to Purchase Ordinary Shares | −348,500 | 0 See Footnotes | Filing · EDGAR | ||
| Apr 25, 2017 | Open-market or private purchase | +587,000 | $5.90 | $3.5M | 2,123,098 See Footnotes | Filing · EDGAR |
| Apr 25, 2017 | Open-market or private purchase | +587,000 | $5.90 | $3.5M | 2,123,098 See Footnotes | Filing · EDGAR |
| Apr 25, 2017 | Open-market or private purchase Warrants to Purchase Ordinary Shares | +293,500 | $0.13 | $37K | 293,500 See Footnotes | Filing · EDGAR |
| Apr 25, 2017 | Open-market or private purchase Warrants to Purchase Ordinary Shares | +293,500 | $0.13 | $37K | 293,500 See Footnotes | Filing · EDGAR |
ViewRay 10% owner · filings 2016 to 2018 · sold $24.1M · bought $4.3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2018 | Open-market or private sale | −153,921 | $9.98 | $1.5M | 7,234,976 See Footnotes | Filing · EDGAR |
| Aug 20, 2018 | Open-market or private sale | −153,921 | $9.98 | $1.5M | 68,898 See Footnotes | Filing · EDGAR |
| Aug 16, 2018 | Open-market or private sale | −362,765 | $9.94 | $3.6M | 7,388,897 See Footnotes | Filing · EDGAR |
| Aug 16, 2018 | Open-market or private sale | −3,455 | $9.94 | $34K | 70,364 See Footnotes | Filing · EDGAR |
| Aug 15, 2018 | Open-market or private sale | −77,314 | $9.93 | $768K | 7,751,662 See Footnotes | Filing · EDGAR |
| Aug 15, 2018 | Open-market or private sale | −736 | $9.93 | $7K | 73,819 See Footnotes | Filing · EDGAR |
| Aug 14, 2018 | Open-market or private sale | −20,777 | $9.94 | $207K | 7,828,976 See Footnotes | Filing · EDGAR |
| Aug 14, 2018 | Open-market or private sale | −198 | $9.94 | $2K | 74,555 See Footnotes | Filing · EDGAR |
| Aug 13, 2018 | Open-market or private sale | −86,103 | $9.98 | $859K | 7,849,753 See Footnotes | Filing · EDGAR |
| Aug 13, 2018 | Open-market or private sale | −820 | $9.98 | $8K | 74,753 See Footnotes | Filing · EDGAR |
| Aug 10, 2018 | Open-market or private sale | −678,333 | $9.96 | $6.8M | 7,935,856 See Footnotes | Filing · EDGAR |
| Aug 10, 2018 | Open-market or private sale | −6,460 | $9.96 | $64K | 75,573 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Open-market or private sale | −108,729 | $9.95 | $1.1M | 8,640,328 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Open-market or private sale | −1,036 | $9.95 | $10K | 82,282 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Option or RSU exercised or converted | +19,372 | $5.00 | $97K | 8,659,700 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Option or RSU exercised or converted | +184 | $5.00 | $920 | 82,466 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Option or RSU exercised or converted | +45,203 | $5.00 | $226K | 8,704,903 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Option or RSU exercised or converted | +431 | $5.00 | $2K | 82,897 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Open-market or private sale | −64,575 | $9.91 | $640K | 8,640,328 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Open-market or private sale | −615 | $9.91 | $6K | 82,282 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Open-market or private sale | −26,139 | $9.86 | $258K | 8,614,189 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Open-market or private sale | −249 | $9.86 | $2K | 82,033 See Footnotes | Filing · EDGAR |
| Aug 9, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −19,372 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 9, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −184 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 9, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −45,203 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 9, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −431 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 8, 2018 | Open-market or private sale | −478,107 | $10.00 | $4.8M | 8,749,057 See Footnotes | Filing · EDGAR |
| Aug 8, 2018 | Open-market or private sale | −4,553 | $10.00 | $46K | 83,318 See Footnotes | Filing · EDGAR |
| Aug 7, 2018 | Option or RSU exercised or converted | +26,139 | 9,227,164 See Footnotes | Filing · EDGAR | ||
| Aug 7, 2018 | Option or RSU exercised or converted | +249 | 87,871 See Footnotes | Filing · EDGAR | ||
| Aug 7, 2018 | Option or RSU exercised or converted Restricted Stock Unit | −26,139 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 7, 2018 | Option or RSU exercised or converted Restricted Stock Unit | −249 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 7, 2018 | Open-market or private sale | −50,149 | $10.01 | $502K | 9,201,025 See Footnotes | Filing · EDGAR |
| Aug 7, 2018 | Open-market or private sale | −478 | $10.01 | $5K | 87,622 See Footnotes | Filing · EDGAR |
| Aug 3, 2018 | Open-market or private sale | −118,168 | $11.71 | $1.4M | 9,251,174 See Footnotes | Filing · EDGAR |
| Aug 3, 2018 | Open-market or private sale | −1,125 | $11.71 | $13K | 88,100 See Footnotes | Filing · EDGAR |
| Jan 18, 2017 | Open-market or private purchase | +327,459 | $3.00 | $982K | 9,369,342 See Footnotes | Filing · EDGAR |
| Jan 18, 2017 | Open-market or private purchase | +3,118 | $3.00 | $9K | 89,225 See Footnotes | Filing · EDGAR |
| Jan 18, 2017 | Open-market or private purchase Warrants to purchase common stock | +65,491 | $0.13 | $8K | 403,692 See Footnotes | Filing · EDGAR |
| Jan 18, 2017 | Open-market or private purchase Warrants to purchase common stock | +623 | $0.13 | $78 | 3,843 See Footnotes | Filing · EDGAR |
| Aug 22, 2016 | Open-market or private purchase | +1,127,338 | $2.95 | $3.3M | 9,041,883 See Footnotes | Filing · EDGAR |
| Aug 22, 2016 | Open-market or private purchase | +10,736 | $2.95 | $32K | 86,107 See Footnotes | Filing · EDGAR |
| Aug 22, 2016 | Open-market or private purchase Warrants to purchase common stock | +338,201 | $0.13 | $42K | 338,201 See Footnotes | Filing · EDGAR |
| Aug 22, 2016 | Open-market or private purchase Warrants to purchase common stock | +3,220 | $0.13 | $403 | 3,220 See Footnotes | Filing · EDGAR |
Constellation Pharmaceuticals 10% owner · filings 2018 to 2018 · bought $3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 23, 2018 | Derivative converted | +317,921 | 317,921 See footnote | Filing · EDGAR | ||
| Jul 23, 2018 | Open-market or private purchase | +100,000 | $15.00 | $1.5M | 417,921 See footnote | Filing · EDGAR |
| Jul 23, 2018 | Derivative converted | +317,921 | 317,921 See footnote | Filing · EDGAR | ||
| Jul 23, 2018 | Open-market or private purchase | +100,000 | $15.00 | $1.5M | 417,921 See footnote | Filing · EDGAR |
| Jul 23, 2018 | Derivative converted Series F Preferred Stock | −3,500,000 | 0 See footnote | Filing · EDGAR | ||
| Jul 23, 2018 | Derivative converted Series F Preferred Stock | −3,500,000 | 0 See footnote | Filing · EDGAR |
Crinetics Pharmaceuticals 10% owner · filings 2018 to 2018
No transactions in the filings read; Form 144 notices are listed above.
ARMO BioSciences Director, 10% owner · filings 2018 to 2018
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 22, 2018 | Tendered in a change of control | −3,709,356 | $50.00 | $185.5M | 3,709,356 By OrbiMed Private Investments IV, LP | Filing · EDGAR |
| Jun 22, 2018 | Tendered in a change of control | −409,547 | $50.00 | $20.5M | 409,547 By OrbiMed Private Investments V, LP | Filing · EDGAR |
| Jan 30, 2018 | Derivative converted | +3,709,356 | 3,709,356 By OrbiMed Private Investments IV, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted | +409,547 | 409,547 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series A Convertible Preferred Stock | −1,783,704 | 0 By OrbiMed Private Investments IV, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series B Convertible Preferred Stock | −1,226,156 | 0 By OrbiMed Private Investments IV, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series C Convertible Preferred Stock | −415,869 | 0 By OrbiMed Private Investments IV, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series C-1 Convertible Preferred Stock | −283,627 | 0 By OrbiMed Private Investments IV, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series B-1 Convertible Preferred Stock | −332,271 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series C Convertible Preferred Stock | −45,961 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR | ||
| Jan 30, 2018 | Derivative converted Series C-1 Convertible Preferred Stock | −31,315 | 0 By OrbiMed Private Investments V, LP | Filing · EDGAR |
Adaptimmune Therapeutics Director · filings 2016 to 2018 · sold $14.8M · bought $22.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 6, 2018 | Open-market or private sale | −1,600 | $13.49 | $22K | 4,901,310 See Footnotes | Filing · EDGAR |
| Jun 4, 2018 | Open-market or private sale | −17,100 | $13.57 | $232K | 4,902,910 See Footnotes | Filing · EDGAR |
| Jun 1, 2018 | Open-market or private sale | −50,000 | $13.49 | $675K | 4,920,010 See Footnotes | Filing · EDGAR |
| May 30, 2018 | Open-market or private sale | −121,000 | $13.52 | $1.6M | 4,970,010 See Footnotes | Filing · EDGAR |
| May 14, 2018 | Open-market or private sale | −10,300 | $13.50 | $139K | 5,091,010 See Footnotes | Filing · EDGAR |
| Mar 29, 2018 | Open-market or private sale | −31,983 | $11.53 | $369K | 5,101,310 See Footnotes | Filing · EDGAR |
| Mar 27, 2018 | Open-market or private sale | −1,016,084 | $11.50 | $11.7M | 5,133,293 See Footnotes | Filing · EDGAR |
| Mar 27, 2017 | Open-market or private purchase | +1,190,476 | $4.20 | $5M | 6,149,377 See Footnotes | Filing · EDGAR |
| May 24, 2016 | Open-market or private purchase | +518,400 | $10.48 | $5.4M | 29,753,404 See Footnotes | Filing · EDGAR |
| May 23, 2016 | Open-market or private purchase | +1,191,600 | $10.40 | $12.4M | 29,235,004 See Footnotes | Filing · EDGAR |
| May 20, 2016 | Open-market or private purchase | +2,400 | $10.04 | $24K | 28,043,404 See Footnotes | Filing · EDGAR |
Rhythm Pharmaceuticals 10% owner, Other · filings 2017 to 2018 · sold $4.7M · bought $6M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 22, 2018 | Open-market or private sale | −17,980 | $30.38 | $546K | 2,751,679 See Footnotes | Filing · EDGAR |
| May 22, 2018 | Open-market or private sale | −1,600 | $30.96 | $50K | 2,750,079 See Footnotes | Filing · EDGAR |
| May 21, 2018 | Open-market or private sale | −62,500 | $31.01 | $1.9M | 2,769,659 See Footnotes | Filing · EDGAR |
| May 18, 2018 | Open-market or private sale | −69,136 | $30.77 | $2.1M | 2,832,159 See Footnotes | Filing · EDGAR |
| Oct 10, 2017 | Derivative converted | +2,546,295 | 2,546,295 See Footnotes | Filing · EDGAR | ||
| Oct 10, 2017 | Open-market or private purchase | +355,000 | $17.00 | $6M | 2,901,295 See Footnotes | Filing · EDGAR |
| Oct 10, 2017 | Derivative converted Series A Convertible Preferred Stock | −2,546,295 | 0 See Footnotes | Filing · EDGAR |
Pieris Pharmaceuticals 10% owner, Other · filings 2015 to 2018 · sold $19.8M · bought $1.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 30, 2018 | Open-market or private sale | −989,600 | $6.35 | $6.3M | 4,511,130 See Footnotes | Filing · EDGAR |
| Apr 30, 2018 | Open-market or private sale | −10,400 | $6.35 | $66K | 38,870 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Option or RSU exercised or converted | +6,057 | $4.68 | $28K | 5,506,787 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Option or RSU exercised or converted | +58 | $4.68 | $271 | 49,328 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Option or RSU exercised or converted | +1,765 | $5.08 | $9K | 5,508,552 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Option or RSU exercised or converted | +17 | $5.08 | $86 | 49,345 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Open-market or private sale | −7,822 | $8.98 | $70K | 5,500,730 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Open-market or private sale | −75 | $8.98 | $674 | 49,270 See Footnotes | Filing · EDGAR |
| Feb 13, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −6,057 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −58 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −1,765 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2018 | Option or RSU exercised or converted Stock Option (right to buy) | −17 | 0 See Footnotes | Filing · EDGAR | ||
| Jan 3, 2018 | Open-market or private sale | −1,693,492 | $7.35 | $12.4M | 5,500,730 See Footnotes | Filing · EDGAR |
| Jan 3, 2018 | Open-market or private sale | −16,128 | $7.35 | $119K | 49,270 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +27,241 | $2.00 | $54K | 7,221,463 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +259 | $2.00 | $518 | 65,657 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +5,227 | $3.00 | $16K | 7,226,690 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +50 | $3.00 | $150 | 65,707 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +6,654 | $2.62 | $17K | 7,233,344 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +63 | $2.62 | $165 | 65,770 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +8,717 | $1.94 | $17K | 7,242,061 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +83 | $1.94 | $161 | 65,853 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +10,180 | $1.62 | $16K | 7,252,241 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +97 | $1.62 | $157 | 65,950 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +19,811 | $1.59 | $31K | 7,272,052 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +189 | $1.59 | $301 | 66,139 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +8,097 | $2.05 | $17K | 7,280,149 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +77 | $2.05 | $158 | 66,216 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +9,642 | $1.73 | $17K | 7,289,791 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +92 | $1.73 | $159 | 66,308 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +10,182 | $1.64 | $17K | 7,299,973 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +97 | $1.64 | $159 | 66,405 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +14,858 | $2.01 | $30K | 7,314,831 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +142 | $2.01 | $285 | 66,547 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +10,216 | $2.01 | $21K | 7,325,047 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +97 | $2.01 | $195 | 66,644 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +10,447 | $2.32 | $24K | 7,335,494 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +99 | $2.32 | $230 | 66,743 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +4,971 | $5.64 | $28K | 7,340,465 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted | +47 | $5.64 | $265 | 66,790 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Open-market or private sale | −146,243 | $5.70 | $834K | 7,194,222 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Open-market or private sale | −1,392 | $5.70 | $8K | 65,398 See Footnotes | Filing · EDGAR |
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −27,241 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −259 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −5,227 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −50 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −6,654 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −63 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −8,717 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −83 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −10,180 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −97 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −19,811 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −189 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −8,097 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −77 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −9,642 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −92 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −10,182 | 0 See Footnotes | Filing · EDGAR | ||
| Dec 18, 2017 | Option or RSU exercised or converted Stock Option (right to buy) | −97 | 0 See Footnotes | Filing · EDGAR |
10 earlier transactions are in the filing list below.
Audentes Therapeutics 10% owner · filings 2016 to 2018 · sold $39.8M · bought $500K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 12, 2018 | Open-market or private sale | −1,066 | $36.04 | $38K | 3,556,934 See Footnotes | Filing · EDGAR |
| Mar 12, 2018 | Open-market or private sale | −16,937 | $34.92 | $591K | 3,539,997 See Footnotes | Filing · EDGAR |
| Mar 9, 2018 | Open-market or private sale | −21,300 | $34.67 | $738K | 3,616,700 See Footnotes | Filing · EDGAR |
| Mar 9, 2018 | Open-market or private sale | −47,395 | $35.86 | $1.7M | 3,569,305 See Footnotes | Filing · EDGAR |
| Mar 9, 2018 | Open-market or private sale | −11,305 | $36.44 | $412K | 3,558,000 See Footnotes | Filing · EDGAR |
| Mar 8, 2018 | Open-market or private sale | −58,428 | $34.06 | $2M | 3,638,000 See Footnotes | Filing · EDGAR |
| Mar 6, 2018 | Open-market or private sale | −11,372 | $33.03 | $376K | 3,696,428 See Footnotes | Filing · EDGAR |
| Mar 5, 2018 | Open-market or private sale | −200 | $36.06 | $7K | 3,707,800 See Footnotes | Filing · EDGAR |
| Mar 2, 2018 | Open-market or private sale | −386,080 | $35.06 | $13.5M | 3,743,558 See Footnotes | Filing · EDGAR |
| Mar 2, 2018 | Open-market or private sale | −35,558 | $36.33 | $1.3M | 3,708,000 See Footnotes | Filing · EDGAR |
| Sep 29, 2017 | Open-market or private sale | −672,000 | $28.25 | $19M | 4,129,638 See Footnotes | Filing · EDGAR |
| Sep 7, 2017 | In-the-money option exercised | +5,000 | $15.03 | $75K | 4,806,638 See Footnotes | Filing · EDGAR |
| Sep 7, 2017 | Open-market or private sale | −5,000 | $22.35 | $112K | 4,801,638 See Footnotes | Filing · EDGAR |
| Sep 7, 2017 | In-the-money option exercised Stock Option (right to buy) | −5,000 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted | +627,867 | 852,105 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted | +2,511,441 | 3,363,546 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted | +1,071,992 | 4,435,538 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted | +332,766 | 4,768,304 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Open-market or private purchase | +33,334 | $15.00 | $500K | 4,801,638 See Footnotes | Filing · EDGAR |
| Jul 25, 2016 | Derivative converted Series Seed Preferred Stock | −627,867 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted Series A Preferred Stock | −2,511,441 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted Series B Preferred Stock | −1,071,992 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2016 | Derivative converted Series C Preferred Stock | −332,766 | 0 See Footnotes | Filing · EDGAR |
GLAUKOS Director · filings 2015 to 2018 · sold $104.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 6, 2018 | Open-market or private sale | −93,008 | $30.01 | $2.8M | 66,790 See Footnotes | Filing · EDGAR |
| Mar 6, 2018 | Open-market or private sale | −886 | $30.01 | $27K | 637 See Footnotes | Filing · EDGAR |
| Mar 6, 2018 | Open-market or private sale | −20,114 | $30.77 | $619K | 46,676 See Footnotes | Filing · EDGAR |
| Mar 6, 2018 | Open-market or private sale | −192 | $30.77 | $6K | 445 See Footnotes | Filing · EDGAR |
| Mar 6, 2018 | Open-market or private sale | −46,676 | $32.06 | $1.5M | 0 See Footnotes | Filing · EDGAR |
| Mar 6, 2018 | Open-market or private sale | −445 | $32.06 | $14K | 0 See Footnotes | Filing · EDGAR |
| Mar 5, 2018 | Open-market or private sale | −128,092 | $32.05 | $4.1M | 240,314 See Footnotes | Filing · EDGAR |
| Mar 5, 2018 | Open-market or private sale | −1,220 | $32.05 | $39K | 2,291 See Footnotes | Filing · EDGAR |
| Mar 5, 2018 | Open-market or private sale | −80,516 | $33.06 | $2.7M | 159,798 See Footnotes | Filing · EDGAR |
| Mar 5, 2018 | Open-market or private sale | −768 | $33.06 | $25K | 1,523 See Footnotes | Filing · EDGAR |
| Mar 2, 2018 | Open-market or private sale | −265,766 | $31.92 | $8.5M | 562,839 See Footnotes | Filing · EDGAR |
| Mar 2, 2018 | Open-market or private sale | −2,533 | $31.92 | $81K | 5,362 See Footnotes | Filing · EDGAR |
| Mar 2, 2018 | Open-market or private sale | −194,433 | $32.80 | $6.4M | 368,406 See Footnotes | Filing · EDGAR |
| Mar 2, 2018 | Open-market or private sale | −1,851 | $32.80 | $61K | 3,511 See Footnotes | Filing · EDGAR |
| Sep 5, 2017 | Open-market or private sale | −173,349 | $37.94 | $6.6M | 1,076,444 See Footnotes | Filing · EDGAR |
| Sep 5, 2017 | Open-market or private sale | −1,651 | $37.94 | $63K | 10,256 See Footnotes | Filing · EDGAR |
| Sep 5, 2017 | Open-market or private sale | −189,792 | $39.63 | $7.5M | 886,652 See Footnotes | Filing · EDGAR |
| Sep 5, 2017 | Open-market or private sale | −1,808 | $39.63 | $72K | 8,448 See Footnotes | Filing · EDGAR |
| Sep 5, 2017 | Open-market or private sale | −58,047 | $40.77 | $2.4M | 828,605 See Footnotes | Filing · EDGAR |
| Sep 5, 2017 | Open-market or private sale | −553 | $40.77 | $23K | 7,895 See Footnotes | Filing · EDGAR |
| Sep 1, 2017 | Open-market or private sale | −109,040 | $37.72 | $4.1M | 1,249,793 See Footnotes | Filing · EDGAR |
| Sep 1, 2017 | Open-market or private sale | −1,038 | $37.72 | $39K | 11,907 See Footnotes | Filing · EDGAR |
| Aug 31, 2017 | Open-market or private sale | −44,498 | $37.82 | $1.7M | 1,358,833 See Footnotes | Filing · EDGAR |
| Aug 31, 2017 | Open-market or private sale | −424 | $37.82 | $16K | 12,945 See Footnotes | Filing · EDGAR |
| Aug 17, 2017 | Open-market or private sale | −224,780 | $37.85 | $8.5M | 1,403,331 See Footnotes | Filing · EDGAR |
| Aug 17, 2017 | Open-market or private sale | −2,140 | $37.85 | $81K | 13,369 See Footnotes | Filing · EDGAR |
| Aug 16, 2017 | Open-market or private sale | −64,961 | $38.01 | $2.5M | 1,628,111 See Footnotes | Filing · EDGAR |
| Aug 16, 2017 | Open-market or private sale | −619 | $38.01 | $24K | 15,509 See Footnotes | Filing · EDGAR |
| Aug 15, 2017 | Open-market or private sale | −32,193 | $38.29 | $1.2M | 1,693,072 See Footnotes | Filing · EDGAR |
| Aug 15, 2017 | Open-market or private sale | −307 | $38.29 | $12K | 16,128 See Footnotes | Filing · EDGAR |
| Mar 14, 2017 | Open-market or private sale | −73,401 | $44.54 | $3.3M | 1,725,265 See Footnotes | Filing · EDGAR |
| Mar 14, 2017 | Open-market or private sale | −699 | $44.54 | $31K | 16,435 See Footnotes | Filing · EDGAR |
| Mar 13, 2017 | Open-market or private sale | −208,712 | $45.30 | $9.5M | 1,799,359 See Footnotes | Filing · EDGAR |
| Mar 13, 2017 | Open-market or private sale | −1,998 | $45.30 | $91K | 17,141 See Footnotes | Filing · EDGAR |
| Mar 13, 2017 | Open-market or private sale | −693 | $46.13 | $32K | 1,798,666 See Footnotes | Filing · EDGAR |
| Mar 13, 2017 | Open-market or private sale | −7 | $46.13 | $323 | 17,134 See Footnotes | Filing · EDGAR |
| Mar 10, 2017 | Open-market or private sale | −96,113 | $45.98 | $4.4M | 2,008,071 See Footnotes | Filing · EDGAR |
| Mar 10, 2017 | Open-market or private sale | −915 | $45.98 | $42K | 19,129 See Footnotes | Filing · EDGAR |
| Mar 3, 2017 | Open-market or private sale | −55,246 | $47.05 | $2.6M | 2,104,184 See Footnotes | Filing · EDGAR |
| Mar 3, 2017 | Open-market or private sale | −526 | $47.05 | $25K | 20,044 See Footnotes | Filing · EDGAR |
| Aug 12, 2016 | Open-market or private sale | −13,967 | $33.72 | $471K | 2,159,430 See Footnotes | Filing · EDGAR |
| Aug 12, 2016 | Open-market or private sale | −133 | $33.72 | $4K | 20,570 See Footnotes | Filing · EDGAR |
| Aug 11, 2016 | Open-market or private sale | −159,382 | $33.63 | $5.4M | 2,173,397 See Footnotes | Filing · EDGAR |
| Aug 11, 2016 | Open-market or private sale | −1,518 | $33.63 | $51K | 20,703 See Footnotes | Filing · EDGAR |
| Aug 10, 2016 | Open-market or private sale | −116,825 | $33.77 | $3.9M | 2,332,779 See Footnotes | Filing · EDGAR |
| Aug 10, 2016 | Open-market or private sale | −1,113 | $33.77 | $38K | 22,221 See Footnotes | Filing · EDGAR |
| Aug 3, 2016 | Open-market or private sale | −420,990 | $30.59 | $12.9M | 2,449,604 See Footnotes | Filing · EDGAR |
| Aug 3, 2016 | Open-market or private sale | −4,010 | $30.59 | $123K | 23,334 See Footnotes | Filing · EDGAR |
| Jun 30, 2015 | Derivative converted | +2,854,870 | 2,854,870 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Derivative converted | +27,194 | 27,194 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Option or RSU exercised or converted | +27,346 | 2,882,216 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Shares withheld for tax or exercise price | −11,623 | $18.00 | $209K | 2,870,593 See Footnotes | Filing · EDGAR |
| Jun 30, 2015 | Option or RSU exercised or converted | +261 | 27,455 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Shares withheld for tax or exercise price | −111 | $18.00 | $2K | 27,344 See Footnotes | Filing · EDGAR |
| Jun 30, 2015 | Derivative converted Series D Convertible Preferred Stock | −2,406,441 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Derivative converted Series D Convertible Preferred Stock | −22,923 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Derivative converted Series E Convertible Preferred Stock | −167,898 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Derivative converted Series E Convertible Preferred Stock | −1,599 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Derivative converted Series F Convertible Preferred Stock | −280,531 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 30, 2015 | Derivative converted Series F Convertible Preferred Stock | −2,672 | 0 See Footnotes | Filing · EDGAR |
2 earlier transactions are in the filing list below.
Kala Pharmaceuticals 10% owner · filings 2017 to 2018 · bought $19.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 8, 2018 | Open-market or private purchase | +25,000 | $12.93 | $323K | 3,447,840 See Footnotes | Filing · EDGAR |
| Feb 2, 2018 | Open-market or private purchase | +37,840 | $14.73 | $557K | 3,422,840 See Footnotes | Filing · EDGAR |
| Feb 1, 2018 | Open-market or private purchase | +22,840 | $14.99 | $342K | 3,385,000 See Footnotes | Filing · EDGAR |
| Jan 31, 2018 | Open-market or private purchase | +339,400 | $15.00 | $5.1M | 3,362,160 See Footnotes | Filing · EDGAR |
| Jan 29, 2018 | Open-market or private purchase | +50,000 | $14.99 | $750K | 3,022,760 See Footnotes | Filing · EDGAR |
| Jan 26, 2018 | Open-market or private purchase | +22,760 | $14.93 | $340K | 2,972,760 See Footnotes | Filing · EDGAR |
| Jan 24, 2018 | Open-market or private purchase | +64,637 | $14.91 | $964K | 2,950,000 See Footnotes | Filing · EDGAR |
| Jan 23, 2018 | Open-market or private purchase | +4,363 | $14.99 | $65K | 2,885,363 See Footnotes | Filing · EDGAR |
| Jan 22, 2018 | Open-market or private purchase | +75,000 | $14.98 | $1.1M | 2,881,000 See Footnotes | Filing · EDGAR |
| Jan 19, 2018 | Open-market or private purchase | +74,931 | $14.95 | $1.1M | 2,806,000 See Footnotes | Filing · EDGAR |
| Jan 12, 2018 | Open-market or private purchase | +38,354 | $14.50 | $556K | 2,731,069 See Footnotes | Filing · EDGAR |
| Jan 12, 2018 | Open-market or private purchase | +28,446 | $15.40 | $438K | 2,692,715 See Footnotes | Filing · EDGAR |
| Jan 11, 2018 | Open-market or private purchase | +41,700 | $13.65 | $569K | 2,664,269 See Footnotes | Filing · EDGAR |
| Jan 10, 2018 | Open-market or private purchase | +170,338 | $12.83 | $2.2M | 2,622,569 See Footnotes | Filing · EDGAR |
| Jul 25, 2017 | Derivative converted | +2,055,946 | 2,055,946 See Footnotes | Filing · EDGAR | ||
| Jul 25, 2017 | Open-market or private purchase | +319,333 | $15.00 | $4.8M | 2,375,279 See Footnotes | Filing · EDGAR |
| Jul 25, 2017 | Derivative converted Series C Preferred Stock | −10,707,985 | 0 See Footnotes | Filing · EDGAR |
Loxo Oncology Director · filings 2014 to 2017 · sold $72.8M · bought $3.6M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 8, 2017 | Open-market or private sale | −250,000 | $82.50 | $20.6M | 941,000 See Footnotes | Filing · EDGAR |
| Nov 22, 2017 | Open-market or private sale | −267,000 | $75.00 | $20M | 1,191,000 See Footnotes | Filing · EDGAR |
| Nov 16, 2017 | Open-market or private sale | −46,680 | $72.46 | $3.4M | 1,681,320 See Footnotes | Filing · EDGAR |
| Nov 16, 2017 | Open-market or private sale | −43,300 | $73.48 | $3.2M | 1,638,020 See Footnotes | Filing · EDGAR |
| Nov 16, 2017 | Open-market or private sale | −100,045 | $74.49 | $7.5M | 1,537,975 See Footnotes | Filing · EDGAR |
| Nov 16, 2017 | Open-market or private sale | −71,598 | $75.37 | $5.4M | 1,466,377 See Footnotes | Filing · EDGAR |
| Nov 16, 2017 | Open-market or private sale | −8,377 | $76.23 | $639K | 1,458,000 See Footnotes | Filing · EDGAR |
| Aug 10, 2016 | Open-market or private sale | −447,857 | $26.96 | $12.1M | 1,728,000 See Footnotes | Filing · EDGAR |
| Aug 6, 2014 | Derivative converted | +1,562,499 | 1,562,499 See Footnotes | Filing · EDGAR | ||
| Aug 6, 2014 | Derivative converted | +337,973 | 1,900,472 See Footnotes | Filing · EDGAR | ||
| Aug 6, 2014 | Open-market or private purchase | +275,385 | $13.00 | $3.6M | 2,175,857 See Footnotes | Filing · EDGAR |
| Aug 6, 2014 | Derivative converted Series A Convertible Preferred Stock | −1,562,499 | 0 See Footnotes | Filing · EDGAR | ||
| Aug 6, 2014 | Derivative converted Series B Convertible Preferred Stock | −337,973 | 0 See Footnotes | Filing · EDGAR |
Arsanis 10% owner · filings 2017 to 2017
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 20, 2017 | Derivative converted | +19,533 | 19,533 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted | +252,230 | 271,763 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted | +328,909 | 600,672 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted | +114,320 | 714,992 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted | +653,974 | 1,368,966 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted | +500,000 | $10.00 | $5M | 1,868,966 See Footnotes | Filing · EDGAR |
| Nov 20, 2017 | Derivative converted Series A-1 Convertible Preferred Stock | −66,667 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted Series A-2 Convertible Preferred Stock | −704,846 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted Series B Convertible Preferred Stock | −736,648 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted Series C Convertible Preferred Stock | −229,412 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 20, 2017 | Derivative converted Series D Convertible Preferred Stock | −2,232,014 | 0 See Footnotes | Filing · EDGAR |
Roka BioScience 10% owner · filings 2014 to 2017 · sold $742K · bought $4.6M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 3, 2017 | Open-market or private sale | −199,718 | $0.68 | $136K | 0 See Footnotes | Filing · EDGAR |
| Oct 3, 2017 | Open-market or private sale | −1,899 | $0.68 | $1K | 0 See Footnotes | Filing · EDGAR |
| Sep 29, 2017 | Open-market or private sale | −93,246 | $0.74 | $69K | 199,718 See Footnotes | Filing · EDGAR |
| Sep 29, 2017 | Open-market or private sale | −888 | $0.74 | $657 | 1,899 See Footnotes | Filing · EDGAR |
| Sep 28, 2017 | Open-market or private sale | −376,950 | $0.72 | $271K | 292,964 See Footnotes | Filing · EDGAR |
| Sep 28, 2017 | Open-market or private sale | −3,592 | $0.72 | $3K | 2,787 See Footnotes | Filing · EDGAR |
| Sep 27, 2017 | Open-market or private sale | −52,301 | $0.92 | $48K | 669,914 See Footnotes | Filing · EDGAR |
| Sep 27, 2017 | Open-market or private sale | −498 | $0.92 | $458 | 6,379 See Footnotes | Filing · EDGAR |
| Sep 26, 2017 | Open-market or private sale | −74,096 | $1.03 | $76K | 722,215 See Footnotes | Filing · EDGAR |
| Sep 26, 2017 | Open-market or private sale | −706 | $1.03 | $727 | 6,877 See Footnotes | Filing · EDGAR |
| Aug 24, 2017 | Open-market or private sale | −13,075 | $1.50 | $20K | 796,311 See Footnotes | Filing · EDGAR |
| Aug 24, 2017 | Open-market or private sale | −125 | $1.50 | $188 | 7,583 See Footnotes | Filing · EDGAR |
| Aug 23, 2017 | Open-market or private sale | −1,090 | $1.50 | $2K | 809,386 See Footnotes | Filing · EDGAR |
| Aug 23, 2017 | Open-market or private sale | −10 | $1.50 | $15 | 7,708 See Footnotes | Filing · EDGAR |
| Aug 22, 2017 | Open-market or private sale | −5,448 | $1.52 | $8K | 810,476 See Footnotes | Filing · EDGAR |
| Aug 22, 2017 | Open-market or private sale | −52 | $1.52 | $79 | 7,718 See Footnotes | Filing · EDGAR |
| Aug 21, 2017 | Open-market or private sale | −2,952 | $1.49 | $4K | 815,924 See Footnotes | Filing · EDGAR |
| Aug 21, 2017 | Open-market or private sale | −28 | $1.49 | $42 | 7,770 See Footnotes | Filing · EDGAR |
| Aug 18, 2017 | Open-market or private sale | −66,166 | $1.52 | $101K | 818,876 See Footnotes | Filing · EDGAR |
| Aug 18, 2017 | Open-market or private sale | −630 | $1.52 | $958 | 7,798 See Footnotes | Filing · EDGAR |
| Sep 21, 2016 | Open-market or private purchase Series A Convertible Preferred Stock | +3,962.26 | 3,962.26 See Footnotes | Filing · EDGAR | ||
| Sep 21, 2016 | Open-market or private purchase Series A Convertible Preferred Stock | +37.74 | 37.74 See Footnotes | Filing · EDGAR | ||
| Sep 21, 2016 | Open-market or private purchase Warrants | +5,660,377 | 5,660,377 See Footnotes | Filing · EDGAR | ||
| Sep 21, 2016 | Open-market or private purchase Warrants | +53,909 | 53,909 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +1,112,592 | 1,117,280 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +10,596 | 10,640 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +361,612 | 1,478,892 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +3,443 | 14,083 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +794,178 | 2,273,070 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +7,563 | 21,646 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +537,264 | 2,810,334 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted | +5,116 | 26,762 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Open-market or private purchase | +379,717 | $12.00 | $4.6M | 3,190,051 See Footnotes | Filing · EDGAR |
| Jul 22, 2014 | Open-market or private purchase | +3,616 | $12.00 | $43K | 30,378 See Footnotes | Filing · EDGAR |
| Jul 22, 2014 | Derivative converted Series B Convertible Preferred Stock | −12,238,019 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series B Convertible Preferred Stock | −116,981 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series C Convertible Preferred Stock | −3,992,203 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series C Convertible Preferred Stock | −38,021 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series D Convertible Preferred Stock | −8,475,069 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series D Convertible Preferred Stock | −80,715 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series E Convertible Preferred Stock | −5,931,402 | 0 See Footnotes | Filing · EDGAR | ||
| Jul 22, 2014 | Derivative converted Series E Convertible Preferred Stock | −56,490 | 0 See Footnotes | Filing · EDGAR |
Aeglea BioTherapeutics 10% owner · filings 2016 to 2017 · bought $564K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 21, 2017 | Open-market or private purchase | +7,000 | $5.36 | $38K | 1,469,524 See Footnotes | Filing · EDGAR |
| Feb 17, 2017 | Open-market or private purchase | +71,800 | $5.19 | $373K | 1,462,524 See Footnotes | Filing · EDGAR |
| Feb 16, 2017 | Open-market or private purchase | +30,500 | $5.04 | $154K | 1,390,724 See Footnotes | Filing · EDGAR |
Nabriva Therapeutics Director, 10% owner · filings 2016 to 2016
No transactions in the filings read; Form 144 notices are listed above.
Response Biomedical Director, 10% owner · filings 2012 to 2016 · bought $2.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 29, 2016 | Other acquisition or disposition (see the filing) | −3,604,266 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 29, 2016 | Other acquisition or disposition (see the filing) | −34,291 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 29, 2016 | Other acquisition or disposition (see the filing) | −2,149,902 | 0 See Footnotes | Filing · EDGAR | ||
| Jun 16, 2016 | Open-market or private purchase | +556,339 | $0.56 | $312K | 3,604,266 See Footnotes | Filing · EDGAR |
| Jun 16, 2016 | Open-market or private purchase | +5,294 | $0.56 | $3K | 34,291 See Footnotes | Filing · EDGAR |
| Jun 16, 2016 | Open-market or private purchase | +331,225 | $0.56 | $185K | 2,149,902 See Footnotes | Filing · EDGAR |
| Nov 7, 2013 | Open-market or private purchase | +508,244 | $2.45 | $1.2M | 3,047,927 See Footnotes | Filing · EDGAR |
| Nov 7, 2013 | Open-market or private purchase | +4,816 | $2.45 | $12K | 28,997 See Footnotes | Filing · EDGAR |
| Nov 7, 2013 | Open-market or private purchase | +303,265 | $2.45 | $743K | 1,818,677 See Footnotes | Filing · EDGAR |
| Nov 7, 2013 | Open-market or private purchase Warrant | +254,122 | 254,122 See Footnotes | Filing · EDGAR | ||
| Nov 7, 2013 | Open-market or private purchase Warrant | +2,408 | 2,408 See Footnotes | Filing · EDGAR | ||
| Nov 7, 2013 | Open-market or private purchase Warrant | +151,632 | 151,632 See Footnotes | Filing · EDGAR |
Relypsa 10% owner · filings 2013 to 2016 · sold $221.2M · bought $14.1M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 25, 2016 | Open-market or private sale | −343,600 | $31.98 | $11M | 3,356,400 See Footnotes | Filing · EDGAR |
| Jul 22, 2016 | Open-market or private sale | −3,700,000 | $32.00 | $118.4M | 3,700,000 See Footnotes | Filing · EDGAR |
| Dec 23, 2015 | Open-market or private sale | −47,942 | $26.78 | $1.3M | 7,452,058 See Footnotes | Filing · EDGAR |
| Dec 23, 2015 | Open-market or private sale | −52,058 | $27.54 | $1.4M | 7,400,000 See Footnotes | Filing · EDGAR |
| Dec 22, 2015 | Open-market or private sale | −111,370 | $26.39 | $2.9M | 7,538,630 See Footnotes | Filing · EDGAR |
| Dec 22, 2015 | Open-market or private sale | −38,630 | $27.02 | $1M | 7,500,000 See Footnotes | Filing · EDGAR |
| Dec 21, 2015 | Open-market or private sale | −235,829 | $27.50 | $6.5M | 7,664,171 See Footnotes | Filing · EDGAR |
| Dec 21, 2015 | Open-market or private sale | −14,171 | $28.39 | $402K | 7,650,000 See Footnotes | Filing · EDGAR |
| Oct 22, 2015 | Open-market or private purchase | +189,300 | $11.97 | $2.3M | 7,589,300 See Footnotes | Filing · EDGAR |
| Oct 22, 2015 | Open-market or private purchase | +310,700 | $12.92 | $4M | 7,900,000 See Footnotes | Filing · EDGAR |
| May 18, 2015 | Open-market or private sale | −1,457,551 | $34.13 | $49.7M | 7,400,000 See Footnotes | Filing · EDGAR |
| Sep 17, 2014 | Open-market or private sale | −49,000 | $25.07 | $1.2M | 8,857,551 See footnotes | Filing · EDGAR |
| Sep 16, 2014 | Open-market or private sale | −42,400 | $25.45 | $1.1M | 8,909,151 See footnotes | Filing · EDGAR |
| Sep 16, 2014 | Open-market or private sale | −2,600 | $26.06 | $68K | 8,906,551 See footnotes | Filing · EDGAR |
| Aug 15, 2014 | Open-market or private sale | −990,000 | $26.35 | $26.1M | 8,951,551 See footnotes | Filing · EDGAR |
| Nov 20, 2013 | Derivative converted | +1,904,940 | 1,904,940 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Derivative converted | +1,905,702 | 3,810,642 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Derivative converted | +3,007,297 | 6,817,939 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Derivative converted | +693,991 | 7,511,930 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Option or RSU exercised or converted | +1,417,578 | $0.17 | $241K | 8,929,508 See footnotes | Filing · EDGAR |
| Nov 20, 2013 | Shares withheld for tax or exercise price | −22,166 | $11.00 | $244K | 8,907,342 See footnotes | Filing · EDGAR |
| Nov 20, 2013 | Option or RSU exercised or converted | +327,133 | $0.17 | $56K | 9,234,475 See footnotes | Filing · EDGAR |
| Nov 20, 2013 | Shares withheld for tax or exercise price | −5,116 | $11.00 | $56K | 9,229,359 See footnotes | Filing · EDGAR |
| Nov 20, 2013 | Open-market or private purchase | +712,192 | $11.00 | $7.8M | 9,941,551 See footnotes | Filing · EDGAR |
| Nov 20, 2013 | Derivative converted Series B-1 Preferred Stock | −1,295,845 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Derivative converted Series B-2 Preferred Stock | −1,905,702 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Derivative converted Series C-1 Preferred Stock | −3,007,297 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Derivative converted Series C-2 Preferred Stock | −693,991 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Other acquisition or disposition (see the filing) Warrant to Purchase Preferred Stock | −1,417,578 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Other acquisition or disposition (see the filing) Warrant to Purchase Common Stock | +1,417,578 | 1,417,578 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Option or RSU exercised or converted Warrant to Purchase Common Stock | −1,417,578 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Other acquisition or disposition (see the filing) Warrant to Purchase Preferred Stock | −327,133 | 0 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Other acquisition or disposition (see the filing) Warrant to Purchase Common Stock | +327,133 | 327,133 See footnotes | Filing · EDGAR | ||
| Nov 20, 2013 | Option or RSU exercised or converted Warrant to Purchase Common Stock | −327,133 | 0 See footnotes | Filing · EDGAR |
Selecta Biosciences Director, 10% owner · filings 2016 to 2016 · bought $15.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 27, 2016 | Derivative converted | +11,111 | 12,193 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted | +1,166,884 | 1,280,604 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Open-market or private purchase | +5,189 | $14.00 | $73K | 17,382 See Footnote | Filing · EDGAR |
| Jun 27, 2016 | Open-market or private purchase | +544,811 | $14.00 | $7.6M | 1,825,415 See Footnote | Filing · EDGAR |
| Jun 27, 2016 | Derivative converted Series C Convertible Preferred Stock | −3,628 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series C Convertible Preferred Stock | −380,986 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series D Convertible Preferred Stock | −739 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series D Convertible Preferred Stock | −77,697 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series E Convertible Preferred Stock | −4,351 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series E Convertible Preferred Stock | −456,870 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted | +11,111 | 12,193 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted | +1,166,884 | 1,280,604 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Open-market or private purchase | +5,189 | $14.00 | $73K | 17,382 See Footnote | Filing · EDGAR |
| Jun 27, 2016 | Open-market or private purchase | +544,811 | $14.00 | $7.6M | 1,825,415 See Footnote | Filing · EDGAR |
| Jun 27, 2016 | Derivative converted Series C Convertible Preferred Stock | −3,628 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series C Convertible Preferred Stock | −380,986 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series D Convertible Preferred Stock | −739 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series D Convertible Preferred Stock | −77,697 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series E Convertible Preferred Stock | −4,351 | 0 See Footnote | Filing · EDGAR | ||
| Jun 27, 2016 | Derivative converted Series E Convertible Preferred Stock | −456,870 | 0 See Footnote | Filing · EDGAR |
Intellia Therapeutics Director · filings 2016 to 2016 · bought $4.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 11, 2016 | Derivative converted | +1,847,400 | 1,847,400 See Footnote | Filing · EDGAR | ||
| May 11, 2016 | Derivative converted | +564,780 | 2,412,180 See Footnote | Filing · EDGAR | ||
| May 11, 2016 | Open-market or private purchase | +191,466 | $18.00 | $3.4M | 2,603,646 See Footnote | Filing · EDGAR |
| May 11, 2016 | Open-market or private purchase | +58,534 | $18.00 | $1.1M | 2,662,180 See Footnote | Filing · EDGAR |
| May 11, 2016 | Derivative converted Series B Preferred Stock | −2,857,143 | 0 See Footnote | Filing · EDGAR | ||
| May 11, 2016 | Derivative converted Series B Preferred Stock | −873,475 | 0 See Footnote | Filing · EDGAR |
Otonomy Director · filings 2014 to 2015 · sold $11.6M · bought $2.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 30, 2015 | Open-market or private sale | −2,716 | $28.64 | $78K | 1,850,684 See Footnotes | Filing · EDGAR |
| Nov 30, 2015 | Open-market or private sale | −590 | $29.22 | $17K | 1,850,094 See Footnotes | Filing · EDGAR |
| Nov 27, 2015 | Open-market or private sale | −29,000 | $28.97 | $840K | 1,853,400 See Footnotes | Filing · EDGAR |
| Nov 25, 2015 | Open-market or private sale | −34,800 | $28.91 | $1M | 1,882,400 See Footnotes | Filing · EDGAR |
| Nov 24, 2015 | Open-market or private sale | −36,100 | $28.75 | $1M | 1,917,200 See Footnotes | Filing · EDGAR |
| Nov 23, 2015 | Open-market or private sale | −80,800 | $28.45 | $2.3M | 1,953,300 See Footnotes | Filing · EDGAR |
| Nov 20, 2015 | Open-market or private sale | −83,900 | $28.59 | $2.4M | 2,034,100 See Footnotes | Filing · EDGAR |
| Nov 19, 2015 | Open-market or private sale | −127,300 | $28.60 | $3.6M | 2,118,000 See Footnotes | Filing · EDGAR |
| Nov 17, 2015 | Open-market or private sale | −10,898 | $28.80 | $314K | 2,245,500 See Footnotes | Filing · EDGAR |
| Nov 17, 2015 | Open-market or private sale | −200 | $29.09 | $6K | 2,245,300 See Footnotes | Filing · EDGAR |
| Aug 18, 2014 | Derivative converted | +2,084,523 | 2,084,523 See footnotes | Filing · EDGAR | ||
| Aug 18, 2014 | Open-market or private purchase | +171,875 | $16.00 | $2.8M | 2,256,398 See footnotes | Filing · EDGAR |
| Aug 18, 2014 | Derivative converted Series C Preferred Stock | −1,706,484 | 0 See footnotes | Filing · EDGAR | ||
| Aug 18, 2014 | Derivative converted Series D Preferred Stock | −378,039 | 0 See footnotes | Filing · EDGAR |
Dimension Therapeutics Director, 10% owner · filings 2015 to 2015 · bought $2.6M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 27, 2015 | Derivative converted | +3,250,085 | 3,250,085 See Footnotes | Filing · EDGAR | ||
| Oct 27, 2015 | Derivative converted | +1,947,613 | 5,197,698 See Footnotes | Filing · EDGAR | ||
| Oct 27, 2015 | Open-market or private purchase | +200,000 | $13.00 | $2.6M | 5,397,698 See Footnotes | Filing · EDGAR |
| Oct 27, 2015 | Derivative converted Series A Preferred Stock | −9,500,000 | 0 See Footnotes | Filing · EDGAR | ||
| Oct 27, 2015 | Derivative converted Series B Preferred Stock | −5,692,874 | 0 See Footnotes | Filing · EDGAR |
Sientra 10% owner · filings 2014 to 2015 · sold $10.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Oct 12, 2015 | Open-market or private sale | −285,106 | $5.98 | $1.7M | 1,767,902 See Footnotes | Filing · EDGAR |
| Oct 12, 2015 | Open-market or private sale | −2,785 | $5.98 | $17K | 17,100 See Footnotes | Filing · EDGAR |
| Oct 9, 2015 | Open-market or private sale | −210,668 | $7.03 | $1.5M | 2,053,008 See Footnotes | Filing · EDGAR |
| Oct 9, 2015 | Open-market or private sale | −2,041 | $7.03 | $14K | 19,885 See Footnotes | Filing · EDGAR |
| Oct 8, 2015 | Open-market or private sale | −396,163 | $7.24 | $2.9M | 2,263,676 See Footnotes | Filing · EDGAR |
| Oct 8, 2015 | Open-market or private sale | −3,837 | $7.24 | $28K | 21,926 See Footnotes | Filing · EDGAR |
| Oct 7, 2015 | Open-market or private sale | −53,446 | $7.36 | $393K | 2,659,839 See Footnotes | Filing · EDGAR |
| Oct 7, 2015 | Open-market or private sale | −454 | $7.36 | $3K | 25,763 See Footnotes | Filing · EDGAR |
| Oct 6, 2015 | Open-market or private sale | −6,941 | $7.80 | $54K | 2,713,285 See Footnotes | Filing · EDGAR |
| Oct 6, 2015 | Open-market or private sale | −59 | $7.80 | $460 | 26,217 See Footnotes | Filing · EDGAR |
| Oct 5, 2015 | Open-market or private sale | −136,937 | $8.19 | $1.1M | 2,720,226 See Footnotes | Filing · EDGAR |
| Oct 5, 2015 | Open-market or private sale | −1,163 | $8.19 | $10K | 26,276 See Footnotes | Filing · EDGAR |
| Oct 2, 2015 | Open-market or private sale | −47,497 | $10.34 | $491K | 2,857,163 See Footnotes | Filing · EDGAR |
| Oct 2, 2015 | Open-market or private sale | −403 | $10.34 | $4K | 27,439 See Footnotes | Filing · EDGAR |
| Oct 1, 2015 | Open-market or private sale | −47,100 | $10.34 | $487K | 2,904,660 See Footnotes | Filing · EDGAR |
| Oct 1, 2015 | Open-market or private sale | −400 | $10.34 | $4K | 27,842 See Footnotes | Filing · EDGAR |
| Sep 30, 2015 | Open-market or private sale | −43,471 | $10.17 | $442K | 2,951,760 See Footnotes | Filing · EDGAR |
| Sep 30, 2015 | Open-market or private sale | −369 | $10.17 | $4K | 28,242 See Footnotes | Filing · EDGAR |
| Sep 29, 2015 | Open-market or private sale | −10,469 | $10.08 | $106K | 2,995,231 See Footnotes | Filing · EDGAR |
| Sep 29, 2015 | Open-market or private sale | −89 | $10.08 | $897 | 28,611 See Footnotes | Filing · EDGAR |
| Sep 28, 2015 | Open-market or private sale | −10,513 | $10.30 | $108K | 3,005,700 See Footnotes | Filing · EDGAR |
| Sep 28, 2015 | Open-market or private sale | −89 | $10.30 | $917 | 28,700 See Footnotes | Filing · EDGAR |
| Sep 25, 2015 | Open-market or private sale | −64,400 | $10.07 | $649K | 3,082,702 See Footnotes | Filing · EDGAR |
| Sep 25, 2015 | Open-market or private sale | −800 | $10.07 | $8K | 29,100 See Footnotes | Filing · EDGAR |
| Sep 25, 2015 | Open-market or private sale | −66,489 | $11.07 | $736K | 3,016,213 See Footnotes | Filing · EDGAR |
| Sep 25, 2015 | Open-market or private sale | −311 | $11.07 | $3K | 28,789 See Footnotes | Filing · EDGAR |
| Sep 24, 2015 | Open-market or private sale | −6 | $9.78 | $59 | 3,155,254 See Footnotes | Filing · EDGAR |
| Sep 24, 2015 | Open-market or private sale | −148 | $11.00 | $2K | 29,900 See Footnotes | Filing · EDGAR |
| Sep 24, 2015 | Open-market or private sale | −8,152 | $11.00 | $90K | 3,147,102 See Footnotes | Filing · EDGAR |
Intercept Pharmaceuticals Director · filings 2012 to 2015 · sold $205.3M · bought $5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 17, 2015 | Grant or award from the company | +285 | 1,120,609 See Footnotes | Filing · EDGAR | ||
| Mar 26, 2015 | Open-market or private sale | −5,623 | $281.11 | $1.6M | 1,271,901 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −8,397 | $282.13 | $2.4M | 1,263,504 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −9,357 | $282.87 | $2.6M | 1,254,147 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −16,845 | $284.20 | $4.8M | 1,237,302 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −23,903 | $285.18 | $6.8M | 1,213,399 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −7,611 | $286.24 | $2.2M | 1,205,788 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −18,041 | $287.16 | $5.2M | 1,187,747 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −26,028 | $288.11 | $7.5M | 1,161,719 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −15,131 | $289.07 | $4.4M | 1,146,588 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −13,974 | $290.02 | $4.1M | 1,132,614 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −3,700 | $291.12 | $1.1M | 1,128,914 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −6,000 | $292.13 | $1.8M | 1,122,914 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −2,500 | $293.85 | $735K | 1,120,414 See Footnotes | Filing · EDGAR |
| Mar 26, 2015 | Open-market or private sale | −90 | $294.82 | $27K | 1,120,324 See Footnotes | Filing · EDGAR |
| Mar 25, 2015 | Open-market or private sale | −2,800 | $270.23 | $757K | 1,277,524 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −6,764 | $268.13 | $1.8M | 1,319,160 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −1,539 | $269.10 | $414K | 1,317,621 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −9,574 | $270.13 | $2.6M | 1,308,047 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −6,063 | $271.15 | $1.6M | 1,301,984 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −3,050 | $272.13 | $830K | 1,298,934 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −2,700 | $273.19 | $738K | 1,296,234 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −12,066 | $275.00 | $3.3M | 1,284,168 See Footnotes | Filing · EDGAR |
| Mar 24, 2015 | Open-market or private sale | −3,844 | $275.56 | $1.1M | 1,280,324 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −40,598 | $270.70 | $11M | 1,444,726 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −7,764 | $271.70 | $2.1M | 1,436,962 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −8,638 | $272.79 | $2.4M | 1,428,324 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −11,869 | $273.89 | $3.3M | 1,416,455 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −3,579 | $274.86 | $984K | 1,412,876 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −37,666 | $275.95 | $10.4M | 1,375,210 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −8,195 | $276.96 | $2.3M | 1,367,015 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −14,152 | $278.00 | $3.9M | 1,352,863 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −3,668 | $279.00 | $1M | 1,349,195 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −9,465 | $280.00 | $2.7M | 1,339,730 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −6,306 | $281.01 | $1.8M | 1,333,424 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −3,500 | $282.00 | $987K | 1,329,924 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −1,548 | $283.29 | $439K | 1,328,376 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −52 | $283.44 | $15K | 1,328,324 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −1,400 | $286.04 | $400K | 1,326,924 See Footnotes | Filing · EDGAR |
| Mar 23, 2015 | Open-market or private sale | −1,000 | $288.60 | $289K | 1,325,924 See Footnotes | Filing · EDGAR |
| Aug 26, 2014 | Open-market or private sale | −10,400 | $299.13 | $3.1M | 1,536,182 See Footnotes | Filing · EDGAR |
| Aug 26, 2014 | Open-market or private sale | −45,058 | $300.11 | $13.5M | 1,491,124 See Footnotes | Filing · EDGAR |
| Aug 26, 2014 | Open-market or private sale | −5,400 | $301.36 | $1.6M | 1,485,724 See Footnotes | Filing · EDGAR |
| Aug 26, 2014 | Open-market or private sale | −400 | $302.34 | $121K | 1,485,324 See Footnotes | Filing · EDGAR |
| Aug 25, 2014 | Open-market or private sale | −12,558 | $294.67 | $3.7M | 1,584,024 See Footnotes | Filing · EDGAR |
| Aug 25, 2014 | Open-market or private sale | −25,442 | $295.52 | $7.5M | 1,558,582 See Footnotes | Filing · EDGAR |
| Aug 25, 2014 | Open-market or private sale | −10,010 | $296.59 | $3M | 1,548,572 See Footnotes | Filing · EDGAR |
| Aug 25, 2014 | Open-market or private sale | −1,990 | $297.26 | $592K | 1,546,582 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −3,704 | $292.70 | $1.1M | 1,652,878 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −4,468 | $293.85 | $1.3M | 1,648,410 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −3,254 | $294.96 | $960K | 1,645,156 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −7,062 | $296.21 | $2.1M | 1,638,094 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −6,192 | $296.86 | $1.8M | 1,631,902 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −9,985 | $297.76 | $3M | 1,621,917 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −100 | $298.61 | $30K | 1,621,817 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −3,985 | $300.21 | $1.2M | 1,617,832 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −1,710 | $301.42 | $515K | 1,616,122 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −1,100 | $302.55 | $333K | 1,615,022 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −1,193 | $303.77 | $362K | 1,613,829 See Footnotes | Filing · EDGAR |
| Aug 14, 2014 | Open-market or private sale | −1,732 | $305.14 | $529K | 1,612,097 See Footnotes | Filing · EDGAR |
25 earlier transactions are in the filing list below.
Mirati Therapeutics 10% owner · filings 2013 to 2015 · sold $2.3M · bought $4.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 3, 2015 | Open-market or private purchase | +100,000 | $20.00 | $2M | 1,267,000 See Footnotes | Filing · EDGAR |
| Jul 1, 2014 | Open-market or private sale | −5,000 | $20.04 | $100K | 1,167,000 See Footnotes | Filing · EDGAR |
| Jun 30, 2014 | Open-market or private sale | −9,283 | $20.33 | $189K | 1,176,717 See Footnotes | Filing · EDGAR |
| Jun 30, 2014 | Open-market or private sale | −4,717 | $21.11 | $100K | 1,172,000 See Footnotes | Filing · EDGAR |
| Jun 27, 2014 | Open-market or private sale | −79,120 | $21.79 | $1.7M | 1,195,212 See Footnotes | Filing · EDGAR |
| Jun 27, 2014 | Open-market or private sale | −9,212 | $23.09 | $213K | 1,186,000 See Footnotes | Filing · EDGAR |
| Oct 29, 2013 | Open-market or private purchase | +125,000 | $17.50 | $2.2M | 1,274,332 See Footnotes | Filing · EDGAR |
Acceleron Pharma Other · filings 2013 to 2013
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 24, 2013 | Derivative converted | +1,127,346 | 1,133,171 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +422,101 | 424,282 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +175,419 | 1,308,590 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +65,680 | 489,962 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +23,442 | 1,332,032 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +8,777 | 498,739 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +133,930 | 1,465,962 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +50,145 | 548,884 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +35,873 | 1,501,835 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +13,431 | 562,315 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +38,924 | 1,540,759 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted | +14,574 | 576,889 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series B Convertible Preferred Stock | −1,127,346 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series B Convertible Preferred Stock | −422,101 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series C Convertible Preferred | −175,419 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series C Convertible Preferred Stock | −65,680 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series D Convertible Preferred | −23,442 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series D Convertible Preferred Stock | −8,777 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series E Convertible Preferred | −83,097 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series E Convertible Preferred Stock | −31,113 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series E Convertible Preferred | −22,612 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series E Convertible Preferred | −8,466 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series F Convertible Preferred | −38,924 | 0 See footnote | Filing · EDGAR | ||
| Sep 24, 2013 | Derivative converted Series F Convertible Preferred | −14,574 | 0 See footnote | Filing · EDGAR |
Ambit Biosciences 10% owner · filings 2013 to 2013 · bought $5.7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 23, 2013 | Open-market or private purchase | +12,380 | $6.99 | $87K | 1,476,702 See Footnotes | Filing · EDGAR |
| May 23, 2013 | Open-market or private purchase | +120 | $6.99 | $839 | 14,067 See Footnotes | Filing · EDGAR |
| May 22, 2013 | Open-market or private purchase | +21,100 | $6.86 | $145K | 1,464,322 See Footnotes | Filing · EDGAR |
| May 22, 2013 | Open-market or private purchase | +200 | $6.86 | $1K | 13,947 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Derivative converted | +367,315 | 378,122 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted | +3,498 | 3,600 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted | +219,863 | 597,985 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted | +2,094 | 5,694 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted | +181,689 | 779,674 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted | +1,730 | 7,424 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Open-market or private purchase | +593,618 | $8.00 | $4.7M | 1,373,292 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Open-market or private purchase | +5,653 | $8.00 | $45K | 13,077 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Open-market or private purchase | +61,910 | $8.00 | $495K | 1,435,202 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Open-market or private purchase | +590 | $8.00 | $5K | 13,667 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Open-market or private purchase | +8,020 | $6.90 | $55K | 1,443,222 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Open-market or private purchase | +80 | $6.90 | $552 | 13,747 See Footnotes | Filing · EDGAR |
| May 21, 2013 | Derivative converted Series E Convertible Preferred Stock | −8,815,565 | 0 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted Series E Convertible Preferred Stock | −83,959 | 0 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted Series D-2 Convertible Preferred Stock | −5,276,702 | 0 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted Series D-2 Convertible Preferred Stock | −50,256 | 0 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted Series D Convertible Preferred Stock | −1,973,439 | 0 See Footnotes | Filing · EDGAR | ||
| May 21, 2013 | Derivative converted Series D Convertible Preferred Stock | −18,795 | 0 See Footnotes | Filing · EDGAR | ||
| May 20, 2013 | Open-market or private purchase | +10,500 | $6.78 | $71K | 10,807 See Footnotes | Filing · EDGAR |
| May 20, 2013 | Open-market or private purchase | +100 | $6.78 | $678 | 102 See Footnotes | Filing · EDGAR |
Supernus Pharmaceuticals 10% owner · filings 2012 to 2013 · sold $4.3M · bought $5.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 13, 2013 | Open-market or private sale | −108,900 | $7.58 | $825K | 2,183,000 See Footnotes | Filing · EDGAR |
| Feb 13, 2013 | Open-market or private sale | −41,100 | $7.58 | $311K | 817,000 See Footnotes | Filing · EDGAR |
| Feb 12, 2013 | Open-market or private sale | −110,700 | $7.52 | $833K | 2,291,900 See Footnotes | Filing · EDGAR |
| Feb 12, 2013 | Open-market or private sale | −41,483 | $7.52 | $312K | 858,100 See Footnotes | Filing · EDGAR |
| Dec 18, 2012 | Open-market or private sale | −100,000 | $7.08 | $708K | 0 See Footnotes | Filing · EDGAR |
| Dec 17, 2012 | Open-market or private sale | −197,815 | $6.85 | $1.4M | 100,000 See Footnotes | Filing · EDGAR |
| May 4, 2012 | Derivative converted | +1,668,472 | 1,668,472 See Footnotes | Filing · EDGAR | ||
| May 4, 2012 | Derivative converted | +624,710 | 624,710 See Footnotes | Filing · EDGAR | ||
| May 4, 2012 | Derivative converted | +206,816 | 206,816 See Footnotes | Filing · EDGAR | ||
| May 4, 2012 | Open-market or private purchase | +734,128 | $5.00 | $3.7M | 2,402,600 See Footnotes | Filing · EDGAR |
| May 4, 2012 | Open-market or private purchase | +274,873 | $5.00 | $1.4M | 899,583 See Footnotes | Filing · EDGAR |
| May 4, 2012 | Open-market or private purchase | +90,999 | $5.00 | $455K | 297,815 See Footnotes | Filing · EDGAR |
| May 4, 2012 | Derivative converted Series A Convertible Preferred Stock | −6,673,891 | 0 See Footnotes | Filing · EDGAR | ||
| May 4, 2012 | Derivative converted Series A Convertible Preferred Stock | −2,498,842 | 0 See Footnotes | Filing · EDGAR | ||
| May 4, 2012 | Derivative converted Series A Convertible Preferred Stock | −827,627 | 0 See Footnotes | Filing · EDGAR |
Anthera Pharmaceuticals Director · filings 2010 to 2013 · sold $9.5M · bought $1.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 30, 2013 | Open-market or private purchase | +5,700,000 | 7,462,000 See Footnotes | Filing · EDGAR | ||
| Jan 25, 2013 | Open-market or private purchase | +1,762,000 | $0.65 | $1.1M | 1,762,000 See Footnotes | Filing · EDGAR |
| Jun 29, 2012 | Open-market or private sale | −1,283,300 | $0.73 | $942K | 0 See Footnotes | Filing · EDGAR |
| Mar 22, 2012 | Open-market or private sale | −1,306,700 | $2.40 | $3.1M | 1,283,300 See Footnotes | Filing · EDGAR |
| Mar 21, 2012 | Open-market or private sale | −125,000 | $2.87 | $358K | 2,590,000 See Footnotes | Filing · EDGAR |
| Mar 20, 2012 | Open-market or private sale | −116,800 | $2.90 | $339K | 2,715,000 See Footnotes | Filing · EDGAR |
| Dec 13, 2011 | Open-market or private sale | −16,200 | $6.50 | $105K | 2,831,800 See Footnotes | Filing · EDGAR |
| Dec 9, 2011 | Open-market or private sale | −40,000 | $6.75 | $270K | 2,848,000 See Footnotes | Filing · EDGAR |
| Nov 18, 2011 | Open-market or private sale | −3,000 | $6.50 | $20K | 2,888,000 See Footnotes | Filing · EDGAR |
| Nov 17, 2011 | Open-market or private sale | −24,000 | $6.67 | $160K | 2,891,000 See Footnotes | Filing · EDGAR |
| Nov 16, 2011 | Open-market or private sale | −25,000 | $6.87 | $172K | 2,915,000 See Footnotes | Filing · EDGAR |
| Nov 15, 2011 | Open-market or private sale | −50,000 | $6.93 | $347K | 2,940,000 See Footnotes | Filing · EDGAR |
| Nov 14, 2011 | Open-market or private sale | −5,000 | $6.95 | $35K | 2,990,000 See Footnotes | Filing · EDGAR |
| Nov 11, 2011 | Open-market or private sale | −5,000 | $7.14 | $36K | 2,995,000 See Footnotes | Filing · EDGAR |
| Jun 10, 2011 | Open-market or private sale | −30,000 | $8.18 | $245K | 3,000,000 See Footnotes | Filing · EDGAR |
| Jun 9, 2011 | Open-market or private sale | −37,000 | $8.11 | $300K | 3,030,000 See Footnotes | Filing · EDGAR |
| Jun 8, 2011 | Open-market or private sale | −33,000 | $8.02 | $265K | 3,067,000 See Footnotes | Filing · EDGAR |
| May 26, 2011 | Open-market or private sale | −34,200 | $8.53 | $292K | Filing · EDGAR | |
| May 25, 2011 | Open-market or private sale | −4,800 | $8.65 | $42K | Filing · EDGAR | |
| May 18, 2011 | Open-market or private sale | −69,334 | $8.03 | $557K | 3,139,000 See Footnotes | Filing · EDGAR |
| May 17, 2011 | Open-market or private sale | −100,000 | $8.32 | $832K | 3,208,334 See Footnotes | Filing · EDGAR |
| May 16, 2011 | Open-market or private sale | −12,000 | $7.20 | $86K | 3,308,334 See Footnotes | Filing · EDGAR |
| May 11, 2011 | Open-market or private sale | −13,000 | $7.22 | $94K | 3,320,334 See Footnotes | Filing · EDGAR |
| May 10, 2011 | Open-market or private sale | −106,400 | $7.23 | $769K | 3,333,334 See Footnotes | Filing · EDGAR |
| May 9, 2011 | Open-market or private sale | −10,000 | $7.26 | $73K | 3,439,734 See Footnotes | Filing · EDGAR |
| Sep 30, 2010 | Open-market or private purchase | +19,900 | $4.08 | $81K | 3,449,734 See Footnotes | Filing · EDGAR |
Amarin Director · filings 2011 to 2012 · sold $95.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Sep 4, 2012 | Sale under a 10b5-1 plan | −231,456 | $14.43 | $3.3M | 594,300 See Footnotes | Filing · EDGAR |
| Sep 4, 2012 | Sale under a 10b5-1 plan | −2,244 | $14.43 | $32K | 5,700 See Footnotes | Filing · EDGAR |
| Jul 27, 2012 | Sale under a 10b5-1 plan | −362,844 | $14.61 | $5.3M | 825,756 See Footnotes | Filing · EDGAR |
| Jul 27, 2012 | Sale under a 10b5-1 plan | −3,456 | $14.61 | $50K | 7,944 See Footnote | Filing · EDGAR |
| Jun 19, 2012 | Open-market or private sale | −611,200 | $12.91 | $7.9M | 1,188,600 See Footnotes | Filing · EDGAR |
| Jun 19, 2012 | Open-market or private sale | −5,900 | $12.91 | $76K | 11,400 See Footnote | Filing · EDGAR |
| May 2, 2011 | Open-market or private sale | −32,600 | $16.30 | $531K | 1,799,800 See Footnotes | Filing · EDGAR |
| May 2, 2011 | Open-market or private sale | −300 | $16.30 | $5K | 17,300 See Footnote | Filing · EDGAR |
| Apr 29, 2011 | Open-market or private sale | −99,000 | $16.01 | $1.6M | 1,832,400 See Footnotes | Filing · EDGAR |
| Apr 29, 2011 | Open-market or private sale | −1,000 | $16.01 | $16K | 17,600 See Footnote | Filing · EDGAR |
| Apr 21, 2011 | Open-market or private sale | −247,633 | $16.18 | $4M | 2,426,667 See Footnotes | Filing · EDGAR |
| Apr 21, 2011 | Open-market or private sale | −2,367 | $16.18 | $38K | 23,333 See Footnote | Filing · EDGAR |
| Apr 21, 2011 | Open-market or private sale | −495,267 | $16.91 | $8.4M | 1,931,400 See Footnotes | Filing · EDGAR |
| Apr 21, 2011 | Open-market or private sale | −4,733 | $16.91 | $80K | 18,600 See Footnote | Filing · EDGAR |
| Apr 20, 2011 | Open-market or private sale | −792,400 | $15.79 | $12.5M | 2,674,300 See Footnotes | Filing · EDGAR |
| Apr 20, 2011 | Open-market or private sale | −7,600 | $15.79 | $120K | 25,700 See Footnote | Filing · EDGAR |
| Apr 18, 2011 | Sale under a 10b5-1 plan | −1,756,471 | $14.86 | $26.1M | 4,682,029 See Footnotes | Filing · EDGAR |
| Apr 18, 2011 | Sale under a 10b5-1 plan | −16,668 | $14.86 | $248K | 44,832 See Footnote | Filing · EDGAR |
| Apr 18, 2011 | Sale under a 10b5-1 plan | −1,214,227 | $15.65 | $19M | 3,467,802 See Footnotes | Filing · EDGAR |
| Apr 18, 2011 | Sale under a 10b5-1 plan | −11,522 | $15.65 | $180K | 33,310 See Footnote | Filing · EDGAR |
| Apr 18, 2011 | Sale under a 10b5-1 plan | −1,102 | $16.26 | $18K | 3,466,700 See Footnotes | Filing · EDGAR |
| Apr 18, 2011 | Sale under a 10b5-1 plan | −10 | $16.26 | $163 | 33,300 See Footnote | Filing · EDGAR |
| Mar 28, 2011 | Open-market or private sale | −92,200 | $7.35 | $678K | 6,438,500 See Footnotes | Filing · EDGAR |
| Mar 28, 2011 | Open-market or private sale | −900 | $7.35 | $7K | 61,500 See Footnote | Filing · EDGAR |
| Mar 25, 2011 | Open-market or private sale | −56,400 | $7.47 | $421K | 6,530,700 See Footnotes | Filing · EDGAR |
| Mar 25, 2011 | Open-market or private sale | −500 | $7.47 | $4K | 62,400 See Footnote | Filing · EDGAR |
| Mar 24, 2011 | Open-market or private sale | −22,800 | $7.50 | $171K | 6,587,100 See Footnotes | Filing · EDGAR |
| Mar 24, 2011 | Open-market or private sale | −200 | $7.50 | $2K | 62,900 See Footnote | Filing · EDGAR |
| Mar 21, 2011 | Open-market or private sale | −76,300 | $7.05 | $538K | 6,609,900 See Footnotes | Filing · EDGAR |
| Mar 21, 2011 | Open-market or private sale | −700 | $7.05 | $5K | 63,100 See Footnote | Filing · EDGAR |
| Mar 15, 2011 | Open-market or private sale | −49,500 | $7.24 | $358K | 6,686,200 See Footnotes | Filing · EDGAR |
| Mar 15, 2011 | Open-market or private sale | −500 | $7.24 | $4K | 63,800 See Footnote | Filing · EDGAR |
| Mar 14, 2011 | Open-market or private sale | −74,300 | $7.33 | $545K | 6,735,700 See Footnotes | Filing · EDGAR |
| Mar 14, 2011 | Open-market or private sale | −700 | $7.33 | $5K | 64,300 See Footnote | Filing · EDGAR |
| Mar 11, 2011 | Open-market or private sale | −99,100 | $7.43 | $736K | 6,810,000 See Footnotes | Filing · EDGAR |
| Mar 11, 2011 | Open-market or private sale | −900 | $7.43 | $7K | 65,000 See Footnote | Filing · EDGAR |
| Mar 7, 2011 | Open-market or private sale | −24,800 | $7.68 | $190K | 6,909,100 See Footnotes | Filing · EDGAR |
| Mar 7, 2011 | Open-market or private sale | −200 | $7.68 | $2K | 65,900 See Footnote | Filing · EDGAR |
| Mar 4, 2011 | Open-market or private sale | −42,600 | $7.62 | $325K | 6,933,900 See Footnotes | Filing · EDGAR |
| Mar 4, 2011 | Open-market or private sale | −400 | $7.62 | $3K | 66,100 See Footnote | Filing · EDGAR |
| Mar 3, 2011 | Open-market or private sale | −6,900 | $7.76 | $54K | 6,976,500 See Footnotes | Filing · EDGAR |
| Mar 3, 2011 | Open-market or private sale | −100 | $7.76 | $776 | 66,500 See Footnote | Filing · EDGAR |
| Mar 2, 2011 | Open-market or private sale | −94,100 | $7.72 | $726K | 6,983,400 See Footnotes | Filing · EDGAR |
| Mar 2, 2011 | Open-market or private sale | −900 | $7.72 | $7K | 66,600 See Footnote | Filing · EDGAR |
| Mar 1, 2011 | Open-market or private sale | −49,500 | $7.56 | $374K | 7,077,500 See Footnotes | Filing · EDGAR |
| Mar 1, 2011 | Open-market or private sale | −500 | $7.56 | $4K | 67,500 See Footnote | Filing · EDGAR |
| Feb 28, 2011 | Open-market or private sale | −99,100 | $7.73 | $766K | 7,127,000 See Footnotes | Filing · EDGAR |
| Feb 28, 2011 | Open-market or private sale | −900 | $7.73 | $7K | 68,000 See Footnote | Filing · EDGAR |
Complete Genomics 10% owner · filings 2010 to 2012 · sold $3.3M · bought $5.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jul 13, 2012 | Open-market or private sale | −474,800 | $2.51 | $1.2M | 2,922,141 See Footnotes | Filing · EDGAR |
| Jul 13, 2012 | Open-market or private sale | −4,500 | $2.51 | $11K | 27,859 See Footnotes | Filing · EDGAR |
| Jul 12, 2012 | Open-market or private sale | −218,624 | $2.85 | $623K | 3,396,941 See Footnotes | Filing · EDGAR |
| Jul 12, 2012 | Open-market or private sale | −2,076 | $2.85 | $6K | 32,359 See Footnotes | Filing · EDGAR |
| Jul 11, 2012 | Open-market or private sale | −503,144 | $2.90 | $1.5M | 3,615,565 See Footnotes | Filing · EDGAR |
| Jul 11, 2012 | Open-market or private sale | −4,792 | $2.90 | $14K | 34,435 See Footnotes | Filing · EDGAR |
| Nov 16, 2010 | Derivative converted | +2,252,898 | 2,252,898 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Derivative converted | +1,267,070 | 3,519,968 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Open-market or private purchase | +597,091 | $9.00 | $5.4M | 4,117,059 See Footnotes | Filing · EDGAR |
| Nov 16, 2010 | Derivative converted | +21,456 | 21,456 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Derivative converted | +12,068 | 33,524 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Open-market or private purchase | +5,687 | $9.00 | $51K | 39,211 See Footnotes | Filing · EDGAR |
| Nov 16, 2010 | Derivative converted Series D Preferred Stock | −2,252,898 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Derivative converted Series D Preferred Stock | −21,456 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Derivative converted Series E Preferred Stock | −1,267,070 | 0 See Footnotes | Filing · EDGAR | ||
| Nov 16, 2010 | Derivative converted Series E Preferred Stock | −12,068 | 0 See Footnotes | Filing · EDGAR |
Pacira Pharmaceuticals 10% owner · filings 2011 to 2012 · sold $4.2M · bought $3.7M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 12, 2012 | Open-market or private sale | −62,400 | $11.03 | $688K | 2,446,700 See footnotes | Filing · EDGAR |
| Mar 12, 2012 | Open-market or private sale | −700 | $11.03 | $8K | 2,446,000 See footnotes | Filing · EDGAR |
| Mar 9, 2012 | Open-market or private sale | −36,700 | $11.25 | $413K | 2,509,400 See footnotes | Filing · EDGAR |
| Mar 9, 2012 | Open-market or private sale | −300 | $11.25 | $3K | 2,509,100 See footnotes | Filing · EDGAR |
| Feb 29, 2012 | Open-market or private sale | −3,000 | $10.86 | $33K | 2,546,100 See footnotes | Filing · EDGAR |
| Feb 28, 2012 | Open-market or private sale | −10,000 | $11.12 | $111K | 2,549,200 See footnotes | Filing · EDGAR |
| Feb 28, 2012 | Open-market or private sale | −100 | $11.12 | $1K | 2,549,100 See footnotes | Filing · EDGAR |
| Feb 27, 2012 | Open-market or private sale | −28,700 | $11.05 | $317K | 2,559,500 See footnotes | Filing · EDGAR |
| Feb 27, 2012 | Open-market or private sale | −300 | $11.05 | $3K | 2,559,200 See footnotes | Filing · EDGAR |
| Feb 3, 2012 | Open-market or private sale | −49,500 | $10.79 | $534K | 2,588,700 See footnotes | Filing · EDGAR |
| Feb 3, 2012 | Open-market or private sale | −500 | $10.79 | $5K | 2,588,200 See footnotes | Filing · EDGAR |
| Feb 2, 2012 | Open-market or private sale | −23,100 | $10.85 | $251K | 2,638,400 See footnotes | Filing · EDGAR |
| Feb 2, 2012 | Open-market or private sale | −200 | $10.85 | $2K | 2,638,200 See footnotes | Filing · EDGAR |
| Feb 1, 2012 | Open-market or private sale | −69,300 | $11.01 | $763K | 2,662,200 See footnotes | Filing · EDGAR |
| Feb 1, 2012 | Open-market or private sale | −700 | $11.01 | $8K | 2,661,500 See footnotes | Filing · EDGAR |
| Oct 31, 2011 | Open-market or private sale | −96,554 | $10.53 | $1M | 2,732,387 See footnotes | Filing · EDGAR |
| Oct 31, 2011 | Open-market or private sale | −887 | $10.53 | $9K | 2,731,500 See footnotes | Filing · EDGAR |
| Feb 8, 2011 | Derivative converted | +1,473,645 | 1,566,625 See footnotes | Filing · EDGAR | ||
| Feb 8, 2011 | Derivative converted | +14,035 | 1,580,660 See footnote | Filing · EDGAR | ||
| Feb 8, 2011 | Derivative converted | +705,845 | $13.44 | $9.5M | 2,286,505 See footnotes | Filing · EDGAR |
| Feb 8, 2011 | Derivative converted | +6,722 | $13.44 | $90K | 2,293,227 See footnote | Filing · EDGAR |
| Feb 8, 2011 | Open-market or private purchase | +265,331 | $7.00 | $1.9M | 2,558,558 See footnotes | Filing · EDGAR |
| Feb 8, 2011 | Open-market or private purchase | +2,526 | $7.00 | $18K | 2,561,084 See footnote | Filing · EDGAR |
| Feb 8, 2011 | Open-market or private purchase | +265,330 | $7.00 | $1.9M | 2,826,414 See footnotes | Filing · EDGAR |
| Feb 8, 2011 | Open-market or private purchase | +2,527 | $7.00 | $18K | 2,828,941 See footnote | Filing · EDGAR |
| Feb 8, 2011 | Derivative converted Series A Convertible Preferred Stock | −1,473,645 | 0 See footnote | Filing · EDGAR | ||
| Feb 8, 2011 | Derivative converted Series A Convertible Preferred Stock | −14,035 | 0 See footnote | Filing · EDGAR | ||
| Feb 8, 2011 | Derivative converted Convertible Promissory Notes | −705,845 | 0 See footnote | Filing · EDGAR | ||
| Feb 8, 2011 | Derivative converted Convertible Promissory Notes | −6,722 | 0 See footnote | Filing · EDGAR |
ChemoCentryx 10% owner · filings 2012 to 2012
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 13, 2012 | Derivative converted | +44,817 | 44,817 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted | +2,201,388 | 2,201,388 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted | +908,509 | 908,509 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted Series B Preferred Stock | −78,928 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted Series C Preferred Stock | −10,706 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted Series B Preferred Stock | −3,888,423 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted Series C Preferred Stock | −514,354 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted Series B Preferred Stock | −1,574,345 | 0 See Footnotes | Filing · EDGAR | ||
| Feb 13, 2012 | Derivative converted Series C Preferred Stock | −242,674 | 0 See Footnotes | Filing · EDGAR |
Athersys 10% owner · filings 2007 to 2011 · sold $552K · bought $16.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Apr 26, 2011 | Open-market or private sale | −7,625 | $2.90 | $22K | 1,600,450 See Footnotes | Filing · EDGAR |
| Apr 26, 2011 | Open-market or private sale | −75 | $2.90 | $218 | 15,250 See Footnote | Filing · EDGAR |
| Apr 25, 2011 | Open-market or private sale | −36,250 | $2.90 | $105K | 1,608,075 See Footnotes | Filing · EDGAR |
| Apr 25, 2011 | Open-market or private sale | −350 | $2.90 | $1K | 15,325 See Footnote | Filing · EDGAR |
| Apr 21, 2011 | Open-market or private sale | −1,975 | $2.90 | $6K | 1,644,325 See Footnotes | Filing · EDGAR |
| Apr 21, 2011 | Open-market or private sale | −25 | $2.90 | $73 | 15,675 See Footnote | Filing · EDGAR |
| Apr 20, 2011 | Open-market or private sale | −1,300 | $2.90 | $4K | 1,646,300 See Footnotes | Filing · EDGAR |
| Apr 18, 2011 | Open-market or private sale | −15,600 | $2.93 | $46K | 1,647,600 See Footnotes | Filing · EDGAR |
| Apr 18, 2011 | Open-market or private sale | −100 | $2.93 | $293 | 15,700 See Footnote | Filing · EDGAR |
| Apr 15, 2011 | Open-market or private sale | −29,900 | $2.90 | $87K | 1,663,200 See Footnotes | Filing · EDGAR |
| Apr 15, 2011 | Open-market or private sale | −300 | $2.90 | $870 | 15,800 See Footnote | Filing · EDGAR |
| Apr 14, 2011 | Open-market or private sale | −20,700 | $2.91 | $60K | 1,693,100 See Foonotes | Filing · EDGAR |
| Apr 14, 2011 | Open-market or private sale | −200 | $2.91 | $582 | 16,100 See Foonote | Filing · EDGAR |
| Apr 13, 2011 | Open-market or private sale | −47,200 | $2.94 | $139K | 1,713,800 See Footnotes | Filing · EDGAR |
| Apr 13, 2011 | Open-market or private sale | −500 | $2.94 | $1K | 16,300 See Footnotes | Filing · EDGAR |
| Apr 12, 2011 | Open-market or private sale | −14,200 | $2.90 | $41K | 1,761,000 See Footnotes | Filing · EDGAR |
| Apr 12, 2011 | Open-market or private sale | −100 | $2.90 | $290 | 16,800 See Footnote | Filing · EDGAR |
| Apr 11, 2011 | Open-market or private sale | −12,900 | $2.91 | $38K | 1,775,200 See Footnotes | Filing · EDGAR |
| Apr 11, 2011 | Open-market or private sale | −100 | $2.91 | $291 | 16,900 See Footnote | Filing · EDGAR |
| Jan 7, 2010 | Other acquisition or disposition (see the filing) | −4,947 | 1,805,100 See Footnotes | Filing · EDGAR | ||
| Dec 28, 2009 | Other acquisition or disposition (see the filing) | −1,800,153 | 1,810,047 See Footnotes | Filing · EDGAR | ||
| Mar 17, 2009 | Open-market or private purchase | +110,000 | $0.84 | $92K | 3,610,200 See Footnotes | Filing · EDGAR |
| Mar 16, 2009 | Open-market or private purchase | +52,200 | $0.65 | $34K | 3,500,200 See Footnotes | Filing · EDGAR |
| May 22, 2008 | Open-market or private purchase | +268,000 | $2.40 | $643K | 3,448,000 See Footnotes | Filing · EDGAR |
| May 21, 2008 | Open-market or private purchase | +130,000 | $2.40 | $312K | 3,180,000 See Footnotes | Filing · EDGAR |
| May 13, 2008 | Open-market or private purchase | +50,000 | $2.40 | $120K | 3,050,000 See Footnotes | Filing · EDGAR |
| Jun 8, 2007 | Grant or award from the company Director's Stock Option (right to buy) | −75,000 | 75,000 See Footnote | Filing · EDGAR | ||
| Jun 8, 2007 | Open-market or private purchase Warrant (right to buy) | −750,000 | 750,000 See Footnotes | Filing · EDGAR | ||
| Jun 8, 2007 | Grant or award from the company Director's Stock Option (right to buy) | −75,000 | 75,000 See Footnote | Filing · EDGAR | ||
| Jun 8, 2007 | Open-market or private purchase Warrant (right to buy) | −750,000 | 750,000 See Footnotes | Filing · EDGAR | ||
| Jun 8, 2007 | Grant or award from the company Director's Stock Option (right to buy) | −75,000 | 75,000 See Footnote | Filing · EDGAR | ||
| Jun 8, 2007 | Open-market or private purchase Warrant (right to buy) | −750,000 | 750,000 See Footnotes | Filing · EDGAR | ||
| Jun 8, 2007 | Open-market or private purchase | +3,000,000 | $5.00 | $15M | 3,000,000 See footnote | Filing · EDGAR |
| Jun 8, 2007 | Grant or award from the company Director stock option (right to purchase) | −75,000 | 75,000 See footnote | Filing · EDGAR | ||
| Jun 8, 2007 | Open-market or private purchase Warrant (right to purchase) | −750,000 | 750,000 See footnote | Filing · EDGAR |
NxStage Medical Director · filings 2008 to 2010 · sold $33.9M · bought $25.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 9, 2010 | Open-market or private sale | −2,356 | $22.60 | $53K | 0 direct | Filing · EDGAR |
| Oct 13, 2010 | Other acquisition or disposition (see the filing) | −1,009,524 | 2,690,476 See Footnotes | Filing · EDGAR | ||
| Oct 13, 2010 | Other acquisition or disposition (see the filing) | +2,356 | 2,356 direct | Filing · EDGAR | ||
| Sep 15, 2010 | Open-market or private sale | −54,000 | $16.23 | $876K | 3,700,000 See Footnotes | Filing · EDGAR |
| Sep 14, 2010 | Open-market or private sale | −96,000 | $16.49 | $1.6M | 3,754,000 See Footnotes | Filing · EDGAR |
| Sep 13, 2010 | Open-market or private sale | −100,000 | $16.70 | $1.7M | 3,850,000 See Footnotes | Filing · EDGAR |
| Sep 10, 2010 | Open-market or private sale | −193,900 | $16.52 | $3.2M | 3,950,000 See Footnotes | Filing · EDGAR |
| Sep 9, 2010 | Open-market or private sale | −8,800 | $16.36 | $144K | 4,143,900 See Footnotes | Filing · EDGAR |
| Sep 8, 2010 | Open-market or private sale | −7,000 | $16.50 | $116K | 4,152,700 See Footnotes | Filing · EDGAR |
| Sep 7, 2010 | Open-market or private sale | −40,100 | $16.79 | $673K | 4,159,700 See Footnotes | Filing · EDGAR |
| Aug 18, 2010 | Open-market or private sale | −100,200 | $16.94 | $1.7M | 4,199,800 See Footnotes | Filing · EDGAR |
| Aug 17, 2010 | Open-market or private sale | −288,000 | $17.06 | $4.9M | 4,300,000 See Footnotes | Filing · EDGAR |
| Aug 16, 2010 | Open-market or private sale | −112,000 | $17.11 | $1.9M | 4,588,000 See Footnotes | Filing · EDGAR |
| Aug 4, 2010 | Open-market or private sale | −101,100 | $16.31 | $1.6M | 4,700,000 See Footnotes | Filing · EDGAR |
| Aug 3, 2010 | Open-market or private sale | −199,200 | $16.41 | $3.3M | 4,801,100 See Footnotes | Filing · EDGAR |
| Aug 2, 2010 | Open-market or private sale | −17,400 | $16.39 | $285K | 5,000,300 See Footnotes | Filing · EDGAR |
| Jul 28, 2010 | Open-market or private sale | −128,000 | $16.66 | $2.1M | 5,017,700 See Footnotes | Filing · EDGAR |
| Jul 27, 2010 | Open-market or private sale | −572,556 | $16.93 | $9.7M | 5,145,700 See Footnotes | Filing · EDGAR |
| Aug 26, 2008 | Open-market or private purchase | +27,700 | $3.50 | $97K | 5,718,256 See Footnotes | Filing · EDGAR |
| Aug 25, 2008 | Open-market or private purchase | +108,900 | $3.37 | $367K | 5,690,556 See Footnotes | Filing · EDGAR |
| Aug 21, 2008 | Open-market or private purchase | +26,100 | $3.25 | $85K | 5,581,656 See Footnotes | Filing · EDGAR |
| Jul 23, 2008 | Grant or award from the company Director's Stock Option (right to buy) | +11,667 | 11,667 See Footnotes | Filing · EDGAR | ||
| Jul 23, 2008 | Grant or award from the company Director's Stock Option (right to buy) | +11,667 | 11,667 See Footnotes | Filing · EDGAR | ||
| Jul 23, 2008 | Grant or award from the company Director's Stock Option (right to buy) | +11,667 | 11,667 See Footnotes | Filing · EDGAR | ||
| May 23, 2008 | Open-market or private purchase Warrant (right to buy) | +1,111,111 | 1,111,111 See Footnotes | Filing · EDGAR | ||
| May 23, 2008 | Open-market or private purchase Warrant (right to buy) | +1,111,111 | 1,111,111 See Footnotes | Filing · EDGAR | ||
| May 23, 2008 | Open-market or private purchase | +5,555,556 | $4.50 | $25M | 5,555,556 See Footnotes | Filing · EDGAR |
| May 23, 2008 | Open-market or private purchase Warrant (right to buy) | +1,111,111 | 1,111,111 See Footnotes | Filing · EDGAR |
Kun Run Biotechnology 10% owner · filings 2010 to 2010
No transactions in the filings read; Form 144 notices are listed above.
Biodel Director · filings 2007 to 2009 · sold $2.4M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 10, 2009 | Open-market or private sale | −26,988 | $5.24 | $141K | 1,485,904 See footnotes | Filing · EDGAR |
| Jun 9, 2009 | Other acquisition or disposition (see the filing) | −300,000 | 1,512,892 See footnotes | Filing · EDGAR | ||
| Feb 12, 2008 | Open-market or private sale | −154,000 | $14.48 | $2.2M | 1,812,892 See footnote | Filing · EDGAR |
| Feb 2, 2008 | Grant or award from the company Director's Stock Option (right to buy) | +10,000 | 10,000 See Footnote | Filing · EDGAR | ||
| May 16, 2007 | Derivative converted | +1,258,756 | 1,966,892 See footnote | Filing · EDGAR | ||
| May 16, 2007 | Derivative converted Series B Convertible Preferred Stock | −1,258,756 | 0 See footnote | Filing · EDGAR |
ARYx Therapeutics 10% owner · filings 2007 to 2009 · sold $8M · bought $3M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 22, 2009 | Open-market or private sale | −2,000,000 | $4.00 | $8M | 1,340,139 See Footnotes | Filing · EDGAR |
| Nov 14, 2008 | Open-market or private purchase Common Stock Warrants (right to buy) | +364,395 | 364,395 See footnote | Filing · EDGAR | ||
| Nov 14, 2008 | Open-market or private purchase | +1,214,646 | 3,340,139 See footnote | Filing · EDGAR | ||
| Nov 14, 2008 | Open-market or private purchase Common Stock Warrants (right to buy) | +364,395 | 364,395 See footnote | Filing · EDGAR | ||
| Nov 13, 2007 | Derivative converted | +1,825,493 | 1,825,493 FN | Filing · EDGAR | ||
| Nov 13, 2007 | Open-market or private purchase | +300,000 | $10.00 | $3M | 2,125,493 FN | Filing · EDGAR |
| Nov 13, 2007 | Derivative converted Series C Conv. Pfd. Stk. | −897,866 | 0 FN | Filing · EDGAR | ||
| Nov 13, 2007 | Derivative converted Series D Conv. Pfd. Stk. | −604,228 | 0 FN | Filing · EDGAR | ||
| Nov 13, 2007 | Derivative converted Series E Conv. Pfd. Stk. | −323,399 | 0 FN | Filing · EDGAR |
Cryocor 10% owner · filings 2005 to 2007
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 14, 2007 | Other acquisition or disposition (see the filing) | −842,504 | 389,432 See Footnote | Filing · EDGAR | ||
| Jul 13, 2005 | Derivative converted | +1,096,936 | 1,231,936 FN | Filing · EDGAR | ||
| Jul 13, 2005 | Derivative converted Series D Redeemable Convertible Preferred Stock | −30,241,936 | 1,096,936 FN | Filing · EDGAR | ||
| Jul 13, 2005 | Open-market or private sale | +135,000 | $11.00 | $1.5M | 1,231,936 FN, 1, 2, 3 | Filing · EDGAR |
Insulet Director · filings 2007 to 2007
Volcano Director · filings 2006 to 2006
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 20, 2006 | Derivative converted | +1,578,832 | 1,578,832 By Caduceus Private Investments II, LP | Filing · EDGAR | ||
| Jun 20, 2006 | Derivative converted | +591,146 | 591,146 By Caduceus Private Investments II (QP), LP | Filing · EDGAR | ||
| Jun 20, 2006 | Derivative converted | +195,705 | 195,705 By UBS Juniper Crossover Fund, L.L.C. | Filing · EDGAR | ||
| Jun 20, 2006 | Derivative converted Series C Convertible Preferred Stock | −1,734,981 | 0 By Caduceaus Private Investments II, LP | Filing · EDGAR | ||
| Jun 20, 2006 | Derivative converted Series C Convertible Preferred Stock | −649,612 | 0 By Caduceaus Private Investments II (QP), LP | Filing · EDGAR | ||
| Jun 20, 2006 | Derivative converted Series C Convertible Preferred Stock | −215,061 | 0 By UBS Juniper Crossover Fund, L.L.C. | Filing · EDGAR |
Avanir Pharmaceuticals Director · filings 2006 to 2006 · sold $6.2M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 31, 2006 | Other acquisition or disposition (see the filing) | −629,121 | $9.79 | $6.2M | 1,706,137 FN | Filing · EDGAR |
| May 31, 2006 | Open-market or private sale | −629,121 | $9.79 | $6.2M | 1,706,137 FN | Filing · EDGAR |
| Feb 13, 2006 | Grant or award from the company | +6,435 | 6,435 See FN | Filing · EDGAR | ||
| Feb 13, 2006 | Grant or award from the company | +2,335,258 | $5.08 | $11.9M | 2,335,258 See FN | Filing · EDGAR |
Given Imaging Director, 10% owner · filings 2004 to 2006 · sold $5.5M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 26, 2006 | Other acquisition or disposition (see the filing) warrants | +0 | 2,302 FN 3 and 4 | Filing · EDGAR | ||
| May 24, 2006 | Open-market or private sale | −22,500 | $18.14 | $408K | 3,610,402 FN 3 and 4 | Filing · EDGAR |
| Sep 21, 2004 | Other acquisition or disposition (see the filing) | −235,005 | $39.32 | $9.2M | 3,637,255 see footnotes below | Filing · EDGAR |
| Jun 23, 2004 | Open-market or private sale | −170,000 | $30.08 | $5.1M | 3,872,260 see footnotes below | Filing · EDGAR |
Dov Pharmaceutical Director · filings 2003 to 2006 · sold $6.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 16, 2006 | Open-market or private sale | −547,491 | $3.25 | $1.8M | 548,000 FN | Filing · EDGAR |
| May 16, 2006 | Open-market or private sale | −11,422 | $3.25 | $37K | 11,400 FN | Filing · EDGAR |
| May 16, 2006 | Open-market or private sale | −258,858 | $3.25 | $841K | 258,000 FN | Filing · EDGAR |
| Aug 15, 2005 | Open-market or private sale | −138,400 | $18.24 | $2.5M | 2,028,028 FN | Filing · EDGAR |
| Aug 12, 2005 | Open-market or private sale | −85,000 | $18.47 | $1.6M | 2,166,428 FN | Filing · EDGAR |
Orphan Medical Director · filings 2005 to 2005
No transactions in the filings read; Form 144 notices are listed above.
Aerogen 10% owner · filings 2004 to 2004
No transactions in the filings read; Form 144 notices are listed above.
Memory Pharmaceuticals Director · filings 2004 to 2004
Orthovita 10% owner · filings 2003 to 2004 · sold $790K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 14, 2004 | Open-market or private sale | −200,000 | $3.95 | $790K | 5,350,000 See footnote | Filing · EDGAR |
| Jan 14, 2004 | Open-market or private purchase | −200,000 | $3.95 | $790K | 5,350,000 See | Filing · EDGAR |
| Jan 12, 2004 | Open-market or private purchase | −815,145 | $3.79 | $3.1M | 5,550,000 See | Filing · EDGAR |
| Sep 25, 2003 | Open-market or private purchase | −2,030,100 | $3.50 | $7.1M | 6,365,144 See footnote 1 and 2 | Filing · EDGAR |
| Jul 22, 2003 | Open-market or private purchase | +8,395,244 | 8,395,244 see footnote 2 and 6 | Filing · EDGAR | ||
| Jul 22, 2003 | Open-market or private purchase Warrant | −6 | 0 see footnote 2 and 6 | Filing · EDGAR | ||
| Jul 22, 2003 | Open-market or private purchase Preferred Stock | −1,000 | 0 see footnote 2 and 6 | Filing · EDGAR | ||
| Oct 18, 2002 | Open-market or private purchase Warrant | +3 | 6 see footnote 2 and 6 | Filing · EDGAR | ||
| Oct 18, 2002 | Open-market or private purchase Preferred Stock | +500 | 1,000 see footnote 2 and 6 | Filing · EDGAR |
Lifecell 10% owner · filings 2003 to 2003 · sold $4M
All 671 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 29, 2026 | Form 3 | Aspen Neuroscience ASPE | Filing · EDGAR |
| Sep 30, 2026 | Form 4 | ADARx Pharmaceuticals ADRX | Filing · EDGAR |
| Sep 24, 2026 | Form 3 | ADARx Pharmaceuticals ADRX | Filing · EDGAR |
| Sep 23, 2026 | Form 4 | Electra Therapeutics ETRA | Filing · EDGAR |
| Sep 18, 2026 | Form 3 | Electra Therapeutics ETRA | Filing · EDGAR |
| Aug 12, 2026 | Form 4 | BlossomHill Therapeutics BLSM | Filing · EDGAR |
| Aug 11, 2026 | Form 4 | Braveheart Bio BRVE | Filing · EDGAR |
| Aug 6, 2026 | Form 3 | BlossomHill Therapeutics BLSM | Filing · EDGAR |
| Aug 5, 2026 | Form 3 | Braveheart Bio BRVE | Filing · EDGAR |
| Jul 29, 2026 | Form 3 | Yarrow Bioscience YARW | Filing · EDGAR |
| Jul 29, 2026 | Form 4 | Scribe Therapeutics SCTX | Filing · EDGAR |
| Jul 23, 2026 | Form 3 | Scribe Therapeutics SCTX | Filing · EDGAR |
| Jul 9, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Jul 2, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Jun 24, 2026 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jun 22, 2026 | Form 144 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jun 22, 2026 | Form 144 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jun 17, 2026 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jun 15, 2026 | Form 144 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jun 15, 2026 | Form 144 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jun 15, 2026 | Form 4 | Shattuck Labs STTK | Filing · EDGAR |
| Jun 9, 2026 | Form 4 | Shattuck Labs STTK | Filing · EDGAR |
| Jun 1, 2026 | Form 4 | Q32 Bio QTTB | Filing · EDGAR |
| Jun 1, 2026 | Form 144/A | Sionna Therapeutics SION | Filing · EDGAR |
| May 29, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| May 29, 2026 | Form 144 | Sionna Therapeutics SION | Filing · EDGAR |
| May 11, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Apr 28, 2026 | Form 4 | Traws Pharma TRAW | Filing · EDGAR |
| Apr 23, 2026 | Form 4 | Prelude Therapeutics PRLD | Filing · EDGAR |
| Apr 21, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Apr 16, 2026 | Form 4 | ImageneBio IKNA | Filing · EDGAR |
| Apr 16, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Apr 9, 2026 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Apr 9, 2026 | Form 144 | Adicet Bio TORC | Filing · EDGAR |
| Mar 31, 2026 | Form 144 | Keros Therapeutics KROS | Filing · EDGAR |
| Feb 4, 2026 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Dec 29, 2025 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Dec 19, 2025 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Dec 18, 2025 | Form 4 | Keros Therapeutics KROS | Filing · EDGAR |
| Nov 26, 2025 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Nov 24, 2025 | Form 144 | Sionna Therapeutics SION | Filing · EDGAR |
| Oct 27, 2025 | Form 4 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Oct 23, 2025 | Form 144 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Oct 20, 2025 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Oct 20, 2025 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Oct 20, 2025 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Oct 10, 2025 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Sep 12, 2025 | Form 4 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Sep 10, 2025 | Form 144 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Sep 2, 2025 | Form 4 | Shattuck Labs STTK | Filing · EDGAR |
| Sep 2, 2025 | Form 3 | Shattuck Labs STTK | Filing · EDGAR |
| Aug 12, 2025 | Form 4 | Turnstone Biologics TSBX | Filing · EDGAR |
| Jul 30, 2025 | Form 4 | ImageneBio IKNA | Filing · EDGAR |
| Jul 21, 2025 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Jul 15, 2025 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Jul 7, 2025 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Jul 1, 2025 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jun 26, 2025 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jun 24, 2025 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| May 16, 2025 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 24, 2025 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Apr 17, 2025 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Apr 15, 2025 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Apr 14, 2025 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Apr 11, 2025 | Form 4 | Compass Therapeutics CMPX | Filing · EDGAR |
| Apr 9, 2025 | Form 144 | Compass Therapeutics CMPX | Filing · EDGAR |
| Apr 4, 2025 | Form 4 | Edgewise Therapeutics EWTX | Filing · EDGAR |
| Mar 26, 2025 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Mar 21, 2025 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Mar 12, 2025 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Mar 10, 2025 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Mar 10, 2025 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Mar 10, 2025 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Feb 19, 2025 | Form 4 | MBX Biosciences MBX | Filing · EDGAR |
| Feb 10, 2025 | Form 4 | Sionna Therapeutics SION | Filing · EDGAR |
| Feb 6, 2025 | Form 3 | Sionna Therapeutics SION | Filing · EDGAR |
| Jan 27, 2025 | Form 4 | Traws Pharma TRAW | Filing · EDGAR |
| Jan 14, 2025 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jan 8, 2025 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jan 6, 2025 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Dec 26, 2024 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Dec 11, 2024 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Dec 6, 2024 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Dec 4, 2024 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Nov 5, 2024 | Form 4 | Lomond Therapeutics Holdings | Filing · EDGAR |
| Nov 5, 2024 | Form 3 | Lomond Therapeutics Holdings | Filing · EDGAR |
| Oct 17, 2024 | Form 4 | Upstream Bio | Filing · EDGAR |
| Oct 10, 2024 | Form 3 | Upstream Bio | Filing · EDGAR |
| Sep 23, 2024 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Sep 23, 2024 | Form 3 | Traws Pharma TRAW | Filing · EDGAR |
| Sep 18, 2024 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Sep 17, 2024 | Form 4 | MBX Biosciences MBX | Filing · EDGAR |
| Sep 16, 2024 | Form 144 | Passage BIO PASG | Filing · EDGAR |
| Sep 12, 2024 | Form 3 | MBX Biosciences MBX | Filing · EDGAR |
| Aug 28, 2024 | Form 4 | ARS Pharmaceuticals | Filing · EDGAR |
| Aug 23, 2024 | Form 4 | ARS Pharmaceuticals | Filing · EDGAR |
| Aug 15, 2024 | Form 4 | Keros Therapeutics KROS | Filing · EDGAR |
| Aug 15, 2024 | Form 4 | scPharmaceuticals | Filing · EDGAR |
| Aug 13, 2024 | Form 144 | Keros Therapeutics KROS | Filing · EDGAR |
| Aug 13, 2024 | Form 144 | Keros Therapeutics KROS | Filing · EDGAR |
| Jul 17, 2024 | Form 4 | Terns Pharmaceuticals | Filing · EDGAR |
| Jul 15, 2024 | Form 144 | Terns Pharmaceuticals | Filing · EDGAR |
| Jul 15, 2024 | Form 144 | Terns Pharmaceuticals | Filing · EDGAR |
| Jul 15, 2024 | Form 144 | Terns Pharmaceuticals | Filing · EDGAR |
| Jul 2, 2024 | Form 4 | TELA Bio | Filing · EDGAR |
| Jun 28, 2024 | Form 144 | TELA Bio | Filing · EDGAR |
| Jun 20, 2024 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| May 20, 2024 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| May 20, 2024 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| May 17, 2024 | Form 144 | Enliven Therapeutics IMRA | Filing · EDGAR |
| May 17, 2024 | Form 144 | Enliven Therapeutics IMRA | Filing · EDGAR |
| May 8, 2024 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| May 3, 2024 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 26, 2024 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 23, 2024 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 18, 2024 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 15, 2024 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 12, 2024 | Form 3/A | Traws Pharma TRAW | Filing · EDGAR |
| Apr 5, 2024 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| Apr 3, 2024 | Form 3 | Traws Pharma TRAW | Filing · EDGAR |
| Mar 27, 2024 | Form 3 | Q32 Bio QTTB | Filing · EDGAR |
| Mar 4, 2024 | Form 144 | Verona Pharma | Filing · EDGAR |
| Feb 14, 2024 | Form 4 | Theseus Pharmaceuticals | Filing · EDGAR |
| Jan 31, 2024 | Form 4 | ArriVent Biopharma | Filing · EDGAR |
| Jan 26, 2024 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Jan 25, 2024 | Form 3 | ArriVent Biopharma | Filing · EDGAR |
| Jan 25, 2024 | Form 4 | Edgewise Therapeutics EWTX | Filing · EDGAR |
| Jan 16, 2024 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| Dec 29, 2023 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| Dec 27, 2023 | Form 144 | Alpine Immune Sciences | Filing · EDGAR |
| Dec 27, 2023 | Form 144 | Alpine Immune Sciences | Filing · EDGAR |
| Dec 20, 2023 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Dec 15, 2023 | Form 144/A | Disc Medicine GMTX | Filing · EDGAR |
| Dec 15, 2023 | Form 144/A | Disc Medicine GMTX | Filing · EDGAR |
| Dec 15, 2023 | Form 144/A | Disc Medicine GMTX | Filing · EDGAR |
| Dec 15, 2023 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Dec 14, 2023 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Dec 12, 2023 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Dec 12, 2023 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Dec 12, 2023 | Form 144 | Disc Medicine GMTX | Filing · EDGAR |
| Nov 24, 2023 | Form 4 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Nov 22, 2023 | Form 144 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Oct 4, 2023 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Oct 2, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Oct 2, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Oct 2, 2023 | Form 144 | NeuroPace NPCE | Filing · EDGAR |
| Sep 21, 2023 | Form 4/A | ImageneBio IKNA | Filing · EDGAR |
| Sep 14, 2023 | Form 4 | ImageneBio IKNA | Filing · EDGAR |
| Aug 31, 2023 | Form 4 | ARS Pharmaceuticals | Filing · EDGAR |
| Aug 30, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Aug 30, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Aug 21, 2023 | Form 144/A | Galecto | Filing · EDGAR |
| Aug 21, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Aug 21, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Aug 17, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Aug 15, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Aug 15, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Aug 2, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Jul 31, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Jul 31, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Jul 27, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Jul 25, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Jul 25, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Jul 24, 2023 | Form 4 | Turnstone Biologics TSBX | Filing · EDGAR |
| Jul 20, 2023 | Form 3 | Turnstone Biologics TSBX | Filing · EDGAR |
| Jul 19, 2023 | Form 4 | Theseus Pharmaceuticals | Filing · EDGAR |
| Jul 17, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Jul 13, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Jul 13, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Jun 29, 2023 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Jun 29, 2023 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jun 15, 2023 | Form 144 | Gracell Biotechnologies | Filing · EDGAR |
| May 24, 2023 | Form 4 | Prelude Therapeutics PRLD | Filing · EDGAR |
| May 19, 2023 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| May 15, 2023 | Form 4 | Verona Pharma | Filing · EDGAR |
| May 11, 2023 | Form 144 | Verona Pharma | Filing · EDGAR |
| May 8, 2023 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| May 2, 2023 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| Apr 21, 2023 | Form 4 | TELA Bio | Filing · EDGAR |
| Apr 19, 2023 | Form 144 | TELA Bio | Filing · EDGAR |
| Apr 17, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Apr 12, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Apr 10, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Apr 10, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Apr 7, 2023 | Form 4 | Galecto | Filing · EDGAR |
| Apr 5, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Apr 5, 2023 | Form 144 | Galecto | Filing · EDGAR |
| Feb 27, 2023 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Feb 23, 2023 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| Feb 17, 2023 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Jan 3, 2023 | Form 4 | Disc Medicine GMTX | Filing · EDGAR |
| Jan 3, 2023 | Form 3 | Disc Medicine GMTX | Filing · EDGAR |
| Dec 28, 2022 | Form 4 | Terns Pharmaceuticals | Filing · EDGAR |
| Dec 27, 2022 | Form 4 | Verona Pharma | Filing · EDGAR |
| Nov 29, 2022 | Form 4 | scPharmaceuticals | Filing · EDGAR |
| Nov 25, 2022 | Form 4 | Tricida | Filing · EDGAR |
| Nov 10, 2022 | Form 4 | Compass Therapeutics CMPX | Filing · EDGAR |
| Nov 9, 2022 | Form 4 | Theseus Pharmaceuticals | Filing · EDGAR |
| Sep 21, 2022 | Form 4 | Third Harmonic Bio | Filing · EDGAR |
| Sep 16, 2022 | Form 4 | Edgewise Therapeutics EWTX | Filing · EDGAR |
| Sep 14, 2022 | Form 3 | Third Harmonic Bio | Filing · EDGAR |
| Sep 14, 2022 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Aug 18, 2022 | Form 4 | Terns Pharmaceuticals | Filing · EDGAR |
| Aug 17, 2022 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Aug 10, 2022 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Jul 1, 2022 | Form 4 | Sierra Oncology | Filing · EDGAR |
| Jun 28, 2022 | Form 4 | Arcutis Biotherapeutics | Filing · EDGAR |
| Jun 24, 2022 | Form 4 | ImageneBio IKNA | Filing · EDGAR |
| May 31, 2022 | Form 4 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| May 20, 2022 | Form 4 | Edgewise Therapeutics EWTX | Filing · EDGAR |
| May 13, 2022 | Form 4 | Compass Therapeutics CMPX | Filing · EDGAR |
| May 10, 2022 | Form 4 | Compass Therapeutics CMPX | Filing · EDGAR |
| May 5, 2022 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| May 5, 2022 | Form 4/A | Passage BIO PASG | Filing · EDGAR |
| Apr 8, 2022 | Form 4 | Arcutis Biotherapeutics | Filing · EDGAR |
| Mar 31, 2022 | Form 4 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Feb 15, 2022 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| Jan 28, 2022 | Form 4 | Sierra Oncology | Filing · EDGAR |
| Jan 27, 2022 | Form 4 | 89bio | Filing · EDGAR |
| Jan 24, 2022 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jan 21, 2022 | Form 4 | Theseus Pharmaceuticals | Filing · EDGAR |
| Jan 20, 2022 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jan 13, 2022 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Jan 13, 2022 | Form 4 | Theseus Pharmaceuticals | Filing · EDGAR |
| Dec 30, 2021 | Form 4 | Janux Therapeutics | Filing · EDGAR |
| Dec 23, 2021 | Form 4 | Janux Therapeutics | Filing · EDGAR |
| Dec 17, 2021 | Form 4 | Janux Therapeutics | Filing · EDGAR |
| Dec 14, 2021 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Nov 17, 2021 | Form 4 | Tricida | Filing · EDGAR |
| Nov 8, 2021 | Form 4 | Compass Therapeutics CMPX | Filing · EDGAR |
| Oct 14, 2021 | Form 4 | Theseus Pharmaceuticals | Filing · EDGAR |
| Oct 6, 2021 | Form 3 | Theseus Pharmaceuticals | Filing · EDGAR |
| Sep 22, 2021 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Sep 21, 2021 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| Sep 8, 2021 | Form 4 | Repare Therapeutics | Filing · EDGAR |
| Sep 2, 2021 | Form 4 | Repare Therapeutics | Filing · EDGAR |
| Aug 30, 2021 | Form 4 | Repare Therapeutics | Filing · EDGAR |
| Aug 25, 2021 | Form 4 | Repare Therapeutics | Filing · EDGAR |
| Aug 19, 2021 | Form 4 | Repare Therapeutics | Filing · EDGAR |
| Aug 17, 2021 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Jul 23, 2021 | Form 4/A | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jul 21, 2021 | Form 4 | Acutus Medical | Filing · EDGAR |
| Jul 16, 2021 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Jul 6, 2021 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Jun 30, 2021 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Jun 25, 2021 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Jun 16, 2021 | Form 4 | Janux Therapeutics | Filing · EDGAR |
| Jun 14, 2021 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Jun 10, 2021 | Form 3 | Janux Therapeutics | Filing · EDGAR |
| Jun 9, 2021 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Apr 26, 2021 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 23, 2021 | Form 4 | NeuroPace NPCE | Filing · EDGAR |
| Apr 22, 2021 | Form 4 | Synlogic | Filing · EDGAR |
| Apr 20, 2021 | Form 3 | NeuroPace NPCE | Filing · EDGAR |
| Apr 13, 2021 | Form 4/A | ImageneBio IKNA | Filing · EDGAR |
| Apr 1, 2021 | Form 4 | ImageneBio IKNA | Filing · EDGAR |
| Mar 31, 2021 | Form 4 | Edgewise Therapeutics EWTX | Filing · EDGAR |
| Mar 31, 2021 | Form 4 | Oric Pharmaceuticals | Filing · EDGAR |
| Mar 26, 2021 | Form 4 | Oric Pharmaceuticals | Filing · EDGAR |
| Mar 25, 2021 | Form 3 | Edgewise Therapeutics EWTX | Filing · EDGAR |
| Mar 25, 2021 | Form 3 | ImageneBio IKNA | Filing · EDGAR |
| Mar 23, 2021 | Form 4 | Oric Pharmaceuticals | Filing · EDGAR |
| Mar 18, 2021 | Form 4 | Oric Pharmaceuticals | Filing · EDGAR |
| Mar 15, 2021 | Form 4 | Oric Pharmaceuticals | Filing · EDGAR |
| Mar 3, 2021 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Feb 19, 2021 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Feb 19, 2021 | Form 4 | Decibel Therapeutics | Filing · EDGAR |
| Feb 18, 2021 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Feb 11, 2021 | Form 3 | Decibel Therapeutics | Filing · EDGAR |
| Feb 10, 2021 | Form 3 | Disc Medicine GMTX | Filing · EDGAR |
| Feb 9, 2021 | Form 4 | Terns Pharmaceuticals | Filing · EDGAR |
| Feb 4, 2021 | Form 3 | Terns Pharmaceuticals | Filing · EDGAR |
| Jan 26, 2021 | Form 4 | Prevail Therapeutics | Filing · EDGAR |
| Jan 12, 2021 | Form 4 | Prelude Therapeutics PRLD | Filing · EDGAR |
| Jan 11, 2021 | Form 4 | Cti Biopharma | Filing · EDGAR |
| Jan 5, 2021 | Form 3 | Verona Pharma | Filing · EDGAR |
| Dec 30, 2020 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| Dec 10, 2020 | Form 4 | Aerpio Pharmaceuticals | Filing · EDGAR |
| Dec 9, 2020 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| Dec 8, 2020 | Form 4 | ARS Pharmaceuticals | Filing · EDGAR |
| Dec 4, 2020 | Form 4 | Kinnate Biopharma | Filing · EDGAR |
| Dec 3, 2020 | Form 3 | ARS Pharmaceuticals | Filing · EDGAR |
| Dec 2, 2020 | Form 3 | Kinnate Biopharma | Filing · EDGAR |
| Nov 19, 2020 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Nov 4, 2020 | Form 4 | Galecto | Filing · EDGAR |
| Oct 28, 2020 | Form 3 | Galecto | Filing · EDGAR |
| Oct 6, 2020 | Form 4 | Arcutis Biotherapeutics | Filing · EDGAR |
| Oct 5, 2020 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Oct 5, 2020 | Form 4 | LogicBio Therapeutics | Filing · EDGAR |
| Sep 30, 2020 | Form 4/A | Prelude Therapeutics PRLD | Filing · EDGAR |
| Sep 29, 2020 | Form 4 | Prelude Therapeutics PRLD | Filing · EDGAR |
| Sep 29, 2020 | Form 4 | Graybug Vision | Filing · EDGAR |
| Sep 29, 2020 | Form 4 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Sep 24, 2020 | Form 3 | Graybug Vision | Filing · EDGAR |
| Sep 24, 2020 | Form 3 | Prelude Therapeutics PRLD | Filing · EDGAR |
| Sep 24, 2020 | Form 3 | PMV Pharmaceuticals PMVP | Filing · EDGAR |
| Sep 23, 2020 | Form 4 | 89bio | Filing · EDGAR |
| Sep 17, 2020 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Aug 19, 2020 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Aug 14, 2020 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Aug 12, 2020 | Form 4 | Acutus Medical | Filing · EDGAR |
| Aug 11, 2020 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Aug 5, 2020 | Form 3 | Acutus Medical | Filing · EDGAR |
| Jul 16, 2020 | Form 3 | Pandion Therapeutics | Filing · EDGAR |
| Jul 2, 2020 | Form 4 | Fusion Pharmaceuticals | Filing · EDGAR |
| Jun 25, 2020 | Form 4 | Repare Therapeutics | Filing · EDGAR |
| Jun 25, 2020 | Form 3 | Fusion Pharmaceuticals | Filing · EDGAR |
| Jun 23, 2020 | Form 4 | Compass Therapeutics CMPX | Filing · EDGAR |
| Jun 23, 2020 | Form 3 | Compass Therapeutics CMPX | Filing · EDGAR |
| Jun 18, 2020 | Form 3 | Repare Therapeutics | Filing · EDGAR |
| May 26, 2020 | Form 4 | scPharmaceuticals | Filing · EDGAR |
| May 20, 2020 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Apr 28, 2020 | Form 4 | Oric Pharmaceuticals | Filing · EDGAR |
| Apr 23, 2020 | Form 3 | Oric Pharmaceuticals | Filing · EDGAR |
| Apr 16, 2020 | Form 4 | Alector | Filing · EDGAR |
| Apr 13, 2020 | Form 4 | Keros Therapeutics KROS | Filing · EDGAR |
| Apr 9, 2020 | Form 4 | Alector | Filing · EDGAR |
| Apr 9, 2020 | Form 144 | Paper or text filing, not machine-readable | EDGAR |
| Apr 9, 2020 | Form 144 | Paper or text filing, not machine-readable | EDGAR |
| Apr 7, 2020 | Form 3 | Keros Therapeutics KROS | Filing · EDGAR |
| Apr 2, 2020 | Form 4 | Alector | Filing · EDGAR |
| Mar 30, 2020 | Form 144 | Paper or text filing, not machine-readable | EDGAR |
| Mar 30, 2020 | Form 144 | Paper or text filing, not machine-readable | EDGAR |
| Mar 25, 2020 | Form 4 | Alector | Filing · EDGAR |
| Mar 24, 2020 | Form 144 | Paper or text filing, not machine-readable | EDGAR |
| Mar 24, 2020 | Form 144 | Paper or text filing, not machine-readable | EDGAR |
| Mar 16, 2020 | Form 4 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Mar 11, 2020 | Form 3 | Enliven Therapeutics IMRA | Filing · EDGAR |
| Mar 10, 2020 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Mar 10, 2020 | Form 3 | Cti Biopharma | Filing · EDGAR |
| Mar 5, 2020 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Mar 4, 2020 | Form 4 | Alector | Filing · EDGAR |
| Mar 3, 2020 | Form 4 | Passage BIO PASG | Filing · EDGAR |
| Feb 27, 2020 | Form 3 | Passage BIO PASG | Filing · EDGAR |
| Feb 7, 2020 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Feb 4, 2020 | Form 4 | Arcutis Biotherapeutics | Filing · EDGAR |
| Jan 31, 2020 | Form 4 | Sierra Oncology | Filing · EDGAR |
| Jan 30, 2020 | Form 3 | Arcutis Biotherapeutics | Filing · EDGAR |
| Jan 13, 2020 | Form 4 | Alector | Filing · EDGAR |
| Dec 26, 2019 | Form 4 | Alector | Filing · EDGAR |
| Dec 19, 2019 | Form 4 | Alector | Filing · EDGAR |
| Dec 12, 2019 | Form 4 | Tricida | Filing · EDGAR |
| Nov 29, 2019 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Nov 26, 2019 | Form 3 | Sierra Oncology | Filing · EDGAR |
| Nov 13, 2019 | Form 4 | TELA Bio | Filing · EDGAR |
| Nov 13, 2019 | Form 4 | 89bio | Filing · EDGAR |
| Nov 8, 2019 | Form 3 | 89bio | Filing · EDGAR |
| Nov 7, 2019 | Form 3 | TELA Bio | Filing · EDGAR |
| Oct 31, 2019 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Sep 19, 2019 | Form 4 | SpringWorks Therapeutics | Filing · EDGAR |
| Sep 12, 2019 | Form 3 | SpringWorks Therapeutics | Filing · EDGAR |
| Aug 9, 2019 | Form 4 | Alector | Filing · EDGAR |
| Aug 8, 2019 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jul 1, 2019 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jun 26, 2019 | Form 4 | Prevail Therapeutics | Filing · EDGAR |
| Jun 19, 2019 | Form 3 | Prevail Therapeutics | Filing · EDGAR |
| May 22, 2019 | Form 4 | Principia Biopharma | Filing · EDGAR |
| May 13, 2019 | Form 4 | NextCure | Filing · EDGAR |
| May 8, 2019 | Form 3 | NextCure | Filing · EDGAR |
| Apr 24, 2019 | Form 4 | Turning Point Therapeutics | Filing · EDGAR |
| Apr 16, 2019 | Form 3 | Turning Point Therapeutics | Filing · EDGAR |
| Apr 5, 2019 | Form 4 | Tricida | Filing · EDGAR |
| Apr 3, 2019 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Mar 11, 2019 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Feb 19, 2019 | Form 4 | Avedro | Filing · EDGAR |
| Feb 13, 2019 | Form 3 | Avedro | Filing · EDGAR |
| Feb 11, 2019 | Form 4 | Alector | Filing · EDGAR |
| Feb 6, 2019 | Form 3 | Alector | Filing · EDGAR |
| Jan 23, 2019 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| Dec 13, 2018 | Form 4 | Synthorx | Filing · EDGAR |
| Dec 13, 2018 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| Dec 6, 2018 | Form 3 | Synthorx | Filing · EDGAR |
| Oct 25, 2018 | Form 4 | LogicBio Therapeutics | Filing · EDGAR |
| Oct 19, 2018 | Form 4 | SI-BONE | Filing · EDGAR |
| Oct 18, 2018 | Form 3 | LogicBio Therapeutics | Filing · EDGAR |
| Oct 16, 2018 | Form 3 | SI-BONE | Filing · EDGAR |
| Oct 11, 2018 | Form 4 | Guardant Health | Filing · EDGAR |
| Oct 3, 2018 | Form 3 | Guardant Health | Filing · EDGAR |
| Sep 26, 2018 | Form 3 | Arvinas Holding Company | Filing · EDGAR |
| Sep 20, 2018 | Form 4 | Principia Biopharma | Filing · EDGAR |
| Sep 19, 2018 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Sep 13, 2018 | Form 3 | Principia Biopharma | Filing · EDGAR |
| Sep 7, 2018 | Form 4 | SteadyMed | Filing · EDGAR |
| Aug 21, 2018 | Form 4/A | ViewRay | Filing · EDGAR |
| Aug 21, 2018 | Form 4/A | ViewRay | Filing · EDGAR |
| Aug 20, 2018 | Form 4 | ViewRay | Filing · EDGAR |
| Aug 15, 2018 | Form 4 | ViewRay | Filing · EDGAR |
| Aug 10, 2018 | Form 4 | ViewRay | Filing · EDGAR |
| Aug 7, 2018 | Form 4 | ViewRay | Filing · EDGAR |
| Jul 24, 2018 | Form 4 | Constellation Pharmaceuticals | Filing · EDGAR |
| Jul 18, 2018 | Form 3 | Constellation Pharmaceuticals | Filing · EDGAR |
| Jul 17, 2018 | Form 3 | Crinetics Pharmaceuticals | Filing · EDGAR |
| Jul 2, 2018 | Form 4 | Tricida | Filing · EDGAR |
| Jul 2, 2018 | Form 4 | Aerpio Pharmaceuticals | Filing · EDGAR |
| Jun 27, 2018 | Form 3 | Tricida | Filing · EDGAR |
| Jun 22, 2018 | Form 4 | ARMO BioSciences | Filing · EDGAR |
| Jun 6, 2018 | Form 4 | Adaptimmune Therapeutics | Filing · EDGAR |
| Jun 1, 2018 | Form 4 | Adaptimmune Therapeutics | Filing · EDGAR |
| May 24, 2018 | Form 4 | Rhythm Pharmaceuticals | Filing · EDGAR |
| May 21, 2018 | Form 4 | Rhythm Pharmaceuticals | Filing · EDGAR |
| May 16, 2018 | Form 4 | Adaptimmune Therapeutics | Filing · EDGAR |
| May 9, 2018 | Form 4 | Inspire Medical Systems | Filing · EDGAR |
| May 2, 2018 | Form 3 | Inspire Medical Systems | Filing · EDGAR |
| May 2, 2018 | Form 4 | Pieris Pharmaceuticals | Filing · EDGAR |
| Mar 29, 2018 | Form 4 | Adaptimmune Therapeutics | Filing · EDGAR |
| Mar 14, 2018 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Mar 12, 2018 | Form 4 | Audentes Therapeutics | Filing · EDGAR |
| Mar 6, 2018 | Form 4 | GLAUKOS | Filing · EDGAR |
| Mar 6, 2018 | Form 4 | Audentes Therapeutics | Filing · EDGAR |
| Feb 23, 2018 | Form 4 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Feb 15, 2018 | Form 4 | Pieris Pharmaceuticals | Filing · EDGAR |
| Feb 12, 2018 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Feb 6, 2018 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Feb 2, 2018 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Jan 30, 2018 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Jan 30, 2018 | Form 4 | Adicet Bio TORC | Filing · EDGAR |
| Jan 30, 2018 | Form 4 | ARMO BioSciences | Filing · EDGAR |
| Jan 30, 2018 | Form 4 | Synlogic | Filing · EDGAR |
| Jan 25, 2018 | Form 3 | Adicet Bio TORC | Filing · EDGAR |
| Jan 25, 2018 | Form 3 | ARMO BioSciences | Filing · EDGAR |
| Jan 24, 2018 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Jan 19, 2018 | Form 3 | Xtant Medical Holdings XTNT | Filing · EDGAR |
| Jan 12, 2018 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Jan 12, 2018 | Form 3 | Kala Pharmaceuticals | Filing · EDGAR |
| Jan 4, 2018 | Form 4 | Pieris Pharmaceuticals | Filing · EDGAR |
| Dec 20, 2017 | Form 4 | Pieris Pharmaceuticals | Filing · EDGAR |
| Dec 12, 2017 | Form 4 | Loxo Oncology | Filing · EDGAR |
| Nov 27, 2017 | Form 4 | Loxo Oncology | Filing · EDGAR |
| Nov 21, 2017 | Form 4 | scPharmaceuticals | Filing · EDGAR |
| Nov 20, 2017 | Form 4 | Loxo Oncology | Filing · EDGAR |
| Nov 20, 2017 | Form 4 | Arsanis | Filing · EDGAR |
| Nov 16, 2017 | Form 3 | scPharmaceuticals | Filing · EDGAR |
| Nov 15, 2017 | Form 3 | Arsanis | Filing · EDGAR |
| Oct 10, 2017 | Form 4 | Rhythm Pharmaceuticals | Filing · EDGAR |
| Oct 5, 2017 | Form 4 | Roka BioScience | Filing · EDGAR |
| Oct 4, 2017 | Form 3 | Rhythm Pharmaceuticals | Filing · EDGAR |
| Oct 2, 2017 | Form 4 | Roka BioScience | Filing · EDGAR |
| Sep 29, 2017 | Form 4 | Audentes Therapeutics | Filing · EDGAR |
| Sep 28, 2017 | Form 4 | Roka BioScience | Filing · EDGAR |
| Sep 11, 2017 | Form 4 | Audentes Therapeutics | Filing · EDGAR |
| Sep 5, 2017 | Form 4 | GLAUKOS | Filing · EDGAR |
| Aug 30, 2017 | Form 3 | Synlogic | Filing · EDGAR |
| Aug 25, 2017 | Form 4 | Roka BioScience | Filing · EDGAR |
| Aug 22, 2017 | Form 4 | Roka BioScience | Filing · EDGAR |
| Aug 17, 2017 | Form 4 | GLAUKOS | Filing · EDGAR |
| Jul 27, 2017 | Form 4 | Kala Pharmaceuticals | Filing · EDGAR |
| Jul 26, 2017 | Form 4 | Alpine Immune Sciences | Filing · EDGAR |
| Jul 26, 2017 | Form 3 | Alpine Immune Sciences | Filing · EDGAR |
| Jul 19, 2017 | Form 3 | Kala Pharmaceuticals | Filing · EDGAR |
| Jun 15, 2017 | Form 4 | Cti Biopharma | Filing · EDGAR |
| Jun 9, 2017 | Form 3 | Cti Biopharma | Filing · EDGAR |
| Apr 27, 2017 | Form 4 | SteadyMed | Filing · EDGAR |
| Mar 28, 2017 | Form 4 | Adaptimmune Therapeutics | Filing · EDGAR |
| Mar 17, 2017 | Form 4 | Aerpio Pharmaceuticals | Filing · EDGAR |
| Mar 17, 2017 | Form 3 | Aerpio Pharmaceuticals | Filing · EDGAR |
| Mar 14, 2017 | Form 4 | GLAUKOS | Filing · EDGAR |
| Mar 7, 2017 | Form 4 | GLAUKOS | Filing · EDGAR |
| Feb 21, 2017 | Form 4 | Aeglea BioTherapeutics | Filing · EDGAR |
| Jan 20, 2017 | Form 4 | ViewRay | Filing · EDGAR |
| Dec 30, 2016 | Form 3 | Nabriva Therapeutics | Filing · EDGAR |
| Dec 1, 2016 | Form 4 | Response Biomedical | Filing · EDGAR |
| Sep 23, 2016 | Form 4 | Roka BioScience | Filing · EDGAR |
| Aug 24, 2016 | Form 4 | ViewRay | Filing · EDGAR |
| Aug 12, 2016 | Form 4 | GLAUKOS | Filing · EDGAR |
| Aug 12, 2016 | Form 3 | SteadyMed | Filing · EDGAR |
| Aug 12, 2016 | Form 4 | Loxo Oncology | Filing · EDGAR |
| Aug 5, 2016 | Form 4 | GLAUKOS | Filing · EDGAR |
| Jul 26, 2016 | Form 4 | Relypsa | Filing · EDGAR |
| Jul 25, 2016 | Form 4 | Audentes Therapeutics | Filing · EDGAR |
| Jul 19, 2016 | Form 3 | Audentes Therapeutics | Filing · EDGAR |
| Jun 29, 2016 | Form 4 | Selecta Biosciences | Filing · EDGAR |
| Jun 29, 2016 | Form 4 | Selecta Biosciences | Filing · EDGAR |
| Jun 27, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jun 21, 2016 | Form 3 | Selecta Biosciences | Filing · EDGAR |
| Jun 21, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jun 20, 2016 | Form 4 | Response Biomedical | Filing · EDGAR |
| Jun 16, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jun 13, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| May 25, 2016 | Form 4 | Adaptimmune Therapeutics | Filing · EDGAR |
| May 24, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| May 20, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| May 13, 2016 | Form 4 | Intellia Therapeutics | Filing · EDGAR |
| May 5, 2016 | Form 3 | Intellia Therapeutics | Filing · EDGAR |
| Apr 19, 2016 | Form 3 | Aeglea BioTherapeutics | Filing · EDGAR |
| Mar 30, 2016 | Form 3 | ViewRay | Filing · EDGAR |
| Mar 29, 2016 | Form 4 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Mar 22, 2016 | Form 3 | Corvus Pharmaceuticals CRVS | Filing · EDGAR |
| Jan 4, 2016 | Form 3 | Adaptimmune Therapeutics | Filing · EDGAR |
| Dec 23, 2015 | Form 4 | Relypsa | Filing · EDGAR |
| Nov 30, 2015 | Form 4 | Otonomy | Filing · EDGAR |
| Nov 24, 2015 | Form 4 | Otonomy | Filing · EDGAR |
| Nov 19, 2015 | Form 4 | Otonomy | Filing · EDGAR |
| Oct 29, 2015 | Form 4 | Dimension Therapeutics | Filing · EDGAR |
| Oct 22, 2015 | Form 4 | Relypsa | Filing · EDGAR |
| Oct 21, 2015 | Form 3 | Dimension Therapeutics | Filing · EDGAR |
| Oct 13, 2015 | Form 4 | Sientra | Filing · EDGAR |
| Oct 9, 2015 | Form 4 | Sientra | Filing · EDGAR |
| Oct 6, 2015 | Form 4 | Sientra | Filing · EDGAR |
| Oct 1, 2015 | Form 4 | Sientra | Filing · EDGAR |
| Sep 28, 2015 | Form 4 | Sientra | Filing · EDGAR |
| Jul 21, 2015 | Form 4 | Sierra Oncology | Filing · EDGAR |
| Jul 21, 2015 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Jul 15, 2015 | Form 3 | Sierra Oncology | Filing · EDGAR |
| Jul 8, 2015 | Form 4 | Pieris Pharmaceuticals | Filing · EDGAR |
| Jun 30, 2015 | Form 4 | GLAUKOS | Filing · EDGAR |
| Jun 29, 2015 | Form 3 | Pieris Pharmaceuticals | Filing · EDGAR |
| Jun 24, 2015 | Form 3 | GLAUKOS | Filing · EDGAR |
| May 20, 2015 | Form 4 | Relypsa | Filing · EDGAR |
| Mar 30, 2015 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Mar 25, 2015 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Feb 5, 2015 | Form 4 | Mirati Therapeutics | Filing · EDGAR |
| Oct 28, 2014 | Form 3 | Sientra | Filing · EDGAR |
| Sep 18, 2014 | Form 4 | Relypsa | Filing · EDGAR |
| Aug 27, 2014 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Aug 19, 2014 | Form 4 | Otonomy | Filing · EDGAR |
| Aug 19, 2014 | Form 4 | Relypsa | Filing · EDGAR |
| Aug 18, 2014 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Aug 12, 2014 | Form 3 | Otonomy | Filing · EDGAR |
| Aug 11, 2014 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Aug 6, 2014 | Form 4 | Loxo Oncology | Filing · EDGAR |
| Jul 31, 2014 | Form 3 | Loxo Oncology | Filing · EDGAR |
| Jul 24, 2014 | Form 4 | Roka BioScience | Filing · EDGAR |
| Jul 16, 2014 | Form 3 | Roka BioScience | Filing · EDGAR |
| Jul 1, 2014 | Form 4 | Mirati Therapeutics | Filing · EDGAR |
| May 9, 2014 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Apr 11, 2014 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Feb 11, 2014 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Nov 20, 2013 | Form 4 | Relypsa | Filing · EDGAR |
| Nov 14, 2013 | Form 3 | Relypsa | Filing · EDGAR |
| Nov 12, 2013 | Form 4 | Response Biomedical | Filing · EDGAR |
| Nov 12, 2013 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Oct 31, 2013 | Form 4 | Mirati Therapeutics | Filing · EDGAR |
| Oct 23, 2013 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Oct 17, 2013 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Sep 26, 2013 | Form 4 | Acceleron Pharma | Filing · EDGAR |
| Sep 18, 2013 | Form 3 | Acceleron Pharma | Filing · EDGAR |
| Aug 13, 2013 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Jul 16, 2013 | Form 3 | Mirati Therapeutics | Filing · EDGAR |
| May 24, 2013 | Form 4 | Ambit Biosciences | Filing · EDGAR |
| May 22, 2013 | Form 4 | Ambit Biosciences | Filing · EDGAR |
| May 15, 2013 | Form 3 | Ambit Biosciences | Filing · EDGAR |
| May 13, 2013 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Apr 15, 2013 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Feb 14, 2013 | Form 4 | Supernus Pharmaceuticals | Filing · EDGAR |
| Feb 1, 2013 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Jan 29, 2013 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Dec 19, 2012 | Form 4 | Supernus Pharmaceuticals | Filing · EDGAR |
| Oct 16, 2012 | Form 4 | Intercept Pharmaceuticals | Filing · EDGAR |
| Oct 10, 2012 | Form 3 | Intercept Pharmaceuticals | Filing · EDGAR |
| Sep 5, 2012 | Form 4 | Amarin | Filing · EDGAR |
| Jul 30, 2012 | Form 4 | Amarin | Filing · EDGAR |
| Jul 13, 2012 | Form 4 | Complete Genomics | Filing · EDGAR |
| Jul 3, 2012 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Jun 19, 2012 | Form 4 | Amarin | Filing · EDGAR |
| May 8, 2012 | Form 4 | Supernus Pharmaceuticals | Filing · EDGAR |
| Apr 30, 2012 | Form 3 | Supernus Pharmaceuticals | Filing · EDGAR |
| Mar 22, 2012 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Mar 13, 2012 | Form 4 | Pacira Pharmaceuticals | Filing · EDGAR |
| Feb 29, 2012 | Form 4 | Pacira Pharmaceuticals | Filing · EDGAR |
| Feb 15, 2012 | Form 4 | ChemoCentryx | Filing · EDGAR |
| Feb 8, 2012 | Form 3 | ChemoCentryx | Filing · EDGAR |
| Feb 3, 2012 | Form 4 | Pacira Pharmaceuticals | Filing · EDGAR |
| Jan 11, 2012 | Form 3 | Response Biomedical | Filing · EDGAR |
| Dec 13, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Nov 18, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Nov 15, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Nov 2, 2011 | Form 4 | Pacira Pharmaceuticals | Filing · EDGAR |
| Jun 10, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| May 27, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| May 18, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| May 11, 2011 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| May 3, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Apr 29, 2011 | Form 4 | Athersys | Filing · EDGAR |
| Apr 26, 2011 | Form 4/A | Amarin | Filing · EDGAR |
| Apr 25, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Apr 20, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Mar 28, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Mar 23, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Mar 15, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Mar 7, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Mar 2, 2011 | Form 4 | Amarin | Filing · EDGAR |
| Feb 10, 2011 | Form 4 | Pacira Pharmaceuticals | Filing · EDGAR |
| Feb 2, 2011 | Form 3 | Pacira Pharmaceuticals | Filing · EDGAR |
| Jan 3, 2011 | Form 3 | Amarin | Filing · EDGAR |
| Dec 13, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Nov 16, 2010 | Form 4 | Complete Genomics | Filing · EDGAR |
| Nov 10, 2010 | Form 3 | Complete Genomics | Filing · EDGAR |
| Oct 15, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Oct 4, 2010 | Form 4 | Anthera Pharmaceuticals | Filing · EDGAR |
| Oct 4, 2010 | Form 3 | Anthera Pharmaceuticals | Filing · EDGAR |
| Sep 17, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Sep 14, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Sep 9, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Aug 18, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Aug 4, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| Jul 29, 2010 | Form 4 | NxStage Medical | Filing · EDGAR |
| May 10, 2010 | Form 3 | Kun Run Biotechnology | Filing · EDGAR |
| Jan 12, 2010 | Form 4 | Athersys | Filing · EDGAR |
| Jun 11, 2009 | Form 4 | Biodel | Filing · EDGAR |
| May 26, 2009 | Form 4 | ARYx Therapeutics | Filing · EDGAR |
| Mar 18, 2009 | Form 4 | Athersys | Filing · EDGAR |
| Nov 18, 2008 | Form 4 | ARYx Therapeutics | Filing · EDGAR |
| Aug 28, 2008 | Form 4 | NxStage Medical | Filing · EDGAR |
| Aug 25, 2008 | Form 4 | NxStage Medical | Filing · EDGAR |
| Aug 12, 2008 | Form 4 | NxStage Medical | Filing · EDGAR |
| May 30, 2008 | Form 3 | NxStage Medical | Filing · EDGAR |
| May 23, 2008 | Form 4 | Athersys | Filing · EDGAR |
| May 21, 2008 | Form 4 | Athersys | Filing · EDGAR |
| May 15, 2008 | Form 4 | Athersys | Filing · EDGAR |
| Feb 14, 2008 | Form 4 | Biodel | Filing · EDGAR |
| Nov 15, 2007 | Form 4 | ARYx Therapeutics | Filing · EDGAR |
| Nov 7, 2007 | Form 3 | ARYx Therapeutics | Filing · EDGAR |
| Jun 19, 2007 | Form 4 | Cryocor | Filing · EDGAR |
| Jun 12, 2007 | Form 4 | Athersys | Filing · EDGAR |
| Jun 12, 2007 | Form 3 | Athersys | Filing · EDGAR |
| May 18, 2007 | Form 4 | Insulet | Filing · EDGAR |
| May 18, 2007 | Form 4 | Biodel | Filing · EDGAR |
| May 14, 2007 | Form 3 | Insulet | Filing · EDGAR |
| May 10, 2007 | Form 3 | Biodel | Filing · EDGAR |
| Jun 20, 2006 | Form 4 | Volcano | Filing · EDGAR |
| Jun 15, 2006 | Form 3 | Volcano | Filing · EDGAR |
| Jun 5, 2006 | Form 4/A | Avanir Pharmaceuticals | Filing · EDGAR |
| Jun 2, 2006 | Form 4 | Avanir Pharmaceuticals | Filing · EDGAR |
| May 26, 2006 | Form 4 | Given Imaging | Filing · EDGAR |
| May 18, 2006 | Form 4 | Dov Pharmaceutical | Filing · EDGAR |
| Feb 23, 2006 | Form 4 | Avanir Pharmaceuticals | Filing · EDGAR |
| Feb 21, 2006 | Form 3 | Avanir Pharmaceuticals | Filing · EDGAR |
| Aug 22, 2005 | Form 4 | Cryocor | Filing · EDGAR |
| Aug 22, 2005 | Form 3/A | Cryocor | Filing · EDGAR |
| Aug 16, 2005 | Form 4 | Dov Pharmaceutical | Filing · EDGAR |
| Jul 18, 2005 | Form 4 | Cryocor | Filing · EDGAR |
| Jul 14, 2005 | Form 3 | Cryocor | Filing · EDGAR |
| May 6, 2005 | Form 3 | Orphan Medical | Filing · EDGAR |
| Sep 28, 2004 | Form 4 | Given Imaging | Filing · EDGAR |
| May 17, 2004 | Form 3 | Aerogen | Filing · EDGAR |
| Apr 12, 2004 | Form 4 | Memory Pharmaceuticals | Filing · EDGAR |
| Apr 7, 2004 | Form 3 | Memory Pharmaceuticals | Filing · EDGAR |
| Feb 10, 2004 | Form 4/A | Orthovita | Filing · EDGAR |
| Jan 16, 2004 | Form 4/A | Orthovita | Filing · EDGAR |
| Jan 14, 2004 | Form 4/A | Orthovita | Filing · EDGAR |
| Dec 30, 2003 | Form 4 | Lifecell | Filing · EDGAR |
| Sep 29, 2003 | Form 4/A | Orthovita | Filing · EDGAR |
| Sep 4, 2003 | Form 4 | Orthovita | Filing · EDGAR |
| Sep 4, 2003 | Form 3 | Orthovita | Filing · EDGAR |
| Jul 16, 2003 | Form 3 | Dov Pharmaceutical | Filing · EDGAR |
| Jul 16, 2003 | Form 3 | Dov Pharmaceutical | Filing · EDGAR |
| Jun 3, 2003 | Form 4 | Lifecell | Filing · EDGAR |
| Nov 21, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Sep 25, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Sep 17, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Sep 9, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Jul 31, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Jun 21, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Jun 21, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Jun 4, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| May 23, 2002 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
| May 22, 2002 | Form 4/A | Paper or text filing, not machine-readable | EDGAR |
| May 22, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Apr 19, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Apr 12, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Feb 15, 2002 | Form 5 | Paper or text filing, not machine-readable | EDGAR |
| Feb 15, 2002 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Feb 15, 2002 | Form 5 | Paper or text filing, not machine-readable | EDGAR |
| Feb 15, 2002 | Form 5 | Paper or text filing, not machine-readable | EDGAR |
| Nov 1, 2001 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
| Sep 10, 2001 | Form 4 | Paper or text filing, not machine-readable | EDGAR |
| Aug 15, 2001 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
| Jul 19, 2001 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
| Apr 25, 2001 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
| Feb 21, 2001 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
| Jan 11, 2001 | Form 3 | Paper or text filing, not machine-readable | EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.